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ABSTRACT: The design and use of materials in the nanoscale size range
for addressing medical and health-related issues continues to receive
increasing interest. Research in nanomedicine spans a multitude of areas,
including drug delivery, vaccine development, antibacterial, diagnosis and
imaging tools, wearable devices, implants, high-throughput screening
platforms, etc. using biological, nonbiological, biomimetic, or hybrid
materials. Many of these developments are starting to be translated into
viable clinical products. Here, we provide an overview of recent
developments in nanomedicine and highlight the current challenges and
upcoming opportunities for the ﬁeld and translation to the clinic.
Medicine is the science, engineering, and practice ofdiagnosing, treating, curing, monitoring, predicting,and preventing diseases. Most people associate
nanomedicine with pharmaceutical formulations, where soft or
hard particles of nanometer dimensions are injected into humans
for diagnosis and treatment. However, this ﬁeld covers a broader
range of research and development. Nanomedicine diﬀers from
other types of medicine in that it involves the development and
application of materials and technologies with nanometer length
scales to function in all the ways described below.1−5
Properties of nanoscale objects are transitional between
molecular and bulk regimes. Nanoscale properties exist for all
materials, regardless of whether they are found in nature or are
synthetic. However, only synthetic objects are typically con-
sidered part of “nanoscience and engineering”, whereas the study
of biological nanoscale structures is often thought as part of
characterization without considering biological properties.
Because of the transitional nature of “nanoscale” materials, it is
diﬃcult to limit a material’s reach and deﬁne its borders by
strict deﬁnitions and solid numbers (e.g., larger than atoms or
small molecules, but smaller than 100 nm). More importantly,
nanoscale particles can demonstrate new properties that can be
exploited for the design of new therapeutic eﬀects and diagnostics.
Nanomedicine is an interdisciplinary ﬁeld, where nanoscience,
nanoengineering, and nanotechnology interact with the life
sciences. Given the broad scope of nanomedicine, we expect
it eventually to involve all aspects of medicine. Moreover,
nanomedicine, like medicine, can enter the clinics and can be part
of conventional clinical practice assuming all aspects of
translation are satisﬁed, including safety, regulatory, and ethical
requirements. It is expected that nanomedicine will lead to the
development of better devices, drugs, and other applications for
early diagnoses or treatment of a wide range of diseases with high
speciﬁcity, eﬃcacy, and personalization, with the objective being
to enhance patients’ quality of life. In this Nano Focus, we do
not attempt to deﬁne nanomedicine but rather to provide an
overview of recent achievements, materials, and technologies
belonging to nanomedicine.
Nanoparticles (NPs) are key components of nanomedicine,
and currently, a large variety of nanoparticle types exist. How-
ever, no standardized nomenclature exists in the literature;
therefore, terms such as engineered nanomaterials, nonbiological
complex drugs (NBCDs), nanomedicals/nanomedicines, etc. are
used freely. Many nanomaterials can replicate some functions
of globular biological macromolecules.6 Examples are lipid
micelles,7 diﬀerent polymeric nanostructures,8 protein con-
structs,9 ribonucleic acid (RNA) NPs (RNPs),10 carbon dots
(C-dots),11 nanodiamonds (NDs),12 carbon nanotubes
(CNTs),13 graphene,14 as well as inorganic materials such as
mesoporous silica NPs (MSNP), superparamagnetic iron oxide
NPs (SPIONs),15 quantum dots (QDs),16 plasmonic NPs,17 gold
nanoclusters (GNCS),18 upconverting NPs (UCNPs),19 etc.
Many of these nanoscale materials have unique size- and shape-
dependent optical, electronic, and magnetic properties, and these
properties are dependent upon methods to synthesize, to purify,
and to characterize them.20−23 Many researchers note that small
changes in size and shape can signiﬁcantly aﬀect the properties of
the NPs. Precision syntheses are therefore necessary to produce
samples with tightly focused distributions in order to achieve the
targeted functions speciﬁcally and to correlate observed functions
with speciﬁc NP characteristics. Detailed characterization of NP
samples that are used in a medical application is also critical
because onemust know and understandwhat is being injected into
the body. A sample of NPs may be heterogeneous with distinct
subpopulations after synthesis.24,25 Microscopic imaging is
conventionally used, but this technique may be insuﬃcient
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because it is limited to a small number of NPs that may or may not
be representative of the whole sample. Thus, microscopic imaging
may not provide suﬃcient information about surface functional-
ization, composition, and other property-determining features.
Other techniques that are starting to become part of the
characterization scheme of NPs prior to use in humans are
dynamic light scattering, transmission electron microscopy, gel
electrophoresis, and ζ-potential analysis. However, there are no
standardized characterization requirements of NPs26 prior to use
in humans, and thismust be a focus for nanomedicine applications.
The main reason is that the biodistribution and interaction of NPs
with proteins is strongly size- and surface-dependent, and thus, in a
heterogeneous sample, many NPs will distribute diﬀerently and
may exhibit undesired eﬀects or even toxicity. In addition to
characterization, there is also a need to develop new and improved
methods of NP separation and puriﬁcation to produce optimal
samples for nanomedical applications and for studying NP
behavior inside the body27,28 (which is important to design
optimal NP formulations for medical use).
Despite the need to standardize characterization methods,
NPs are expected to improve the detection and diagnosis of
diseases. First, smart NPs can be designed to provide contrast at
the zone of interest and report information about the local
environment after administration into the body. This informa-
tion can aid in imaging the anatomical ﬁne structures of organs
and labeling tissues with certain markers and enables local read-
out of the concentrations of molecules of interest, which helps to
analyze diseases directly inside the human body. Second, NPs are
key components of many high-throughput diagnostics machines
that can analyze extracted samples (such as blood, tissue, etc.)
outside of the body for rapidly detecting biological makers and
molecular alterations. The ability to analyze multiple biomarkers
simultaneously may improve diagnostic precision. Moreover,
multifunctional or theranostic NPs that can simultaneously
diagnose, treat, and even monitor therapeutic eﬃcacy are being
engineered.29
Nanoparticles are also being developed for the treatment of
disease; NPs are used as delivery vehicles for pharmaceutical
agents,30 as bioactive materials, or as important components in
implants.31 In the case of delivery, NP-based carrier systems have
a unique ability to cross biological barriers. Thus, NPs can enter
tumors via their localized leaky vasculature and are retained due
to poor lymphatic drainage in the tumor microenvironment.32
This passive targeting is called the enhanced permeation and
retention (EPR) eﬀect.33 There is an ongoing debate in the
literature about the eﬀectiveness of active, i.e., ligand/receptor-
mediated targeting, versus passive targeting, but any carrier has
to be delivered to the designated site before it can bind to cell
surface receptors or be retained by other eﬀects.34
In addition to using nanomedicine to diagnose and to treat
diseases, it is also important to establish NPs’ eﬃcacy and safety
in biological systems. After the NP has functioned as designed
after administration into the body, what happens to the carrier
particle when the drug has been delivered or the tissue imaged?
Elimination of the particles can potentially occur via renal or
hepatobiliary clearance. If they do not get cleared, the long-term
fate of the NPs is not clear. These particles may degrade and get
cleared renally because they are small enough to transport
through the kidney’s ﬁltration slits,35−37 or they may accumulate
in diﬀerent organs and interact with oﬀ-target cells. The in vivo
fate of NPs can potentially be a dynamic process, and thus, there
is a need to understand nanobiokinetics (nanopharmacokinetics
and pharmacodynamics), which may relate to unique and
interesting toxicological responses of NPs.
Nanomedicine is not limited to colloidal materials and
technologies to evaluate them for in vivo applications. Nano-
medicine developments go beyond the “magic particulate bullet”
concept.38 Nanomedicine could involve the design of new
scaﬀolds and surfaces for engineering sensors or implantable
systems and electronics to aid in the regeneration of tissues
(i.e., regenerative medicine). Many of these concepts are still at
the early stages of development, but some have already reached
clinical practice.
This Nano Focus article is organized into four subsections
that are focused on speciﬁc applications of materials or systems
with nanoscale properties: (a) in vivo diagnostics, (b) in vitro
diagnostics, (c) in vivo therapeutics, and (d) implantable
nanomaterials.
IN VIVO DIAGNOSIS (“SMART IMAGING”)
A key focus in nanomedicine involves the use of nanomaterials as
contrast agents for anatomical and functional imaging. Using
nanomaterials as contrast agents enables visualization of struc-
tures inside the human body and helps clinicians to delineate
healthy from diseased tissues and to recommend proper treat-
ment. Nanoparticles can be engineered with diﬀerent contrast
properties. The most common modalities are computed
tomography (CT); magnetic resonance imaging (MRI); imaging
of radioactivity, such as positron emission tomography (PET)
or single photon emission computed tomography (SPECT);
ﬂuorescence imaging; and photoacoustic imaging. For all these
techniques, material development is crucial because the NPs are
contrast agents that enable visualization of biological tissues.
For this application, NPs can be engineered to localize in speciﬁc
tissues and potentially produce high contrast.
Computed Tomography. X-ray-based imaging enables
high-resolution anatomical and, in the case of CT also three-
dimensional (3D), imaging of mostly skeletal tissues at unlimited
depth in human applications. Computed tomography imaging is
the work-horse in clinical diagnostics due to the simplicity of
the technique, the comparable low demands on infrastructure,
the rapid image generating, and the low costs for a standard
examination.
In recent years, around 250 out of every 1000 people in the
United States underwent CT imaging.39 Classical X-ray imaging
harnesses the tissue-speciﬁc attenuation of X-ray energy to
generate contrast in the recorded radiographs. Therefore, bones
generate more contrast than soft tissue because of the larger
relative electron density of bone. In order to boost the low
contrast of soft tissue, contrast agents with elements such as
iodine and barium characterized by a high-electron density are
typically applied to visualize blood vessels in gastrointestinal
(GI) tract, tumors, and other soft tissues. In contrast to typical
functional imaging techniques such as PET and SPECT, in CT,
the photons/X-rays are produced outside the body and only
modulated by the tissues through which they travel. Thus, the
large photon ﬂux enables a high signal-to-noise ratio, leading CT
to outperform other 3D imaging techniques in terms of spatial
A key focus in nanomedicine involves
the use of nanomaterials as contrast
agents for anatomical and functional
imaging.
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resolution. However, the weak interaction between tissue and the
incident X-ray beam results in comparably limited sensitivity of
CT, which might explain why speciﬁcally targeting contrast
strategies are virtually non-existent.
This poor sensitivity has encouraged nanomedicine research-
ers to develop nanoparticles as contrast agents for X-ray imaging.
Gold nanoparticles (AuNPs) are central to this development.
Due to its high atomic number and electron density (79 and
19.32 g/cm3, respectively, versus the typical X-ray contrast agent,
iodine, with values of 53 and 4.9 g/cm3, respectively), AuNPs
have higher attenuation coeﬃcients and can be used as contrast
agents for X-ray imaging, CT, and micro-CT.40 The AuNPs are
typically coated with targeting molecules such as folic acid so that
they can highlight distinct tissue structures. Gold nanoclusters
(NCs), which are smaller structures than AuNPs, are also being
developed as CT contrast agents.18,40 Folic-acid-conjugated
AuNCs with silica shells were demonstrated to exhibit good
biocompatibility and could actively target the folic acid receptor
(+) in vitro of MGC-803 cells and in vivo gastric cancer tissues
with 5 mm diameter in nude mice models. The researchers
showed that the use of NCs exhibited excellent contrast for
CT imaging. In addition to CT imaging, these NCs can also be
used for molecular imaging since red ﬂuorescence emission
was observed.41,42 These NCs also penetrated the tumor and
were retained, but their small size enabled them to be cleared
renally.41,42 Thus, these NPs are promising candidates for future
clinical use.
Besides gold, NPs composed of other materials with a high
atomic number are also suited for CT. One example is NaGdF4-
based UCNPs. Besides providing contrast for CT, these NPs can
be imaged optically (see Figure 1). In addition to their ability
to provide contrast for CT, potential toxicity of NPs plays an
important role toward translation to clinics (vide inf ra).
In parallel to the development of new CT contrast agents,
there has also been progress in instrumentation relating to the
preparation and detection of the agents. Novel X-ray sources
such as synchrotrons provide tremendously more ﬂux and a
higher degree of coherence and therefore enable the exploitation
of the wave nature of X-rays for imaging purposes. These novel
X-ray sources have led to new applications like phase contrast
CT, diﬀraction enhanced imaging, and holotomography, to
name a few.44−46 For example, phase contrast CT provides
10−200 times more contrast in soft tissue applications than
classical absorption-based CT.47,48 This gain in contrast directly
translates into an increase in sensitivity. By coupling this
increased sensitivity with the use of target-speciﬁc contrast
agents, submicrometer-scale 3D spatial resolution can be
achieved. This technique can be applied to gather structural
Figure 1. (I) In vitro CT images of (a) lanthanide-doped NaGdF4 upconversion “nanoclusters” (<5 nm) suspended in aqueous solution. (b) CT
attenuation plot (given in Hounsﬁeld units, HU) of NaGdF4 NPs in dependence of the concentration of each sample from 0.2 to 10 mg/mL to
further investigate the CT contrast eﬀect. (II) Images of a control group before injection of NPs: (c) photograph of a nude mouse loaded with
gastric cancerMGC-803 cells; (d) X-ray image, and (e−g) CT images of nudemice from the control group. (III) (h−k)CT images and (IV) (l−n)
MRI images of mice after intravenous injection with NaGdF4 UCNPs, making use of passive targeting (EPR eﬀect). The pulse sequence:
electromagnetic conversion (EC) = 1/141.7 kHz; repetition time (TR time) = 2000; echo time (TE time) = 65.6/Ef (echo frequency).
Parameters of transverse plane: the pulse sequence, EC = 1/141.7 kHz; TR time = 2000; TE time = 43.8/Ef. It took about 6 h to acquire one
image. The relaxivity value of NaGdF4UCNPs at 1.5 T is about 4.5mMs
−1. Adapted with permission from ref 43. Copyright 2015 Royal Society of
Chemistry.
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information indicative of asthma within the lung of a mouse.49
It can also be applied in the visualization of macrophages loaded
with barium sulfate after intracheal instillation.49 In a study by
Dullin et al., the researchers achieved 9 μm resolution, which
enabled the visualization of macrophage function within the
local 3D environment.46 The spatial resolution could be further
improved to 400 nm by using holotomography (see Figure 2).50
TheNP-based CT imaging technologies can potentially change
the way we perform CT-based clinical diagnosis.51 Currently, soft
tissue imaging via CT requires a large dose of iodine- or barium-
containing contrast agents to overcome poor sensitivity. How-
ever, the high dose may not be well tolerated by patients.
Furthermore, it is diﬃcult to design traditional contrast
agents to target speciﬁcally and to bind to cellular biomarkers
or accumulate in tissues of interest such as sites of inﬂammation or
primary tumors and metastasis. Combining targeted AuNPs
with the recent development of energy-resolved detectors,52 the
discrimination of a multitude of diﬀerent materials in a single
CT scan should be possible in the near future. Therefore, the
challenge facing the ﬁeld is to design and to engineer small
NP probes of high-atomic-number materials like iodine, gold, or
barium, conjugated to targeting moieties that speciﬁcally label
certain cell types in vivo, similar to probes used in optical imaging.
Moreover, since novel CT techniques do not focus on X-ray
attenuation but on phase shift or scattering as sources of contrast,
other types of NPs like hollow spheres53 or NPs with X-ray
scattering properties will become increasingly important. Despite
the negative eﬀects of the applied X-ray dose, CT is the most
applied technique in clinical diagnosis (e.g., ∼50% of imaging-
based diagnostics performed in Germany in 2013 were by CT).54
Improved detectors and the implementation of novel algorithms,
especially newly developed reconstruction techniques, have
already dramatically lowered X-ray doses.55 Techniques like
limited angle reconstruction and zoom tomography will further
aid in this development.50,56
Magnetic Resonance Imaging. Magnetic resonance
imaging is widely used for in vivo applications, due to its safety,
spatial resolution, soft tissue contrast, clinical relevance, and
ability to record anatomical and functional information about
soft tissues and organs. Notably, MRI-responsive contrast
agents provide physiological information that complements
routine anatomical images. Since the technology is based on the
interaction of nuclei with surrounding molecules in a magnetic
ﬁeld, MRI has no need for ionizing radiation and possesses
unlimited depth of penetration and unparalleled soft tissue
contrast.57 However, MRI has relatively poor sensitivity in
comparison to nuclear and optical modalities, thus leading to
longer acquisition time and use of large amounts of contrast
agents. Although the introduction of higher magnetic ﬁelds
(higher than 4.7 T) could increase the signal-to-noise ratio,
thereby permitting higher resolution and faster scanning, the
safety of high static magnetic ﬁeld strengths on human health is
of great concern.58,59 The development of hyperpolarized MRI
(i.e., polarization of the nuclear magnetic moments far beyond
thermal equilibrium conditions)60 has improved the sensitivity of
the desired nuclei and enables quantitative in vivo imaging and
real-time metabolic proﬁling using stable isotope precursors.60
Current contrast agents such as paramagnetic agents or SPIONs
play important roles in enhancing contrast in T1 or T2 images,
which provide higher MRI sensitivity and accuracy for imaging
living subjects. These agents accelerate the rate of T1 and T2
relaxation, thereby enhancing local contrast.61 Paramagnetic
agents (e.g., gadolinium-based agents) principally accelerate
longitudinal T1 recovery, generating positive contrast, while
superparamagnetic agents (e.g., iron oxide-based agents such as
SPIONs) primarily increase the rate of dephasing or transverse
T2 decay, resulting in negative contrast eﬀects.
61 However, both
types of agents have been associated with toxic eﬀects, which
needs to be taken into account for their use on humans and in
veterinary medicine (vide inf ra).62,63
Conventional T1 contrast agents such as paramagnetic com-
plexes (based on Gd3+, Mn2+, or Fe3+) are small molecules
that leave the vascular system within minutes and are renally
cleared. The short circulation time makes it diﬃcult to
acquire a high-resolution image of desired sites. Biocompatible
NP-based T1 contrast agents have been developed because they
have a number of advantages over conventional T1 contrast.
64,65
Researchers can tailor the size, shape, and composition; circula-
tion time; target cells and tissues; and optical and physical
properties to meet the biological requirements for optimizing
imaging. For example, Gd(III)−nanodiamond conjugates
enable contrast enhancement with a much smaller amount of
Gd compared to other agents used.66 For example, melanin has
been intensively studied as a target for melanoma imaging and
was recently a major focus for designing a multimodal imaging
nanoplatform. Melanin NPs with diameters of 4.5 nm not
only retain their unique optical properties but also have natural
binding capability with various metal ions. After chelation with
Fe3+ ions and subsequent conjugation with cyclic arginine-
glycine-aspartic acid (RGD) molecules, melanin NPs serve as T1
contrast agents for targeted MRI of U87MG glioblastoma.67,68
In another example, a noncytotoxic asymmetrical cancer-
targeting polymer vesicle based on R-poly(L-glutamic acid)-
block-poly(ε-caprolactone) [R is folic acid or diethylenetriami-
nepentacetatic acid (DTPA)], as shown in Figure 3, was reported
as a T1 MRI contrast agent with enhanced sensitivity, and it also
served as a delivery vehicle for cancer chemotherapy.69 Such
asymmetrical vesicles have a cancer-targeting outer corona
Figure 2. Three-dimensional localization of labeled macrophages
in a 500 μm thick lung section of a healthy mouse, scanned by
holotomography. Three orthogonally oriented slices are shown,
together with automatically labeled barium clusters (green),
representing macrophages loaded with barium sulfate and alveolar
walls in a small region of interest (ROI, yellow). A part of a blood
vessel has been marked semi automatically (purple). Adapted with
permission from ref 50. Copyright 2015 Nature Publishing Group.
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coupled with a Gd(III)-chelating and drug-loading-enhancing
inner corona. Liu and colleagues demonstrated that such vesicles
exhibited an extremely high T1 relaxivity (42.39 mM
−1 s−1, 8-fold
better than that of DTPA-Gd) and anticancer drug loading
eﬃciency (52.6% for doxorubicin hydrochloride, DOX·HCl).69
Moreover, the DOX-loaded vesicles exhibited 2-fold better
antitumor activity than free DOX.69
As T2 contrast agents, SPIONs establish a substantial locally
perturbed dipolar ﬁeld to shorten proton relaxation of the
surrounding tissues signiﬁcantly. The magnetism of NPs under
normal magnetic ﬁeld strengths is dependent on the magneto-
crystalline anisotropy and the size of the NPs. In comparison to
their spherical counterparts, for example, iron oxide NPs with an
octapod shape exhibit an ultrahigh transverse relaxivity value, and
dramatically increase the sensitivity of MRI for early stage cancer
detection, largely due to their eﬀective radius and the local ﬁeld
inhomogeneity of the magnetic core.70 Because of the negative
contrast eﬀect and magnetic susceptibility artifacts, it is still a
major challenge to distinguish the region of signals induced by
iron oxide NPs from low-level background magnetic resonance
(MR) signals originating from adjacent tissues such as bone,
vasculature, calciﬁcation, fat, hemorrhage, blood clots, etc.
As a combination of paramagnetic and SPIONs, e.g., in core/
shell structures,71 dual-mode T1/T2 contrast agents have
been developed for dual T1 and T2 mode MRI because they
help validate reconstruction and visualization of the data in
an accurate and reliable way. However, interference inevitably
occurs when both T1 and T2 contrast agents are integrated into
a single nanostructure in close proximity. The magnetic ﬁeld
induced by the T2 contrast material perturbs the relaxa-
tion process of paramagnetic T1 contrast materials, leading to
undesirable quenching of the T1 signal. Core/shell structures
can eﬃciently reduce their magnetic coupling by introducing
a separating layer between the superparamagnetic core and
paramagnetic shell. Such magnetically decoupled dual-mode
T1/T2 contrast agents not only provide superior MR contrast
eﬀects in both modes, but also enable self-conﬁrmation of
images and essentially function as an “AND logic gate” to reduce
susceptibility artifacts from the raw images to enhance accuracy
of the MRI.72,73 In contrast to core/shell structures, dumbbell
hybrid nanostructures combine T1 and T2 contrast agents
together in a nanocomposite via a bridge NP, which spatially
separates two contrast agents at a certain distance to reduce
their magnetic coupling.74 Unlike core/shell structures where
T2 contrast agents are sequestered within a supporting matrix,
dumbbell nanostructures allow both T1 and T2 contrast agents to
be exposed to their immediate environment without compro-
mising their magnetic properties. Moreover, both surfaces of
T1 and T2 contrast agents are available for subsequent surface
coating for targeting molecular imaging.
Besides being “mere” contrast agents for MRI,75,76 activatable
or “smart” NPs can respond to a change in tumor microenviron-
ment to instigate the therapeutic and diagnostic mechanism.77,78
The most common triggers for activatable NPs are stimuli
such as pH, temperature, redox reactions,79 metabolites, ions,
proteases, ultrasound, and light.80 The tumor microenvironment
regulates tumor progression and the spread of cancer in the body.
Responsive agents capable of reporting diagnostically relevant
physicochemical properties of the microenvironment in which
the contrast agent distributes have gained tremendous attention.
Various nanocarriers have been tested in combination with a
myriad of imaging contrast agents, payload drugs, and targeting
moieties, leading to the formulation of theranostic NPs capable
of delivering therapy concomitant with diagnosis. In the case of
MRI, diﬀerent “smart” NP probes have been demonstrated.
The design of pH-responsive probes is of great interest, since it is
an important physiological parameter and pH dysregulation
can be a cancer marker. Gao and colleagues reported a smart
pH-activatable 19F-probe for detecting speciﬁc and narrow pH
transitions ranging from 5.5 to 7.4 in biological systems.81 They
developed micelles composed of ﬂuorinated polymers with
tertiary amines having diﬀerent pKa values. The protonation of
such amines at pH below their pKa results in micelle disassembly
and 19F-MRI/nuclear magnetic resonance spectroscopy (NMR)
signal activation. They were able to determine the pH through
the identiﬁcation of the corresponding activated 19F-reporter. In
another related example, hypoxia in the tumor microenviron-
ment results in lactic acid production and, hence, acidic
conditions. Zhou and colleagues fabricated pH-triggered NPs
for 19F-MRI and ﬂuorescence imaging (MRI-FI) of cancer
cells.82 19F was attached to AuNPs by acid-labile hydrazone
linkers. Fluorescence imaging revealed highly selective uptake of
these NPs by lung cancer cells. The “trick” to these NPs involves
selective release of 19F-MRI contrast agent after the NPs have
reached the tumor environment. In the acidic intracellular
compartments of cancer cells the 19F detached from the AuNPs
and appreciably enhances the intracellular 19F-MRI signal, as
shown in Figure 4.
Temperature diﬀerences between tissues is a common feature
in pathological conditions, especially in tumors. Thus, a second
class of “smart”NP probes for MRI uses hypersensitive detection
of temperature changes in diﬀerent tissues.83 Langereis and
colleagues84 reported a combined temperature-sensitive lip-
osomal 1H chemical exchange saturation transfer (CEST)85
and 19F magnetic resonance (MR) contrast agent as a potential
carrier system for MRI-guided drug delivery. The liposomes
contain both a chemical shift agent as well as a highly ﬂuorinated
compound. Upon reaching the melting temperature of the
agents’ lipid membrane, the lipo-CEST contrast enhancement
vanishes, due to the release of the chemical shift agent.
Simultaneously, the 19F-MRI probe is freed from the inﬂuence
of the paramagnetic shift agent causing an appearance of a
19F-MRI signal. The combined CEST and 19F-MR temperature-
sensitive liposomal carrier provides CEST-based contrast
enhancement, which can be switched on and oﬀ, to localize the
liposomes before release, while the 19F-MR signal can potentially
quantify local drug release of drugs with MRI.
Redox reactions play crucial roles in biological processes, and
abnormal redox reactions are implicated in various conditions
including liver damage and human immunodeﬁciency virus
(HIV). A third class of “smart” NP probes for MRI uses redox
Figure 3. Illustration of multifunctional asymmetrical polymer
vesicles for ultrasensitive T1 MRI and eﬀective cancer targeted
drug delivery. Adapted from ref 69. Copyright 2015 American
Chemical Society.
ACS Nano Nano Focus
DOI: 10.1021/acsnano.6b06040
ACS Nano 2017, 11, 2313−2381
2319
reactions in the tumor microenvironment for cleavage of atoms
from the NP structure. Kikuchi and co-workers designed redox
activatable NPs to image reducing environments.86 Gd3+
complexes were attached to the surface of 19F containing NPs
by disulﬁde linkers. Vicinity of the Gd3+ to 19F reduces the
transveral relaxation time T2 of the ﬂuorine compounds by the
paramagnetic relaxation enhancement eﬀect, which attenuates
the 19F NMR/MRI signal (see Figure 5). When the disulﬁde
bonds enabling attachment of Gd3+ are reduced, the Gd3+
complexes are cleaved from the NP surface. Then, the T2
NMR/MRI signal of the encapsulated 19F compounds increases,
indicating the presence of the NPs in redox active environment.
Imaging Radiolabels. There has been rapid progress in
the development of NP-based radiolabels.87 Chelators such as
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
and 1,4,7-triazacyclononane-1,4,7-trisacetic acid are commonly
used to label diagnostic positron emitters, e.g., 68Ga or 64Cu, or
therapeutic beta-emitters, e.g., 177Lu or 90Y. The sequential use
of diﬀerent poly(ethylene glycol) (PEG) -coated emitters, e.g.,
68Ga and 177Lu enable multiplexed labeling, as well as improved
circulation time. For this purpose, micelle encapsulation was
introduced for combining a mixture of amphiphiles comprising
chelators bearing the radiolabels, ligands for targeting, and PEG
for surface passivation with originally hydrophobic NPs.88 The
same method could successfully be applied for diﬀerent types of
NPs, such as SPIONs, plasmonic NPs, and core/shell UCNPs.
Sometimes the NPs can be labeled postsynthetically without the
use of chelators for radiometals.89 The resulting radiolabeled NPs
enable researchers to trace their biodistribution when adminis-
tered systemically, and to study fundamental NP in vivo process
(e.g., determining the contribution of active versus passive tumor
targeting in mouse models).90
In fact, radiolabels are particularly suited for quantitative
biodistribution studies. γ-emission is barely absorbed by tissue,
and radioactivity is independent of the probe’s local environ-
ment, i.e., there are no substantial quenching eﬀects such as in the
case of ﬂuorophores, which often exhibit pH-dependent
emission. Using radiolabels produces excellent signals and, there-
fore, a low dose can yield suﬃcient image quality to make a
diagnostic interpretation. One additional advantage is the ability
for multiplexed read-out of radiolabels with diﬀerent γ-emission
energies in parallel. This has been recently used for recording the
biodistribution of several compounds of NPs independently.37
Most NPs are hybrid structures composed of their functional part
(i.e., contrast for imaging) and an organic surface coating that
provides colloidal stability and targeting capability, as well as the
corona of adsorbed proteins.91,92 By adding radiolabels of
diﬀerent energies to diﬀerent parts of the NPs, the NPs could
disintegrate after in vivo administration, i.e., the organic surface
capping may come oﬀ the functional particle core.37 Such studies
in the future will enable imaging of the diﬀerent NP components
to elucidate the fate of the diﬀerent parts of the NP. This will be
important for understanding the biodegradability of all diﬀerent
parts of a NP and their elimination. This is decisive for guiding
the design of NPs for use in in vivo delivery applications. How-
ever, when diﬀerent labeling methods and radioisotopes are used
to label NPs to study their fate, it is crucial to ensure that the
radioisotopes are incorporated onto the NPs with little impact on
their original biological behavior.
Fluorescence Imaging. Fluorescence is a useful imaging
modality because the emission of the probes after excitation can
be visualized by the naked eye or at higher resolution with optical
microscopy. There is an abundance of available ﬂuorophores that
can be tailored to speciﬁc applications. Many traditional organic
ﬂuorophores suﬀer from aggregation-caused quenching (ACQ),
thereby limiting design schemes where speciﬁc interactions
promote ﬂuorophore localization. This has forced researchers to
use dilute solutions (often at the nanomole level) of ﬂuoro-
phores. Given the minuscule amount of ﬂuorophore, they can be
easily photobleached, which imposes a limit on the achievable
contrast. Contrary to ACQ, aggregation-induced emission (AIE)
is where increased aggregation yields a stronger ﬂuorescent
signal.93 This makes AIE ﬂuorogens (AIEgens) good candidates
for bioimaging applications.94 The accumulation of AIEgens at
regions of interest results in the formation of nanoaggregates
(AIE dots), which intensiﬁes the ﬂuorescence signal. The AIE
dots are resistant to photobleaching, enabling high-quality bio-
imaging over a wide time window. They are suitable for long-
term tracking of theranostic processes such as tumor-metastasis
Figure 4. (A) Synthesis of AuNPs capped with folic acid and 19F
contrast agent. Folic acid with a high tumor aﬃnity due to the
overexpression of its receptors on the cancer cells was conjugated
onto the surface of the AuNPs. 19F contrast agent was covalently
conjugated onto the AuNPs via acid-labile hydrazone linkers.
(B) pH-triggered release of the 19F contrast agent from the AuNPs
to the cytosol via the selective removal of the pH-labile cap in the
acidic intracellular compartments of cancer cells. Adapted with
permission from ref 82. Copyright 2014 Royal Society of Chemistry.
Figure 5. Design of redox activatable NPs. Adapted with permission
from ref 86. Copyright 2015 Wiley-VCH Verlag GmbH & Co.
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monitoring, drug delivery/release, and stem-cell therapy.95
Organic AIE dots enjoy almost all advantages of inorganic
QDs,96,97 yet are free of the disadvantages of the latter (e.g.,
cytotoxicity98,99). In addition, AIE molecules and nanoaggre-
gates can be decorated by functional groups with binding
speciﬁcity to particular receptors that enables active target-
ing.94,96,97 Integration of an RGD unit with the AIEgen structure,
for example, has generated integrin-speciﬁc ﬂuorescence turn-on
bioprobes for tumor cell targeting, image-guided drug delivery,
in situ monitoring of therapeutic eﬀect, etc.100,101
Two decades ago, ﬂuorescent semiconductor QDs were
introduced for the ﬂuorescent labeling of biological molecules
and cells.102,103 Due to their narrow emission bands, QDs are
suited for multiplexed read-out, as detailed below.104,105
Semiconductor QDs are also bright and show reduced
photobleaching, which makes them suitable for long-term
imaging at the single-molecule level.106−108 However, semi-
conductor QDs can be cytotoxic toward cells due to the release
of metal ions98,99 and many researchers take this fact
into consideration in designing QDs for their long-term
imaging studies.109−111 For example, CdSe QDs can be coated
with ZnS polymer shells or SiO2 layers to suppress the
dissolution of possibly toxic semiconductor core materials.99
Details about the mechanism for potential toxicity are still under
discussion.
Rare earth (RE)-based nanophosphors, which consist of a
host inorganic matrix doped with luminescent lanthanide (Ln)
cations, constitute another type of luminescent materials. Their
main advantages are their low toxicity, high photostability, high
thermal and chemical stability, high luminescence quantum yield,
and sharp emission bands.112 However, they normally show low
luminescence intensity, which is caused by the low absorption
of the parity-forbidden Ln3+ 4f−4f transitions.113 The optical
properties of such NPs can be further modiﬁed by doping,
as shown recently in the case of Eu3+, Bi3+ codoped REVO4
(RE = Y, Gd) NPs. Intense red luminescence was achieved by
using indirect excitation of the Eu3+ cations via the vanadate
anions. The incorporation of Bi3+ into the REVO4 structure
resulted in a shift of the original absorption band corresponding
to the vanadate toward longer wavelengths, yielding nano-
phosphors excitable by near-ultraviolet and visible light.114
Carbon dots are another class of ﬂuorescent NPs. Carbon dots
are zero-dimensional carbon nanomaterials and possess the
advantageous characteristics of QDs over organic ﬂuorophores,
such as high photostability, tunable emission, and large two-
photon excitation cross sections.11Moreover, C-dot ﬂuorescence
does not blink. They are water-soluble, can be functionalized, can
be produced economically, and have excellent cell permeability
and biocompatibility, making them attractive for intracellular
sensing.11,115,116 Also, C-dots without heavy metal content are
environmentally friendly and can be much safer for biological
applications than traditional Cd-containing QDs.11,115,116 In a
recent study, C-dots were subjected to a systematic safety evalua-
tion involving acute toxicity, subacute toxicity, and genotoxicity
experiments (including a mouse bone marrow micronuclear test
and a Salmonella typhimurium mutagenicity test).117 Carbon dot
dosages of 51 mg/kg weight body showed no signiﬁcant toxic
eﬀects, i.e., no abnormality or lesions, and no genotoxicity in the
organs of the animals.
Nanodiamonds, another group of carbon NPs, are receiving
growing interest for drug delivery and other biomedical
applications because they have good biocompatibility.118 Intra-
venously administered ND complexes at high dosages did
not change serum indicators of liver and systemic toxicity.119
Nanodiamond powder produced by detonation (5−6 nm, see
Figure 6) or other methods (20−50 nm) are readily available in
commercial quantities at moderate cost and are among the most
promising carbon nanomaterials for drug delivery, imaging, and
theranostic applications. Fluorescence of NDs due to nitrogen-
vacancy (NV) centers (see Figure 6) that are composed of a
substitutional nitrogen and a next neighbor vacancy enables
biomedical imaging.120,121 Fluorescent NPs can also be produced
by linking or adsorbing various ﬂuorophores onto NDs. For
example, bright blue ﬂuorescent NDs were produced via covalent
linking of octadecylamine to carboxylic groups on theND surface
(ND-ODA).122 In biomedical imaging, ﬂuorescent NDs com-
bine the advantages of semiconductor QDs (small NP size, high
photostability, and bright multicolor ﬂuorescence) with biocom-
patibility, lack of toxicity, and tunable surface chemistry. Therefore,
they are promising for in vivo imaging. Since the sizes of ND
particles can be smaller than 5 nm NPs, they can be removed by
renal excretion without leaving any toxic residue in the body.123,124
Figure 6. (A) Schematic model of a 5 nm ND with a ﬂuorescent NV center and a variety of surface terminations after oxidative puriﬁcation is
shown. The diamond core is covered by a layer of surface functional groups that stabilize the NP by terminating its dangling bonds. The surface
can also be stabilized by the conversion of sp3 carbon to sp2 carbon. Adapted with permission from ref 118. Copyright 2012 Nature Publishing
Group. (B) Plot showing the strength of binding (KL) versus the monolayer capacity (Amax) based on a Langmuir model for DOX, polymyxin B,
tetracycline, and vancomycin adsorbed on detonation-produced ND from two sources (ZH and ND) with diﬀerent surface chemistries: the
as-received surface, like in the right picture, carboxylated (−COOH) and aminated (−NH2) surfaces. Adapted with permission from
refs 125 and 126. Copyright 2016 Elsevier and copyright 2013 American Chemical Society, respectively.
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Besides using ﬂuorescent NPs as contrast labels for imaging,
“smart” ﬂuorophores that change their ﬂuorescence signal
depending on the local environment can be designed. By
integrating pH-sensitive ﬂuorophores on the surfaces of NPs,
information about their local environment can be gained, for
example, whether they are located extracellularly in neutral
pH or intracellularly inside acidic endosomes/lysosomes.127,128
By combining analyte-sensitive ﬂuorophores with NPs, the
concentrations of diﬀerent analytes in the vicinity of the NPs can
be determined.129,130
Fluorescent NPs based on AIE oﬀer another concept in this
direction. The AIE process has been utilized to develop light-up
biosensors. Cell apoptosis, for example, has been followed in
real time by making use of the AIE process (see Figure 7).131
Tetraphenylethene (TPE), an archetypical AIEgen, has been
functionalized by a short oligopeptide (DEVDK) through
click chemistry, aﬀording DEVDK-TPE, a peptide−AIEgen
adduct. DEVDK-TPE is soluble in aqueous buﬀers and hence
emits no ﬂuorescence (i.e., no residual emission). It remains
nonﬂuorescent in intracellular media after cells internalize it.
During apoptosis, caspase enzyme cleaves the DEVD segment.
The residual segment (K-TPE) is not hydrophilic enough to
be dissolved in aqueous media and thus forms intracellular
nanoaggregates. The aggregate formation turns on the ﬂuo-
rescence of TPE, which is gradually intensiﬁed with the progress of
apoptosis. This enables real-time and in situ monitoring of the
biological process of programmed cell death.131
For cellular and in vivo cancer imaging, Nie, Gao, and their
co-workers have developed a class of activatable NPs based on
the use of copolymer materials with ionizable tertiary amine
groups and covalently conjugated ﬂuorescence dyes.132,133 The
self-assembled NP structures undergo a dramatic and sharp
transition within a narrow range of pH (often less than 0.2 pH
units). This pH-induced transition leads to rapid and complete
dissociation of the nanomicelles. As a result, the covalently linked
dyes change from a self-quenched “oﬀ” state to a highly emissive
bright “on” state. This supersensitive and nonlinear response
to external pH enables targeting acidic organelles in cancer cells
as well as the acidic microenvironment in solid tumors. This
feature is important in addressing the tumor heterogeneity
problem, which is a major challenge for various imaging and
therapeutic approaches based onmolecular or receptor targeting.
By targeting the common “hallmarks” of tumors (i.e., the
acidic habitat or microenvironment and the growth of new
blood vessels or angiogenesis), this work has opened exciting
opportunities in detecting and potentially treating a broad range
of human solid tumors. This approach leads to improved
detection sensitivity because each NP contains multiple dye
molecules, which are turned on (restored to ﬂuorescence) in an
all-or-none fashion, leading to ampliﬁed ﬂuorescence signals that
are many times brighter than those of single dye molecules.
LABORATORY-BASED DIAGNOSIS
(“HIGH-THROUGHPUT SCREENING”)
Nanoparticles can also be used for detection of molecules,
cells, and tissues outside the human body. In this diagnostic
application, the function of the NP is to identify unique bio-
logical molecules in biological ﬂuids that are associated
with the health of the patient. The NPs act as transducers
and are coated with ligands to enable the biorecognition of
unique biological molecules in the ﬂuid in the in vitro sensing
applications. For example, AuNPs have been modiﬁed with
ligands that speciﬁcally bind to a complementary protein.
The presence of these proteins induces the cross-linking of the
NPs (i.e., agglutination). This controlled agglomeration can
be observed colometrically by the change of color of the NP
solution.134,135 These concepts have been later reﬁned, for
example in rapid colorimetric DNA sensing.136,137 This AuNP-
based diagnostic technology has advanced to testing of patient
samples and is now used in the clinic.138 Nanotechnology
presents an opportunity to improve the overall diagnostic process
by lowering the limit of detection, thus enabling high throughput
and multiplexed detections of biological targets with high
sensitivity.
Screening Based on Fluorescence Read-Out. Quantum
dots are frequently used as ﬂuorescence labels in proteins or
nucleic acid assays. One example in this direction is a QD-based
ﬂuorescence polarization assay for screening of antigen surface
epitopes.139 In this example, a method for quickly screening
and identifying dominant B cell epitopes was developed using
hepatitis B virus (HBV) surface antigen as a target. Eleven amino
acid fragments from the HBV surface antigen were synthesized
by 9-ﬂuorenylmethoxy carbonyl solid-phase peptide synthesis
strategy, and then CdTe QDs were used to label the N-terminals
Figure 7. Diagrammatic illustration of the real-time monitoring of cell apoptosis process by DEVDK-TPE, an AIE-active ﬂuorescent bioprobe.
Adapted from ref 131. Copyright 2012 American Chemical Society.
Nanoparticles can also be used for
molecular detection of molecules, cells,
and tissues outside the human body.
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of all peptides. After optimizing the factors for this ﬂuorescence
polarization (FP) immunoassay, the antigenicities of synthetic
peptides were determined by analyzing the recognition and
combination of peptides and standard antibody samples. The
results of the FP assays conﬁrmed that 10 of the 11 synthetic
peptides had distinct antigenicities. In order to screen dominant
antigenic peptides, the FP assays were carried out to investigate
the antibodies against the 10 synthetic peptides of the HBV
surface antigen in 159 samples of anti-HBV surface antigen-
positive antiserum. The results showed that 3 of the 10 antigenic
peptides might be immunodominant, because the antibodies
against them existed more widely among the samples and their
antibody titers were higher than those of other peptides. Using
three dominant antigenic peptides, 293 serum samples were
detected for HBV infection by the FP assays. The results showed
that the antibody-positive ratio was 51.9%, and the sensitivity
and speciﬁcity were 84.3% and 98.2%, respectively. This
QD-based FP assay is a simple, rapid, and convenient method
for determining immunodominant antigenic peptides and has
potential in applications such as epitope mapping, vaccine
designing, or clinical disease diagnosis.
Another application of QDs is multiplexed detection, as
described by Nie and co-workers. Quantum dots have been
incorporated into microbeads to generate barcodes, where
unique optical emission for each bead can be generated by
diﬀerent amounts and sizes of QDs.140 Fluorescent QDs are ideal
optical coders, because they have narrow ﬂuorescence line
widths, size- and shape-tunable emission, photostability, and all
ﬂuorescence emission can be excited with a single wavelength.
Thus, barcodes can be designed with high coding precision,
cost-eﬀective instrumentation can be used by simplifying the
optical components and excitation source for read out, and,
ﬁnally, it has been suggested that over 1 million unique barcodes
can be generated using diﬀerent emitting QDs and intensities.
There are several methods to prepare QD barcodes: (a) the
“swelling” technique, where polystyrene beads are mixed in a
solvent to enable beads to increase in volume, which allows the
diﬀusion of hydrophobic QDs into the outermost layer,140
(b) layer-by-layer (LbL) assembly of diﬀerent emitting QDs
onto the surface of the beads,141 (c) incorporation of QDs inside
a silica NP with a hydrophobic core,142,143 and (d) microﬂuidic
ﬂow focusing to incorporate QDs inside the microbeads.144−146
Each method of barcode preparation has a diﬀerent ﬂuorescence
signal stability. Some formulations tend to expose QDs to small
ions in the buﬀer, which leads to high read-out variability.147
Hence, careful selection of preparation method is required
for reproducibility in the biological assay. This optimization is
important for the use of barcodes in diagnosing patient samples
as outlined in the following examples.
To make use of barcodes for biological applications, the sur-
face of the barcodes typically needs to be coated with bio-
recognition molecules (e.g., oligonucleotides or antibodies).
Panels of diﬀerent, uniquely emitting barcodes can be designed
for detecting “sets” of diseases. For example, a mixture of ﬁve
unique emitting barcodes with three distinct target proteins has
been designed for diagnosing patients with HIV, hepatitis B, and
hepatitis C. The two other barcodes were used as positive and
negative controls. These ﬁve barcodes can be mixed with a
patient’s plasma and secondary probes. If the patient presents
the antigen that recognizes the antibody on the barcode surface
and the secondary probe, molecular assembly forms sandwich
complexes of barcode−patient antigen−secondary probes.
The overall optical signal of the barcode for positive detection
changes upon the assembly process, and can be distinguished
by using ﬂow cytometry148 or a smartphone camera.149 A
demonstration of the use of QD barcodes for diagnosing patient
samples was reported by Ming et al., who found that barcodes
could be used to detect the genetic targets of patients infected with
HIV and hepatitis B.149 Kim et al. described the clinical sensitivity
and speciﬁcity for QD barcode diagnostic analysis of hepatitis B to
be greater than 90%.150 This is a promising step for the clinical
translation of this technology. The QD barcode is an example of a
number of emerging nanotechnology-based diagnostic devices,
where multiplexing occurs by the design of the barcoding system
(e.g., Raman-based barcodes, graphic barcodes).151,152
Novel approaches in instrumentation have also been developed
to enable automation of barcode-based diagnostic assays. Micro-
ﬂuidic chips are an ideal platform for high-throughputmultiplexed
read-out. This approach has been demonstrated by coupling
microﬂuidics with traditional Western blots (WBs) in protein
identiﬁcation.153 Parallel microﬂuidic channels are designed to
incorporate the internal molecular weight marker, loading
control, and antibody titration in one protocol. Compared to
the conventional WB that detects only one protein, the micro-
ﬂuidicWB (μWB) can analyze at least 10 proteins simultaneously
from a single sample, while requiring only about 1%of the amount
of antibody used in conventional WB. For nucleic acid analyses,
microcapillary and loop-mediated isothermal ampliﬁcation are
incorporated (cLAMP) to achieve straightforward, robust,
multiplexed, and point-of-care testing (see Figure 8). The
cLAMP uses capillaries (glass or plastic) to introduce and to
house samples/reagents, segments of water droplets to prevent
contamination, pocket warmers to provide heat, and a hand-held
ﬂashlight for visual read-out of the ﬂuorescence signal. It enables
the simultaneous detection of two regions of the HIV genome
from multiple plasma samples. As few nucleic acid detection
methods can be wholly independent of external power supply and
equipment, the cLAMP holds great promise for point-of-care
applications in resource-poor settings.154 To enhance the
throughput for detection and to integrate the analysis of proteins
and nucleic acids into one protocol, barcode-based bioassays that
are capable of encoding and decoding are introduced. A single
barcoded microchip can carry out tens of individual protein/
nucleic acid assays (encode), and immediately yield all assay
results by a portable barcode reader or a smartphone (decode).
The applicability of barcoded microchips has been demonstrated
by HIV immunoassays for simultaneous detection of three targets
(anti-gp41 antibody, anti-gp120 antibody, and anti-gp36 anti-
body) from six human serum samples. However, the barcode-
based assay can also be applied for the simultaneous detection of
pathogen-speciﬁc oligonucleotides by a single chip containing
both positive and negative controls.155
Another multiplex detection technology that is gaining interest
is “chemical nose” sensors.156 Array-based “chemical nose”
sensors have been designed where individual spots are coated
with chemical agents to recognize speciﬁcmolecules in a complex
analyte mixture. These systems use selective recognition of
analytes, a complementary approach to traditional biomarker-
based strategies. Nanoparticle-based chemical noses have been
used for sensing of sera,157 cell-surface based discrimination
of bacteria,158 and genotyping of cancer cells.159 These systems
used separate recognition elements to generate the selectivity-
based pattern required for analyte identiﬁcation. Recently,
an alternative multiplexing strategy was used to create a high-
throughput multichannel sensor that was able to determine the
mechanism of chemotherapeutics within minutes,160 instead of
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the weeks required for traditional biochemical approaches
(see Figure 9). The multiplexed platform complexed a single
AuNP with three diﬀerent ﬂuorescent proteins (FPs) to detect
drug-induced physicochemical changes on cell surfaces.
This result demonstrates the ability of nanomaterials to sense
minute changes in cell surfaces rapidly, enabling high-throughput
screening. These systems are promising for a wide variety of
applications, including diagnostics for wound bioﬁlms.161
While in the above example, the ﬂuorophores were merely
used as passive labels, they can also be used for active sensing in
intracellular assays. The functionalization of luminescent NPs
and their incorporation into cells provide versatile means to
image cells. However, the design of functional NPs that quanti-
tatively respond to speciﬁc cellular biomarkers or intracellular
conditions remains challenging. Several recent reviews have
addressed advances in the application of luminescent NPs for
intracellular sensing.162−164 Quantum dots have been widely
applied as luminescent transducers for the development of
optical biosensors.165,166 Quantum dots can be functionalized
with moieties that alter their ﬂuorescence properties in response
to particular cellular conditions or cellular biomarkers. This
approach can be used to develop intracellular sensors. As an
example, core/shell CdSe/ZnS QDs were functionalized with a
dopamine-conjugated peptide monolayer to act as pH sensors
(see Figure 10A). Under aerobic conditions, the dopamine
ligands are oxidized to quinone units, which quench the transfer
of electrons. The quenching eﬃciency of the QDs is dependent
on the redox potential of quinone units, which, in turn, are
pH-dependent.167 By altering the pH, the quenching eﬃciency of
the QDs can be tuned.167 The ability of the QDs to respond to
intracellular pH changes was demonstrated experimentally by
Medintz et al.167 By subjecting COS-1 cells loaded with QDs to
extracellular nystatin, which induces pH changes in the cells, the
intracellular pH changes could be quantiﬁed using an in vitro-
derived calibration curve (see Figure 10B).
Similarly, cytochrome c functionalized CdSe/ZnS QDs can
be used for detection of the reactive oxygen species (ROS)
superoxide radical (O2
•−). The O2
•−-mediated reduction of
cytochrome c enhances the ﬂuorescence of QDs. The ability
of the QDs to respond to intracellular changes in O2
•− was
demonstrated experimentally by Li et al.168 By subjecting HeLa
and HL-7702 cells to phorbol myristate-induced generation of
O2
•−, the resulting ﬂuorescence could provide a quantitative
measure of the time-dependent concentration of O2
•− in the
cells.168
Quantum dots can also be applied for the detection of
dihydronicotinamide adenine dinucleotide (NADH).169 CdSe/
ZnS QDs were functionalized with a monolayer of Nile Blue
(NB+), which quenches the ﬂuorescence via an energy transfer
mechanism (see Figure 11A). Freeman et al. demonstrated
that NADH, a cofactor generated via the metabolic Krebs
cycle, induced reduction of NB+ to the colorless NBH reduced
state, which resulted in the recovery of QD ﬂuorescence (see
Figure 11B). The metabolism of HeLa cells can be inhibited
by anticancer drugs, e.g., taxol, which substantially lowers
the intracellular NADH concentration to yield low ﬂuorescence
Figure 8. Illustration of μWB and multiplexed cLAMP carried out in a variety of forms by means of microcapillaries. (A) Proteins are transferred
from a polyacrylamide gel to a polyvinylidene ﬂuoride (PVDF) membrane by electroblotting. (B) μWB chip is assembled by incorporating a
polydimethylsiloxane (PDMS) microﬂuidic network with the blotted PVDF membrane. Panels (A) and (B) adapted from ref 153. Copyright
2010 American Chemical Society. (C) Microﬂuidic channels are oriented perpendicular to the protein bands on the membrane. Antibodies for
speciﬁc proteins are introduced in parallel microﬂuidic channels. Adapted from ref 154. Copyright 2014 American Chemical Society.
ACS Nano Nano Focus
DOI: 10.1021/acsnano.6b06040
ACS Nano 2017, 11, 2313−2381
2324
Figure 9. Multichannel AuNP ﬂuorescent protein sensor, generating diﬀerent responses for drug-induced phenotypes. Clustering of the
mechanisms was performed using linear discriminant analysis, enabling identiﬁcation of new drugs as “known” or “novel”. Adapted from ref 160.
Copyright 2015 Nature Publishing Group.
Figure 10. (A) Dopamine-functionalized QDs for the photoluminescence (PL) sensing of pH via the pH-dependent oxidation of dopamine to the
quinone derivative, and the accompanying electron-transfer quenching of theQDs. (B)Diﬀerential interference contrast (DIC) and ﬂuorescence
confocal imaging of pH-changes in COS-1 cell subjected to internalized pH-responsive dopamine-functionalized QDs (ﬂuorescence at 550 nm)
and co-incorporated red ﬂuorescent Fluorophorex (FLX) 20 nm nanospheres acting as an internal strand, emitting at 680 nm. The calibration
curve corresponding to the intracellular ﬂuorescence changes derived from the confocal ﬂuorescence images is displayed at the bottom. Adapted
with permission from ref 167. Copyright 2010 Nature Publishing Group.
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(see Figure 11C). This latter example highlights the potential
use of intracellular QDs biosensors for drug screening
applications.169
The potential toxicity associated with the intracellular applica-
tion of QDs can be avoided by using alternatives such as C-dots.
Figure 12 illustrates the application of ﬂuorescein-modiﬁed
Figure 11. (A) Schematic analysis of NADH using NB+-functionalized CdSe/ZnS QDs. (B) Calibration curve corresponding to the ﬂuorescence
changes of the CdSe/ZnS QDs upon analyzing diﬀerent concentrations of NADH. (C) Time-dependent ﬂuorescence changes observed upon the
glucose (50 mM)-stimulated activation of the metabolism in HeLa cancer cells loaded with NB+-functionalized CdSe/ZnS QDs in (1) untreated
HeLa cells, (2) Taxol-treated HeLa cells. Inset: Time-dependent confocal microscopy images of a HeLa cell (without Taxol treatment) upon
triggering the metabolism with glucose 50 mM. Adapted with permission from ref 169. Copyright 2008 John Wiley & Sons, Inc.
Figure 12. (A) Schematic pH-stimulated ﬂuorescence changes of ﬂuorescein isothiocyanate (FITC)-functionalized C-dots. (B) Fluorescence
spectra of the FITC-modiﬁed C-dots at diﬀerent pH values. (C) Confocal microscopy images (ﬂuorescence, FL, and bright-ﬁeld BF) following
the spatial pH changes in L929 cells loaded with the FITC-modiﬁed C-dots. Adapted with permission from ref 170. Copyright 2013 IOP
Publishing.
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C-dots as optical transducers in the ﬂuorescence resonance
energy transfer (FRET)-based detection of intracellular pH.170
Carbon dots serve as the donor in the FRET pairing with
ﬂuorescein to provide a ratiometric detection of pH within a
region of pH = 4.0 to pH = 8.0 (Figure 12B). Similar experiments
have been performed with QDs modiﬁed with a pH-sensitive
ﬂuorophore,171 demonstrating that the concept of active pH
sensing can be carried out with a variety of diﬀerent NPmaterials.
Du et al.170 demonstrated the use of ﬂuorescein-functionalized
C-dots in monitoring temporal and spatial intracellular pH
changes in L929 cells using ﬂuorescence spectroscopy (see
Figure 12C).
In addition to the sensor mentioned above, several other
intracellular ﬂuorescent C-dot-based pH sensors have also
been reported.172,173 The quantiﬁcation of intracellular pH is
particularly interesting since abnormal pH values are often
associated with certain diseases such as cancer or Alzheimer’s
disease.174,175 Moreover, functionalized C-dots have been
modiﬁed for intracellular sensing of metal ions.176,177 For
example, quinoline-functionalized C-dots were applied to sense
Zn2+ ions in the intracellular environment (see Figure 13).177
Organic and inorganic polymer NPs have been implemented
as functional units for intracellular sensing applications. For
example, silica NPs have been widely used to transport ﬂuoro-
phores for the intracellular sensing of oxygen levels,178 pH,179 or
metal ions.180 In these systems, the ﬂuorophore embedded
within the SiO2 NPs responds selectively to the intracellular
analyte, thus providing an optical output in response to stimuli.
Often the combination of two ﬂuorophores, where only one
ﬂuorophore responds to the respective analyte, are integrated
with the NPs, to enable the ratiometric detection of the
analyte. For example, the pH-sensitive FITC and pH-insensitive
Ru(bpy)3
2+
ﬂuorophores were incorporated into SiO2 NPs. The
labeled NPs were then applied for sensing the drug-induced
lysosomal pH changes in murine macrophages stimulated by
chloroquine, and for the dexamethasone-induced acidiﬁcation in
apoptotic HeLa cells.181 A sense-and-treat SiO2 NPs system
was demonstrated by the immobilization of Atto 647 dye and a
DOX-functionalized polymer on the SiO2 NP. The func-
tionalized NPs were incorporated in Hep-G2 cells, and the
pH-induced release of the DOX in endosomal and lysosomal
domains of the cells was probed by the two ﬂuorophores, while
releasing the anticancer DOX drug.
Organic polymer NPs exhibit several advantages for trans-
porting intracellular sensing moieties. Many diﬀerent nontoxic
polymer matrices are available and their hydrophilic/hydro-
phobic properties can be tailored for optimal cell permeation.
Furthermore, the versatile methods available to modify polymer
NPs enable the functionalization of recognition ligands,
ﬂuorophores, and cell-targeting ligands and functionalities,
and minimize nonspeciﬁc adsorption. Figure 14 illustrates two
general strategies to assemble polymer-based NPs for intra-
cellular sensing applications. One type of sensing NPs involves
the incorporation of a ﬂuorophore into the NP matrices where it
serves as both binding ligand and optical transducer, panel I.
The second type of intracellular optical sensors involves the
modiﬁcation of the NPs with two functional elements: (i) a
recognition ligand that binds the analyte and (ii) a transducer
that responds optically to the recognition event, panel II. This
two-element NP composite is known as an opt(r)ode, in analogy
to electrochemical sensing electrodes. In this approach, electro-
chemical reactions stimulated by the recognition complex or
intracellular environmental changes, e.g., pH changes, induced by
the sensing events, trigger the optical transducer in the NPs.
Fluorescent sensors for the intracellular detection of spe-
ciﬁc ions such as Cu2+, Mg2+, and Zn2+ were developed182−184
using ion-responsive ﬂuorophores embedded in polymer NPs
(Figure 14, panel I). An interesting optical sensor that follows the
principle shown in Figure 14, panel I, and probes intracellular
levels of H2O2 is depicted in Figure 15. Polyacrylonitrile (BPAN)
NPs modiﬁed with the Schiﬀ base ligands of aminopyridine
boronate ester (50 nm diameter) were used as the sensor NPs
(Figure 15A). In the presence of H2O2, oxidative cleavage of
the boronate ester units occurred, leading to the formation of the
hydroxy-pyridine-substituted polymer nanoparticles, which
exhibited a characteristic ﬂuorescence band at λ = 400 nm.
The intensity of the ﬂuorescence band was correlated with the
concentration of H2O2 (Figure 15B), and other ROS species did
not interfere with it.185
In yet another example, researchers developed bifunctional
polymer NPs that acted as optrodes to probe intracellular levels
of H2O2, according to the principle shown in Figure 14,
panel II.186 They modiﬁed PEG hydrogel nanospheres
(250−350 nm) with horseradish peroxidase (HRP) and the
Amplex Red (10-acetyl-3,7-dihydroxy phenoxazine) transducer
(Figure 16A). In the presence of stress-induced and intracellular
formation of H2O2, the HRP-catalyzed oxidation of Amplex
Red proceeds, yielding the ﬂuorescent resoruﬁn transducer.186
The hydrogel NPs were introduced into macrophages, and
these responded to exogenous H2O2 (100 μM) or endogenous
peroxide stimulated by lipopolysaccharides (1 μg·mL−1).
Figure 13. Carbon-dot-based sensor for the intracellular sensing of Zn2+ ions. Adapted from ref 177. Copyright 2014 Royal Society of Chemistry.
Figure 14. Chemically modiﬁed polymer NPs for intracellular
sensing: (I) NPs function as optically responsive ligands. (II)
Particles functionalized with an analyte recognition unit and an
optical-transducing element. The recognition event activates the
optical transducer.
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Similarly, a nanosensor capable of monitoring intracellular
glucose levels is depicted in Figure 16B). Polyacrylamide NPs
were implemented as a carrying matrix for glucose oxidase, GOx,
and the Ru(II)-tris-bipyridine, Ru(bpy)3
2+, transducer. While the
Ru(bpy)3
2+
ﬂuorescence is quenched by intracellular O2 levels,
the O2-driven GOx-catalyzed oxidation of glucose depletes
the O2 levels, resulting in the triggered-on ﬂuorescence of the
Ru(bpy)3
2+ luminescent probe. As the degree of O2 depletion by
the biocatalytic process is controlled by the concentration of
glucose, the resulting ﬂuorescence of the transducer provided a
quantitative measure for the concentration of glucose.187 The
use of composite polymer NPs carrying enzymes and optical
transducers as bifunctional sensing elements is particularly
attractive since the products generated by many enzyme-driven
processes may activate optical (ﬂuorescent) transducers. The use
of such intracellular nanosensors should be implemented with
caution, however, since intracellular environmental conditions,
e.g., changes in pH, might alter the enzyme activities, thus
perturbing the intracellular nanosensor performances.
Screening Based on Surface Plasmon Resonance.
Plasmonic NPs are also designed for optical read-out,188−192 in
particular, in the form of colorimetric responses. The aggregation
of AuNPs shifts the absorption maximum to longer wavelengths.
Aggregation can be induced by the selective binding of analyte
molecules to the functionalized surfaces of AuNPs.193 The most
popular example in this research direction is DNA detection,
as developed by Mirkin and co-workers.136,194,195 There are now
many similar assays. For example, Stevens and co-workers used
AuNPs to detect the enzyme phospholipase A2 at a concentration
of 700 pM.190 A more complex scheme was used by Pompa and
co-workers to detect cancer-related point mutations in the
Kirsten rat sarcoma viral oncogene homologue (KRAS) gene.189
In this case, AuNP aggregates form when the target gene
hybridizes with the complementary single-stranded capture
probes functionalized to AuNPs. Subsequently, the AuNP−
target-gene complex undergoes a secondary binding event
with DNA-functionalized magnetic Fe3O4 microparticles. In
addition to nucleic acid detection, AuNPs functionalized with
capture antibodies and patterned onto dielectric surfaces can
be used to fabricate a protein biosensor.192 The characteristic
surface plasmon resonance (SPR) of such AuNPs is shifted
by the binding of target proteins, and this spectral shift can
be detected using conventional SPR imaging spectrometers.
Tamiya and co-workers demonstrated a 300-channel version
of this device, capable of label-free detection of targets down
to 100 pg/mL.192
Figure 15. (A) Chemically modiﬁed boronate ester-functionalized BPAN NPs for intracellular ﬂuorescence probing H2O2. (B) Fluorescence
spectra changes of the modiﬁed polymer NPs upon interaction with increasing amounts of H2O2: 0, 20, 40, 60, and 80 μM. Adapted from ref 185.
Copyright 2012 American Chemical Society.
Figure 16. Bifunctional recognition/dye polymer NPs for sensing: (A) Sensing of H2O2 via the HRP-driven oxidation of Amplex-Red to the
ﬂuorescent Resoruﬁn product. (B) Sensing of glucose by the depletion of O2 by the GOx-mediated oxidation of glucose, using Ru(bpy)3
2+ as
auxiliary ﬂuorescent probe.
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Taking advantage of the high cross-section absorbance of
plasmonic NPs, their SPR can also be used in plasmonic-driven
thermal sensing. Qin et al. presented an improved lateral ﬂow
immunoassay using AuNPs, which improved the analytical
sensitivity of the method 32-fold, achieving similar sensitivity to
an enzyme-linked immunosorbent assay (ELISA).196 Further-
more, Polo et al. reported a SPR-based detection of carcino-
embryonic antigen (CEA) with a sensitivity 3 orders of
magnitude better than standard ELISAs using anisotropic
AuNPs.197
One of the emerging techniques related to plasmon resonance
that demonstrated high sensitivity and versatility is the chiro-
plasmonic method developed by Kotov and Xu.198−200 This
technique is based on the giant polarization rotation character-
istic of nanoscale assemblies highly polarizable metallic nano-
particles. The chiroptical eﬀects in these structures are several
orders of magnitude higher than in small organic molecules due
to high polarizability of the inorganic nanomaterials and larger
dimension. Notably, the physics of chiroplasmonic detection
diﬀers from that of red-blue plasmon coupling assays or
screening with Raman scattering based (see below). Polarization
rotation in NP assemblies is primarily based on interactions
of the electromagnetic ﬁeld with asymmetric nanostructures
rather than on the formation of so-called ‘hot spots’ or plas-
mon coupling.201 This diﬀerence is essential for biomedical
diagnostics because it enables detection of long strands of
DNA and large proteins. For instance, translation-inspiring sen-
sitivity was obtained for prostate speciﬁc antigen using this
method.202 Most recently, this method in combination with
UCNPs also enabled dual detection of one of the most promising
diagnostic targets micro RNAs (miRNA) at the levels suﬃcient
for its application in cancer diagnostics.203
Screening based on surface-enhanced Raman scatter-
ing. Surface-enhanced Raman scattering (SERS) is another
class of NP-based molecular detection.204,205 Surface-enhanced
Raman scattering is an ultrasensitive molecular spectroscopy
technique that beneﬁts from the electromagnetic ﬁelds generated
upon excitation of plasmons in nanomaterials. Despite the
Figure 17. (A) Scheme showing prionmutation and prion ultradetection in human blood. Surface-enhanced Raman spectra (SERS) of (a) natural
and (b) spiked human blood; (c) natural and (d) spiked human plasma; (e) spiked human plasma after spectral subtraction of the matrix (human
plasma); (f) the scrambled prion. Adapted with permission from ref 205. Copyright 2011 National Academy of Sciences. (B) (a) Optical spectra
and SERS (mapped at 1548 cm−1, as marked with the arrow below) images of 3T3 cells in the presence of capsules. The SERS spectra (bottom)
show the signals for the colored circles in the image (top). (b) Optical images and intracellular NO formation over time (obtained through the
I1583/(I1583 + I1548) relation) for three diﬀerent samples upon NO induction with hydrogen peroxide (H2O2). A control sample without the
presence of H2O2 is also shown for comparison. Representative normalized SERS spectra obtained at diﬀerent times are shown. The SERS
dashed (blue) and dotted (red) spectra represent the reference vibrational pattern for aminobezenethiol and hydroxybenzenethiol, respectively.
Adapted with permission from ref 212. Copyright 2013 John Wiley & Sons, Inc. (C) (a) Outline of the c-Fos/c-Jun dimerization on the metal
surface and the resulting deformation of the Raman label structure. (b) Details of the 1000−1100 cm−1 spectral regions of the SERS of the
molecular spring (benzenethiol) interfacing the NP and the protein c-Fos.(c) Spectral shift of the benzenethiol band at ca. 1075 cm−1 as a
function of c-Jun concentration (logarithmic scale) in HEPES buﬀer. Adapted from ref 215. Copyright 2013 American Chemical Society. (D) (a)
In vivo cancer targeting and SERS detection by using ScFv-antibody-conjugated AuNPs that recognize the tumor biomarker epidermal growth
factor receptor (EGFR). Top: Photographs showing a laser beam focusing on the tumor site or on the anatomic location of liver. Bottom: SERS
spectra obtained from the tumor and the liver locations by using (a) targeted and (b) nontargeted NPs. Two nude mice bearing human head and
neck squamous cell carcinoma (Tu686) xenograft tumors (3 mm diameter) received 90 mL of ScFv EGFR-conjugated SERS tags or PEGylated
SERS tags (460 pM). The NPs were administered via tail vein single injection. SERS spectra were taken 5 h postinjection. In vivo SERS spectra
were obtained from the tumor site (red) and the liver site (blue) with 2 s signal integration and at 785 nm excitation. The spectra were
background-subtracted and shifted for better visualization. The Raman reporter molecule was malachite green, with distinct spectral signatures
as labeled. Adapted with permission from ref 216. Copyright 2008 Nature Publishing Group.
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impressive detection limits of SERS, down to the single molecule
level,206 its application in diagnosis has been restricted until
recently by the inherent complexity of biological samples. Thus,
direct SERS detection of disease markers have typically been
carried out either in lab samples, where the marker was diluted in
a controlled solution, or in biological samples, where the marker
is characterized by an extraordinary aﬃnity for the plasmonic
surfaces, such as the use of SERS detection for Creutzfeldt-Jakob
prionic diseases (see Figure 17A).205 The use of chemoreceptors,
intermediary molecular species with selective aﬃnity for the
molecular target (i.e., the disease marker),207 has notably
increased the applicability of SERS as an eﬃcient diagnostic
tool. Surface-enhanced Raman scattering has therefore been
applied to ex vivo detection of drugs,208 proteins,209 metabolites
indicative of disease,210 or even toxic ions,211 but also to in vitro
monitoring of relevant small inorganic molecules such as nitric
oxide212 or pH levels213 inside living cells (see Figure 17B).
In this approach, SERS detection is achieved indirectly as the
spectral changes for the chemoreceptor are monitored before
and after reaction with the target analyte, rather than directly
detecting the analyte. Ideally, the chemoreceptor needs to show a
recognizable spectral change, either structural or electronically,
upon conjugation with its target. Although this property can
be found easily in small aromatic molecules, such as aromatic
thiols and amines, porphyrins, and dyes, macromolecules
such as peptides and proteins usually do not present spectrally
discernible diﬀerences. In such cases, however, the use of
molecular springs as an interface between the metallic surface
and the protein chemoreceptor can be employed to monitor the
interactions with the analytical target. This strategy has been
demonstrated successfully in the quantiﬁcation of the oncogenic
protein c-JUN in cell lysates by using the transcription factor
FOS214 coupled with mercaptobenzoic acid as the molecular
spring (see Figure 17C).215 An alternative approach to the use of
SERS for diagnostics and bioimaging relies on the highly intense
signals that can be obtained from plasmonic NPs labeled with
molecules featuring large SERS cross sections. This strategy,
pioneered by Shuming Nie, has been demonstrated extensively
for bioimaging of tumors in mice (see Figure 17D) and for use as
a contrast agent for the multiplex labeling in tissue prepara-
tions.217 The use of diﬀerent Raman labels in combination with
diﬀerent antibodies can further expand the multiplexing
capability of these systems. Moreover, a variety of membrane
receptors can be targeted speciﬁcally to obtain pertinent spatial
information.218 Surface-enhanced Raman scattering NP tags
have also been used for multiplexed detection of circulating
tumor cells and cardiovascular protein biomarkers in blood
samples.219 Nie and co-workers developed a sandwich-type assay
involving magnetic capturing beads and SERS tags for measuring
a panel of four cardiac protein biomarkers (sVCAM-1, suPAR,
HSP70, and CRP). The magnetic beads enable easy puriﬁca-
tion while the SERS tags enable simultaneous quantiﬁcation.
Due to multiplexing, high sensitivity, and the large dynamic
range of SERS, multiple biomarkers can be assessed over a wide
concentration range in a single tube. Since this system removes
many puriﬁcation and enrichment steps, SERS-based assays can
provide better positive and negative predictive values in high-risk
patients. In the context of coronary arterial disease, a major
clinical problem is the prediction of sudden cardiac events such as
plaque rupture and myocardial infarction. Hence, it is important
to develop assays to distinguish high-risk populations for plaque
rupture that require immediate intervention and treatment.
Screening Based on Electronic Read-Out. Nano-
wires220−229 are enabling a novel class of biosensors that are
capable of detecting disease markers in blood, saliva, and urine,
and able to convert the detection events into electronic signals.
Semiconductor nanowire ﬁeld-eﬀect transistors (FETs) make
use of nanowires that are sensitive to surface-binding events.230
This sensitivity is derived from the proximity of the binding
sites to the charge carriers within the nanowire.231−233 Nano-
engineered FETs diﬀer considerably from conventional, micro-
lithography-based FETs for solution-based detection.234−236 For
example, nanoengineering enables miniaturization and also
enables the detector to be close to the target. Silicon nanowires
can detect proteins at 10 fM concentrations in low ionic strength
buﬀers; however, the detection of analyte molecules by nanowire
FETs in high ionic strength (>mM) solutions, including all
physiological solutions of interest, has posed problems. In such
solutions, the Debye length is reduced to 0.2−2.0 nm and the
screening of analyte charge by the electrolytes either reduces
sensitivity or, more often, prevents detection of the analyte
altogether.221,237 Andrews, Weiss, and Yang showed that
aptamer-functionalized FETs can operate in full ionic strength
buﬀer, presumably because of the proximity of the charged
backbone to the gated semiconductor, and thus show promise for
in vivomeasurements.238,239 A recent study demonstrated230 that
backﬁlling antibody-functionalized silicon nanowires with a
PEG layer extends the Debye length, enabling the detection
of prostate-speciﬁed antigen at a concentration of 10 nM in
100 mM phosphate buﬀer.230 Nanowires composed of con-
ductive polymers (e.g., polyaniline240−243) have also been
adapted for electrical biosensing using either FET-based
transduction244,245 or chemoresistive transduction.228,229 In
these systems, the binding sites are either antibodies or virus
particles displaying peptide motifs, both of which are capable of
recognizing and binding analyte molecules. Conveniently, either
of these two “receptors” can be entrained in the polymer from the
polymerization solution during nanowire fabrication. In contrast
to nanowire FETs, transduction of analyte binding to polymer
nanowires is not completely understood. Carbon nanotubes
have been also used as transducers for biosensing.246 All these
biosensors are “label-free”capable of providing a signal cor-
related to the concentration of analyte by immersion in a solution
without added reagents or process steps. Thus, these devices are
ideally suited for use in point-of-care disease diagnostics.
An electrically responsive NP sensing scheme requires
electrical contact. One approach described by Gadopadhyay
et al.240 involves the incorporation of AuNPs into polyaniline
ﬁlms on electrode surfaces.240 In this case, AuNPs facilitate the
attachment of single-stranded DNA (ssDNA) capture strands to
the nanowire, using a thiol-based immobilization scheme.
Binding of target DNA to the ssDNA capture strands impedes
the redox responsiveness of polyaniline and reduces peak cur-
rents by providing an insulating layer to the electrode surface.240
Gadopadhyay et al. demonstrated that target nucleotide
concentrations down to 10−18 M can be detected by monitoring
changes in peak currents. Similarly, QDs have been used as
transducer in electrochemistry based detection schemes.247−254
Biological molecules can also act as transducers that directly
convert binding events into electrical signals. This action can be
in the form of ion channels, which open in response to binding
events and subsequently result in a signal cascade.255 Olfactory
receptors, for example, can be used for the development of
sensitive and selective odor-sensing biosensors.256−258 These
biosensors can screen numerous volatile compounds generated
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by the human body, such as exhaled breath and body odors, to
detect diseases and health conditions.259,260 Olfactory receptors
have also been combined with various transducers such as quartz
crystal microbalance,261−263 SPR sensors,264,265 microelectro-
des,266,267 NPs,268 graphene,269,270 and nanotubes271−277 to
generate diﬀerent types of read-outs. For example, a biosensor
with an electrical read-out was constructed by immobilizing
olfactory receptors on nanotubes.271,272 Similarly, a nanovesicle-
based olfactory biosensor, where nanovesicles with surface
olfactory receptors were immobilized on nanotubes, was
successfully used for cancer diagnosis.263,276,277 In addition to
olfactory receptors, others, such as hormone receptors,268 taste
receptors,278,279 and peptides280 can also eﬃciently be used in
biosensors that can detect components of saliva, tears, blood,
urine, cerebral spinal ﬂuid, mucous, and even tissues.281,282
Similarly, whole cells can be used as transducers, whereby
electric currents of electrically excitable cells are recorded.283
Primary cells284 and stem cells285 from patients have become
interesting targets that can be used as potential tools for per-
sonalized medicine. In addition to whole cells, speciﬁc ion
channels can also be used as transducers. Ion channels are
involved in electrical signal conduction (such as in the nervous
or cardiac systems) as well as in other disease areas such as
oncology,286 cystic ﬁbrosis,287 diabetes,288 and infection.289 The
gold standard for monitoring ion channel currents is the patch
clamp technique,290 which provides highly accurate functional
recordings from single or multiple ion channels in cells.
However, the low throughput and the need for highly trained
operators exclude the classical patch clamp technique frommany
screening applications. This situation changed with the develop-
ment of the planar patch clamp technique.291,292 The latest
generations of planar patch clamp devices like the SyncroPatch
384PE (2013 by Nanion Technologies) enable recordings of up
to 768 cells at a time, and can be integrated into high-throughput
screening cascades of the pharmaceutical industry. Nano-
technology has had a leading role in shaping these technologies
by providing nanopores responsible for sealing the cell and
the detector surface. Such nanopores can be used not only for
electrophysiological measurements of cells, but also have
been used in the context of DNA detection.293 In most cases,
electrophysiological detection is used for monitoring over-
expressing ion channels, which has implications in primary drug
targeting or for eliciting dangerous side eﬀects. One prominent
example is the cardiac herG channel that plays an important role
in heart arrythmia and QT-prolongation.284,285,294−296
At the tissue and organ levels, indicators like electro-
physiological signals have been widely employed for evaluation
of organ function. However, conventional electrodes are
confronted with the mismatch between rigid/planar electrodes
and soft/curvilinear tissues. By designing gold nanobelts with
sinusoidal structures on ﬂexible tripod substrates, one is able to
create stretchable biointegrated electrodes for direct recording
of electrophysiological signals of rat cerebral cortex with
desirable sensitivity and stability.297 The transfer of thin, ﬂexible
electronics onto polymers also enables conformal placement and
measurements.298 Given the abundance of material can-
didates and nanofabrication techniques, more novel and smart
tools capable of monitoring function and quantity would emerge
and boost the development of nanomedicine and its transition
into practical applications.
Biomechanical Assays.Nanoenabled tools can be designed
for diagnostics and therapies based on the mechanical properties
of cells.299 At the subcellular and cellular levels, many biophysical
properties have recently emerged as indicators of cell physiology
and pathology, as complementary or regulatory alternatives for
disease development. Cell migration, for example, can be traced
by removing the trail of adherent cells left on a substrate coated
with AuNPs300,301 or with QDs.110 The morphology of the trails
correlates with the metastatic potential of the cells.302 The force
that adherent cells exert on a substrate can also be measured. For
example, cell-traction-force microscopy based on the deforma-
tion of the polymer substrates on which cells are grown is able to
spatiotemporally map cell traction force as precise as a nano-
newton.303−305 It can also be used to uncover previously hidden
details of drug−cell interactions and mechanical contributions
during cell migration.303−305 For example, previously retarded
cell migration upon NP uptake was attributed to cytoskeleton
disruption. However, the uptake of the NPs actually transforms
cells from the motile phenotype into an adhesive phenotype, as
revealed by the increased cell traction force and altered patterns
of cell traction force.306 More importantly, ultrasensitive cell
traction force microscopy could be competitive to traditional cell
biology methods such as the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assays,307 WB, and ﬂow cytometry,
since early changes can be readily observed under cell-traction-
force microscopy.
IN VIVO TREATMENT (“PARTICLE-BASED DELIVERY”)
Nanoparticles have been designed to treat many diseases, but the
most prominent disease focus has been in cancer. The literature
is replete with large sets of in vivo data obtained from animals, and
some NP formulations for cancer treatment have already been
approved by regulatory agencies and have reached hospitals,
showing much reduced adverse eﬀects compared to bare
drugs.308 However, their therapeutic eﬃcacies are most often
not or only marginally improved.309,310 Thus, there are ongoing
eﬀorts to develop systems with high therapeutic eﬃcacies.311
The key in such developments is to improve the design of the
nanodelivery system by precisely controlling the functions/
properties of the materials.
Nanoparticles as Anticancer Drugs. The cancer drug
delivery process to a solid tumor consists of ﬁve critical steps,
termed the CAPIR cascade: circulation in blood, accumulation
and penetration into the tumor, cellular internalization, and
intracellular drug release. Thus, the overall therapeutic eﬃciency
of a nanomedicine is determined by its eﬃciency in each step
(see Figure 18).312 A nanomedicine eﬃciently accomplishing the
whole CAPIR cascade should have a high therapeutic index.
Correspondingly, such a nanomedicine should have 2R2SP
properties, the abbreviation of “drug retention vs release (2R)”,
“surface stealthy vs sticky (2S)” and “tumor penetration (P)”.313
The 2R indicates the required properties of the nanomedicine in
terms of the loaded drug, i.e., it must tightly retain the drug
without burst release during the transport in blood compart-
ments and tumor tissues, while eﬃciently releasing the drug
at the intracellular target to exert its pharmaceutical action.
Similarly, the 2S gives the needed properties in terms of the NP
surface, which should be stealthy while in blood circulation for
Nanoparticles have been designed to
treat many diseases, but the most
prominent disease focus has been in
cancer.
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passive tumor accumulation, whereas it should become sticky
once nearby the tumor cells to interact with them for eﬃcient
cellular uptake. Besides the 2R2S properties, the nanomedicine
should be able to penetrate in tumor tissues to reach remote
tumor cells from blood vessels. Only if a nanomedicine possesses
2R2SP properties will it be able to accomplish the CAPIR
cascade successfully and to deliver active drugs at the right
time and place to provide an overall high therapeutic eﬃcacy
and favorable prognosis.312,313 Therefore, the current focus
on developing nanomedicines of high therapeutic index lies
on tailoring the basic physiochemical properties of NPs,
i.e., “size, surface properties, and stability (3S nanoproperties)”
to achieve 2R2SP properties to accomplish the CAPIR cascade
eﬃciently.
A demonstration of such a 2R2SP nanomedicine is a
dendrimer core−lipid shell nanoassembly mimicking a “cluster-
bomb”, which shows enhanced eﬃcacy, as demonstrated by Sun
et al.312 The nanocomplex is able to cruise to a tumor, shed
“bomblets” to penetrate into the tumor, and then “ﬁre” at tumor
cells to accomplish the CAPIR cascade. A sixth-generation
nontoxic degradable polyaminoester dendrimer with a diameter
of 5 nmwas chosen as the “bomblet” because of its ability to carry
anticancer drugs and, more importantly, its pH-dependent
2-(N,N-diethylamino)ethyl termini.312,314,315 The lipid shell was
composed of fusogenic DOPE phospholipids, PEGylated DSPE-
PEG lipids, and cholesterol in order to keep the nanoassembly
stable and to provide a stealth surface in the blood compartment.
The 45 nm NPs contained ∼27 5 nm dendrimers surrounded by
a PEGylated lipid layer. The NPs could circulate in blood and
accumulate in the tumor via the EPR eﬀect. Once in the tumor,
the fusion of the lipid layer with the cell membrane released the
dendrimers intracellularly or extracellularly. The nearly neutral
dendrimers were shown to penetrate into tumor tissues easily
due to their size, where the extracellular pH is acidic (pH∼6−7).
The dendrimers were then protonated and became positively
charged, eﬃciently triggering fast cellular uptake, and releasing
the drug inside the cells. The dendrimer−lipid nanoassembly
eﬃciently accomplished the CAPIR cascade and thus exerted
strong anticancer activity in DOX-resistant tumor compared
with typical PEG−PCL micelles.312
Nanoparticulate Delivery Vehicles. A vast number of classes
of nanoparticulate delivery vehicles have been reported.316−351
As demonstrated by Huynh et al.,317 drug-loaded delivery
vehicles are attractive because they can be passively or actively
targeted to cancer tissues to improve anticancer drug selectivity
and thereby reduce severe side eﬀects. Liposomes316 are perhaps
one of the most advanced delivery vehicles concerning clinical
translation, with several formulations approved by the U.S. Food
and Drug Administration (FDA).316 Liposome-based systems
encapsulating drugs are already used in some cancer therapies
(e.g., Myocet, Daunoxome, Doxil). However, liposomes have
some signiﬁcant drawbacks: they have a low capacity to
encapsulate lipophilic drugs, they are manufactured through
processes involving organic solvents, they are often leaky and are
unstable in biological ﬂuids and aqueous solutions.317
Polymeric micelles embedded with drugs can also reduce
undesirable side eﬀects. Micelle formation involves the self-
assembly of amphiphilic molecules in which, upon separation
of hydrophilic and hydrophobic moieties, hollow capsules are
formed. In water, the interior of those micelles forms the
hydrophobic container, whereas the outside imposes the hydro-
philic interface. Encapsulation of anticancer drugs withinmicelles
can reduce toxicity and improve circulation.318,352,353 For
example, nephrotoxicity is signiﬁcantly reduced by loading
cisplatin into polymeric micelles.318 Shielding the cisplatin-
loaded core with PEG improves longevity in blood circulation by
reducing acute kidney accumulation of polymeric micelles. In this
regard, the secondary structure of the micelle core also plays a
critical role in stabilizing polymeric micelles in diluted conditions
in the blood. For example, since the core-forming segment in this
formulation is poly(L-glutamic acid) (PLG), cisplatin binding to
the side chain of the PLG segment induces α-helix formation.
Regular assembly of cisplatin-bound helical bundles in the core
is key to keeping the micellar structure intact during blood
circulation.319 Five diﬀerent formulations of polymeric micellar
drugs based on poly(ethylene glycol)-poly(amino acid) block
copolymers, developed by Kataoka and colleagues, are already
in clinical translation in Asia and North America.320 Speciﬁcally,
a polymeric micellar drug loaded with paclitaxel is close to
completing its Phase III clinical trial, and is expected to be up for
approval soon. Polymeric micelles thus provide a mature plat-
form with numerous advantages to improve patient compliance
appreciably, including outpatient treatment without hospital-
ization.
Micelles can also be jointly fabricated with polymers as well as
lipids. Microﬂuidic chips can be used for the controlled pro-
duction of these micelles for the delivery of therapeutic
agents.321,322 By adopting a microﬂuidic platform (see Figure 19),
NPs of varying water content and rigidity but with the same
chemical composition, size, and surface properties can be
synthesized. It is important to be able to vary the properties of
these micelles eﬃciently since cellular uptake can be entirely
dependent on these characteristics. For example, rigid or “hard”
NPs, with less interfacial water between the polymeric core and
lipid shell, can enter cells more easily than those that are ﬂexible
(“soft”). In contrast, bigger particles have poor accumulation in
cells.128,323 In this regard, a hollow-structured rigid nanovesicle
(RNV) was fabricated to entrap various hydrophilic reagents
eﬀectively by multistage microﬂuidic chips in one step, without
complicated synthesis, extensive use of emulsiﬁers or stabilizers,
or laborious puriﬁcation procedures. The RNVs contain a hollow
water core, a rigid poly(lactic-co-glycolic acid) (PLGA) shell, and
an outermost lipid layer. The entrapment eﬃciency of
Figure 18. (A) Five-step CAPIR cascade in targeted cancer drug
delivery. Reprinted with permission from ref 312. Copyright 2014
John Wiley & Sons, Inc. (B) Needed properties of a nanomedicine
capable of accomplishing the cascade.
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hydrophilic reagents such as calcein, rhodamine B, and small
interfering ribonucleic acid (siRNA) inside the hollow water core
of RNVs was approximately 90%.42
Unlike micelles, polymer capsules provide a delivery platform
for encapsulating hydrophilic drugs. Polymer capsules can be
formed with entirely hydrophilic polymers, for example, the
LbL approach can form these capsules by templating parti-
cles.324,325,354 While such capsules are often on the micrometer
scale, smaller polymer NPs can be obtained from polymer
capsules by thermal shrinkage.327 In this approach, hollow
capsules “ﬁlled” with a desired medicine with an even poly-
electrolyte layer number are subjected to elevated temperatures
(above the temperature of the glass transition temperature of the
polyelectrolyte complex, i.e., ∼40 °C). At temperatures above
60 °C, polymeric NPs are formed.
In contrast to the aforementioned NPs, where lab-made
synthesis is required, exosomes are naturally occurring nano-
sized-vesicles endogenously secreted by cells.328 They are
involved in intercellular and tissue-level communication by trans-
ferring biological material (i.e., microRNAs [miRNAs], siRNA)
among cells. Exosomes exhibit great potential as nanocarriers for
a wide range of therapies, including inﬂammatory diseases and
cancer,329 as well as for diagnosis.330
Nanocarriers are not always in the form of vesicles; there are
numerous other types of delivery vehicles including water-solu-
ble polymers, dendrimers, and even polysaccharides.331,334,340,341
Water-soluble polymers in a random coil conformation can be
eﬃcient carriers of anticancer drugs.324,331 Recently, backbone
degradable N-(2-hydroxypropyl)methacrylamide (HPMA)
copolymer−drug conjugates synthesized by reversible addition−
fragmentation chain transfer copolymerization demonstrated
high eﬃcacy in treating solid tumors. These conjugates contain
a degradable oligopeptide sequence (GFLG) in the backbone and
drug in the backbone and at the termini. This design permits the
use of high molecular weight, long-circulating polymer carriers
without impairing their biocompatibility (the carrier will degrade
into fragments that will be eliminated from the body).355
Consequently, as a result of maintaining the concentration
gradient (blood to tumor) for an extended period of time, the
EPR eﬀect is considerably more eﬀective: the drug can accu-
mulate in solid tumor to a higher extent. Conjugates with
epirubicin,332 DOX,333 and a combination of conjugates with
gemcitabine (GEM) and paclitaxel8 were highly eﬀective in the
treatment of experimental ovarian cancer using this platform.
Dendrimers334 are another form of polymeric NPs, which have
the advantage of being nearly monodisperse, in contrast to
polymerization products, while having a deﬁned structure and
composition.334,335 Remarkably, dendrimers with adequate
hydrophilicity, unlike liposomes and polymer micelles, do not
have a critical micelle concentration.336 Therefore, dendrimers
should not “in principle” fragment upon dilution.337 Addition-
ally, the number of functional groups grows exponentially as
the number of generations increases. These features make
dendrimers a powerful platform for drug delivery. Drugs can be
loaded into the dendrimers in diﬀerent ways, such as by
encapsulation or by covalent binding of the drug. Drug encap-
sulation can be realized in unimolecular micelles or in
supramolecular assemblies.338 This approach enables encapsu-
lation of the most widely used chemotherapeutic agents,
e.g., DOX, methotrexate, paclitaxel, and campthothecin.335 The
covalent binding of drugs is traditionally used to overcome
the encapsulation problems, and the drugs are linked to the
dendrimer surface using groups that will be cleaved following
cellular uptake (e.g., cis-aconityl or acyl hydrazine groups, ester
groups or disulﬁde groups).335 All these characteristics distin-
guish these materials as potential carriers for diﬀerent therapeutic
applications.339
Another class of carrier vehicles is based on polysaccharides,
such as chitosan, which are promising carriers for oral delivery of
therapeutic proteins.356 The oral route is considered to be the
most convenient and comfortable means of drug administration
for patients.357 Chitosan is a biocompatible polysaccharide
derived from the shells of crustaceans. It is a mucoadhesive agent
and a permeation enhancer that is able to mediate the opening of
tight junctions between epithelial cells reversibly.358 A NP carrier
system formed by self-assembly of positively charged chitosan
and negatively charged poly(γ-glutamic acid) in an aqueous
milieu has been developed for delivering protein drugs
orally.340,341 The as-prepared chitosan NPs are pH-responsive
in the intestines, because the pKa of chitosan is approximately 6.5.
The working mechanism for this oral delivery system is that the
mucoadhesive chitosan NPs adhere to and inﬁltrate the mucus
layer on the intestinal surface. The inﬁltrated NPs can transiently
open the tight junctions between epithelial cells while becoming
unstable and disintegrated, owing to their pH-responsiveness,
and releasing the loaded protein. The released protein then
permeates the paracellular pathway via opened tight junctions,
ultimately absorbing into the systemic circulation.342 However,
the enhanced absorption of therapeutic proteins, as delivered by
chitosan NPs, occurs mainly in the duodenum, most likely
because chitosan is insoluble in a neutral/basic pH environment
in the jejunum and ileum.343 Additionally, these chitosan NPs are
not able to protect the released protein from degradation by the
proteases present in the mucus layer. One strategy of inhibiting
intestinal protease activities is to remove essential metal ions
such as Ca2+ from the enzyme structure using chelating agents
such as ethylene glycol tetraacetic acid (EGTA). Furthermore,
the use of chelating agents for removing extracellular Ca2+ can
disrupt intercellular junctions and increase paracellular perme-
ability. According to reported experiments, EGTA-conjugated
chitosan NPs can signiﬁcantly reduce enzymatic degradation by
the speciﬁc removal of extracellular Ca2+ from the intestinal
lumen. This enhanced stability causes intracellular internal-
ization of junctional components, and thereby increases the
Figure 19. Scheme of a two-stage microﬂuidic platform for
assembling polymer−lipid hybrid NPs with varying amounts of
water. (a) Nanoparticles composed of the lipid shell and PLGA core
are produced by injecting the PLGA solution in the ﬁrst stage and
lipid−PEG solution in the second stage (mode 1, P−L NPs).
(b) Nanoparticles composed of the lipid shell, interfacial water layer,
and PLGA core are produced by injecting the lipid−PEG solution in
the ﬁrst stage and the PLGA solution in the second stage (mode 2,
P−W−L NPs). Adapted with permission from ref 322. Copyright
2015 John Wiley & Sons, Inc.
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absorption of protein throughout the small intestine.344 A recent
large animal study performed with beagle dogs revealed that
EGTA-conjugated chitosan NPs could successfully deliver
proteins into the plasma.345 Although chitosan-based NPs are
promising for oral delivery of therapeutic proteins, further
preclinical studies are required to test their eﬃcacy and safety.
Proteins can themselves form the basis of another class of drug
carriers.346 The abundant plasma protein, serum albumin, has
been successfully converted into a drug transporter and was
launched to the market in 2005 for delivering the anticancer drug
paclitaxel (Abraxane).347 Serum albumin is a nontoxic, non-
antigenic, and biodegradable material. In fact, albumins are
excellent charge-reversible materials. Albumins have character-
istic isoelectric points, due to the existence of both carboxylic acid
and amino groups. When the environmental pH is higher than
the pI, albumins have more negative charge on their surface,
otherwise albumins are more positively charged. In addition, the
pI of albumins can be adjusted by changing the ratio between the
carboxylic acid and amino groups through chemical modiﬁca-
tions. By tuning charge, albuminNPs have been successfully used
to deliver negatively charged nucleic acids as biomolecules for
gene therapy.359 Recent approaches broadened the applicability
of this successful platform and there is further development of
novel features that aims to advance intelligent drug delivery.
Boronic-acid-rich albumin NPs have been equipped with tar-
geting peptides cRGD on the surface and DOX encapsulated
inside the NPs.348 The boronic acid groups enhance the recog-
nition of NPs to cancer cells, since the boronic acids reversibly
interact with overexpressed sialic acid residues. Encouraged by
the success of albumin NPs, other endogenous proteins are being
investigated such as milk casein,349 or the iron-transport pro-
tein ferritin.350 Proteins in their denatured form reproducibly
enable the attachment of PEG chains as well as drug molecules
to improve circulation times and solubility. In this way,
polypeptide−PEG copolymers of human serum albumin have
been obtained that can form small micelles. These micelles were
able to transport and to release multiple copies of the drug DOX
in leukemia cells via a two-step release mechanism.351
Similar to protein carriers, ribonucleic acid (RNA) nano-
technology has emerged as a potential platform for drug delivery
applications. This use is largely due to the ability to design
structures with high thermodynamic stability, and favorable and
distinctive in vivo attributes.360 RNA can act both as a delivery
vehicle as well as an active therapeutic agent. As an example, Qiu
et al. combined the bacteriophage phi29 DNA packaging motor
pRNA three-way junction (3WJ) with folic acid, a near-infrared
(NIR) marker, and BRCAA1 (breast cancer associated antigen 1,
AF208045) siRNA (see Figure 20).43 These RNA NPs comprise
functionality for targeting, imaging, delivery, gene silencing, and
regression of gastric cancer. In vitro assays revealed that the RNA
NPs speciﬁcally bind to gastric cancerMGC803 cells. The siRNA
incorporated in the RNA NPs thereby signiﬁcantly silences
the BRCAA1 gene. The apoptosis of gastric cancer cells was
observed as a result of silencing the antiapoptosis factor BCl-2
and up-regulation of the proapoptosis factor Rb and Bax
expression. Animal trials using a gastric tumor-bearing nude mice
model conﬁrmed that these RNA NPs could be used to image
gastric cancer in vivo, while showing little accumulation in crucial
organs and tissues several hours postsystemic injection. The
growth of the gastric tumor noticeably decreased during the
course of treatment. No damage to important organs by the RNA
NPs was detected. All results show that RNA nanotechnology
can overcome some conventional cancer therapeutic limitations
and open new opportunities for speciﬁc delivery of therapeutics
such as siRNA, miRNA, and/or chemotherapeutic drugs to
stomach cancer. In recent work, siRNA attached to glucose-
modiﬁed AuNPs (AuNP@PEG@glucose@siRNA) were applied
in vitro to a luciferase-CMT/167 adenocarcinoma cancer cell line
and in vivo to the lungs of B6 albino mice.361 The siRNA-bearing
NPs induced the expression of pro-apoptotic proteins such as
Fas/CD95 and caspases 3 and 9 in CMT/167 adenocarcinoma
cells in a dose-dependent manner, independent of the inﬂam-
matory response. Moreover, in vivo pulmonary delivered siRNA-
bearing NPs were capable of targeting c-Myc gene expression
(a crucial regulator of cell proliferation and apoptosis) via in vivo
RNA interference (RNAi) in tumor tissue. This led to an ∼80%
reduction in tumor size without associated inﬂammation. Over-
all, RNA NPs can improve therapeutic eﬃcacy while reducing
toxicity and side eﬀects and therefore provide an avenue for use
in clinical tumor therapy in the near future.
Nanodiamonds are among the most promising carbon nano-
materials for drug delivery, as well as imaging and theranostic
applications. Nanodiamonds that are ∼5 nm have a large
accessible surface and tailorable surface chemistry, combined
with unique optical, mechanical, and thermal properties.118
In drug delivery, the rational surface modiﬁcation of NDs allows
for enhanced adsorption and chemical binding of the drugs for
sustained or triggered drug release. Both the amount of drug
adsorbed and the strength of adsorption can be controlled by
the surface chemistry. By attaching drugs to the surface of NDs
and by achieving controlled release, it is possible to renew the
potency of anticancer chemotherapeutics.125 Similarly, the devel-
opment of NDs for targeted delivery of antibiotics and other
drugs may also restore the drug eﬃciency and reduce systemic
toxicity. Currently, NDs are being investigated for the delivery
and sustained release of anticancer chemotherapeutics,119,363
Figure 20. Global structure of therapeutic RNA NPs with BRCAA1
siRNA. (A) Design of the RNA NPs. The left image shows the NP
structure as used in animal trials. On the right, an extended structure
imaged by atomic forcemicroscopy (AFM) is shown. (B) AFM image
of extended 3WJ RNA NPs. The RNA complex as shown in (A) on
the left is estimated to be around 10 nm in size. Due to convolution of
the tip size (∼10 nm in diameter) in AFM images, features smaller
than the size of the tip cannot be resolved. To characterize the
structure of the RNA constructs, the 3WJ NPs were extended by
39−60 base pairs (in red color, A, on the right), which is within the
persistence length of dsRNA and will not aﬀect the 3WJ folding as
described before by Shu et al.,362 to generate the AFM image as
shown. Adapted with permission from ref 360. Copyright 2015
Nature Publication Group.
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nucleic acids,364 and insulin.365 Nanodiamonds have also been
demonstrated for covalent binding of proteins, sometimes
enhancing their activity.366
Similarly, inorganic NPs are frequently used as delivery vehi-
cles. Among the inorganic nanocarriers, mesoporous silica nano-
particles (MSNPs) have emerged as a multifunctional platform
that enables the development of custom-designed treatment
modalities for disease-speciﬁc applications. One example is the
use of MSNPs to address cancer-speciﬁc challenges such as the
dysplastic stroma of pancreatic ductal adenocarcinoma (PDAC).
The stroma serves as a treatment barrier due to inaccessible
tumor blood vessels as well as the expression of cytidine
deaminase, which is responsible for rapid degradation of the ﬁrst
line chemotherapeutic agent, GEM. It is possible to use a variety
of MSNP designs to address the stromal barrier, including
drug delivery to decrease the stromal abundance or negotiating
vascular access by interfering with the action of pericytes that
closely adhere to vascular fenestrations in the stromal blood
vessels (see Figure 21A).367−370 In one formulation, a MSNP
carrier was developed to deliver a small-molecule inhibitor of the
TGF-β receptor kinase, which is responsible for providing the
cellular signal for the adherence of pericytes to endothelial
cells.371 This was accomplished by placing a polycationic
polymer on the NP surface to interact with the small molecule
inhibitor via hydrogen bonding. Under acidic conditions, the
small molecule inhibitor was rapidly released in the tumor
stroma. When used as a ﬁrst-wave carrier, this NP construct
opened vascular fenestrations within 1−2 h, thereby making it
possible for a second-wave carrier (e.g., a liposome) to deliver
GEM to the tumor site (see Figure 21B).371 Another formulation
included the development of a dual delivery carrier, where a lipid-
bilayer-coated MSNP (LB-MSNP) was used to codeliver a
synergistic GEM/paclitaxel combination to the site of orthotopic
human tumor implants in the pancreas of a murine model.372
This dual-delivery MSNP carrier was ∼10× more potent than
Abraxane, which recently received FDA approval in combination
with GEM. Not only did the ratiometric-designed carrier
suppress the tumor stroma, but it also decreased the expression
of cytidine deaminase, enabling increased uptake of activated
GEM at the cancer site (see Figure 21C).372 The LB-MSNP
could also be used with considerable eﬃcacy to deliver irinotecan
to the pancreatic cancer site. This result can be achieved using a
remote loading method in which the drug is imported for high
loading eﬃciency across the lipid bilayer through the use of
a proton gradient.373 This carrier was more eﬀective than a
liposomal equivalent that was recently approved by the FDA, but
it also improved safety because of its more stable drug retention.
Together, these examples demonstrate the use of multifunctional
MSNPs for the treatment of pancreatic cancer.
Naturally there are many more types of NPs used for delivery
applications, such as CNTs, graphene, and also the already
mentioned inorganic NPs such as SPIONs, plasmonic NPs, etc.
However, due to their sheer number, it is impossible to describe
them all in this Nano Focus.
Targeting. Targeting of NPs refers to delivery to speciﬁc
tissues and cells in vivo. Nanoparticles can be designed to be
stealthy to escape immune clearance and avoid nonspeciﬁc cell
uptake but should also be capable of being sticky to target tissues
and interacting with and/or be taken up by desired cells.
Nanoparticles can passively or actively accumulate in the desired
tissue via transport through leaky vessels and unique intraorgan
pressures, or adhere to speciﬁc biological structures in the
targeted tissue via molecule recognition to surface-bound
ligands.374 Recently, researchers designed smarter NPs that can
turn from stealthy to sticky. Switching between these two
properties may enhance the biodistribution and targeting of NPs
to diseased tissues.
Researchers have found inspiration in nature by using
principles of viruses, transport proteins and their interactions
with cell membranes, to achieve “stealthy and sticky” properties.
Mimicking envelope-type viruses, diﬀerent envelope-type375,376
or shell-sheddable nanocarriers377,378 have been explored to
enhance the distribution of NPs in target tissue. Polymers with
strong antifouling properties, such as PEG or zwitterionic
polymers, were tethered onto NPs by cleavable anchor groups
that are responsive to diﬀerent stimuli, e.g., pH, redox, and
proteolytic enzymes. The NPs with the stealthy shell had
prolonged circulation times and enhanced accumulation in solid
Figure 21. (A) Schematic to show the barriers and challenges that are
responsible for failed chemotherapy in PDAC. This includes
abundant dysplastic stroma, which serves as a physical and biological
barrier, interference in vascular access and the presence of a high
local concentration of deaminase activity, which leads to in activation
of GEM. Trichrome staining of human PDAC is also shown: blue
staining is collagen deposition. (B) Two-wave approach for PDAC
treatment. PEI/PEG-MSNP binds to the TGFβ inhibitor, LY364947.
The complexation is highly stable in the physiological conditions, but
can be disrupted in the acidic stromal environment. NIR-labeled
particles retention was increased 10-fold prior to injecting the TGFβi
carrier into mice with BxPC3 xenografts (circle), with signiﬁcantly
decreased pericyte coverage on endothelial cells in tumor blood
vessel. Reprinted from ref 371. Copyright 2013 American Chemical
Society. (C) Schematic describing GEM trapping in MSNP pores,
which are sealed oﬀ by the LB that contains a subtoxic dose of
paclitaxel (PTX). Ratiometric codelivery of GEM/PTX by LB-MSNP
inhibits PANC-1 orthotopic tumor growth through increased
delivery of GEM at the tumor site. GEM/PTX loaded LB-MSNP
leads to CDA inhibition in parallel with increased oxidative stress.
Adapted from ref 372. Copyright 2015 American Chemical Society.
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tumors due to the EPR eﬀect, i.e., passive targeting. The unique
stimuli within the targeting tissue enable the NP to release the
shell, thus converting from stealthy into sticky. In a similar
direction, zwitterionic surfaces containing mixed positive and
negative charges have received great attention due to their
unique stealthy properties and their similarity to proteins. Many
proteins behave stealthily to most cells and they can have long
circulation times in vivo. However, they can alternate between
“stealthy and sticky” under even a slight stimulus such as a minor
change in pH.379 Although the detailed mechanism of this
change has not been elucidated and might indeed be complex,
the zwitterionic properties of amino acids and the mixed-charge
structures of proteins might contribute to this feature. By exploit-
ing pH changes in diﬀerent structures (e.g., in tumor tissues,
6.5−6.8; in endosomes, 5.5−6.8; and in lysosomes, 4.0−5.0),
zwitterionic polymer-based NPs, capable of altering their charge
densities in diﬀerent tissues, can be prepared. This responsive-
ness involves introducing a surface moiety sensitive to tumor
extracellular acidity (pH ∼6.8)379 as the anionic part of the
zwitterionic polymer (see Figure 22).
Nanoparticles can also be covered by neoglycoconjugates, or
sugar-like functional groups and other functionalities such
as thiol groups, to convert the NPs from stealthy to sticky.
Though typically uncharged, such glycan-based ligands provide
extremely high stability in bioﬂuids, while minimizing non-
speciﬁc cell internalization. Whereas much research has been
carried out with nanometer-size AuNPs,381 these moieties have
only recently been shown to work for larger AuNPs with various
morphologies, including nanorods.375,382 Interestingly, even
though the stealthiness was shown to be superior to that of
PEG ligands, speciﬁc protein-binding was retained, enabling the
AuNPs to target cell types that overexpress certain protein
receptors. The NPs thus exhibit prolonged circulation times due
to the pronounced antifouling properties of the zwitterionic
polymer. However, when the NPs are in an acidic tumor
environment, surface charges change from negative to positive,
leading to enhanced cellular uptake and accumulation of the NPs
within tumor tissue. Compared with the NPs that switch their
charge states by cleavage of the responsive covalent bonds,
charge conversion of weakly electrolytic groups at diﬀerent pH
proceeds rapidly and better mimics the changes in charge density
of amino acid segments within proteins. Surface engineering of
inorganic NPs viamix-charged ligands can enhance NP retention
in tumors by modulating the aggregation of NPs.380,383,384 The
mixed-charge modiﬁed AuNPs present not only a transition from
stealthy to sticky under the acidic extracellular pH of solid
tumors, but also a signiﬁcant aggregation of NPs with much
higher tumor accumulation, retention, and cellular internal-
ization. Aggregation of AuNPs can also shift the surface plasmon
band to the near-infrared wavelengths for photothermal
therapy.385 Moreover, recent studies on 3D spheroids of liver
cells made in inverted colloidal crystals demonstrated that
targeted nanotubes display unusually fast passive diﬀusion in the
tissues.386 Such an eﬀect originates from the eﬀective two-
dimensional (2D) translation of nanotubes over the surface of
the cells in the tissues when the attractive forces between
nanotubes are balanced with electrostatic repulsion. This ﬁnding
suggests that nanoscale design of drug delivery vehicles can result
in deep and eﬀective penetration into the tumors.
In addition to tailoring the surface properties of NPs, opti-
mizing the sizes of NPs is also particularly important for tumor
accumulation, penetration, and ﬁnally treatment eﬃcacy,387
particularly in targeting stroma-rich tumors.388 By using micelles,
ranging from 20 to 300 nm with the same chemical structure and
physical properties, Wang et al. found that the blood circulation
time and tumor accumulation of micelles increased with an
increase in their diameters; with optimal diameters ranging from
100 to 160 nm. However, higher tumor accumulation of the large
micelles (100 nm) did not result in signiﬁcantly improved
therapeutic eﬃcacy, because larger micelles had poorer tumor
penetration than did smaller micelles (30 nm). An optimal size
that balances drug accumulation and penetration in tumors is
critical for improving the therapeutic eﬃcacy of nanoparticulate
formulations.387 The size eﬀect is more pronounced in pancreatic
tumors, which usually have thicker stroma and hypovascular
characteristics that limit NP penetration. In the same direction,
Kataoka and co-workers discovered that tuning the size of
polymeric micelles in the range below 50 nm signiﬁcantly
improved the penetrability into stroma-rich pancreatic tumor
and consequently improved antitumor eﬃcacy.367 In addition,
30 nm polymeric micelles loaded with cisplatin have proceeded
onto Phase III clinical trials for the treatment of pancreatic cancer
patients by extending survival times in Phase I/II compared to
standard treatment using GEM.
Apart from passive targeting, as described above, there are also
exciting recent developments in actively targeting NPs. As one of
the early studies in designing integrin-targeted nanomedicines,
RGD-modiﬁed stealth liposomes achieved higher intracellular
levels of DOX.389 In recent years, more novel ligands against
various tumor targets have been employed by making use of
diﬀerent targeting motifs, including alpha-conotoxin ImI,
PHSCNK, lanreotide, octreotide and chlorotoxin for alpha 7
nAChR, integrin α5β1, somatostatin receptors, and chloride
channels.390−394 However, receptor redistribution induced by
ligand binding decreases receptor aﬃnity for ligands. A special
dimeric RGDwith proper distance between two RGDmotifs was
used to circumvent this problem.395 On the other hand, an
electrically neutral but hydrophobic penetration peptide was
introduced to modify NPs against diﬀerent breast cancer cell
phenotypes irrespective of their receptor expression, displaying
lasting accumulation and better inhibition of the tumor.396 Still,
there are ongoing discussions about the beneﬁts of active versus
passive targeting.34,397
Besides ligand-mediated active targeting, active physical
targeting has also been demonstrated. Magnetic focusing can
Figure 22. Interchange between “stealthy and sticky” for zwitterionic
polymer micelles (left) and the mix-charged AuNPs (right). Adapted
with permission from ref 379 and 380. Copyright 2012 and 2014 John
Wiley & Sons, Inc.
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enrich iron oxide NPs in the tumor region. Materials most
commonly used for magnetic drug delivery contain metal or
metal oxide NPs, such as SPIONs. Superparamagnetic iron oxide
NPs consist of an iron oxide core, often coated with organic
materials such as fatty acids, polysaccharides, or polymers to
improve colloidal stability and to prevent separation into NPs
and carrier medium.398,399 For some applications, a permanent
magnet is placed in the targeted region prior to the
administration of magnetic NPs. This has been done for ferric
steel implants, which were placed in the subarachnoid space in an
in vitro human spine model prior to NP administration into the
spine.400 Similarly, dilute microferrimagnetic wires implanted
within blood vessels in combination with an externally applied
magnetic ﬁeld can provide speciﬁc enrichment of simultaneously
administered ferromagnetic NPs.401 The challenge of NP
enrichment in deeper body regions was addressed by He and
co-workers, who deployed Halbach-like magnet arrays.402 Nacev
et al. also developed a sophisticated approach based on fast
magnetic pulses on ferromagnetic rods that led to reversing the
sign of the potential energy term in Earnshaw’s theorem. This
process enabled a quasi-static, stable trap between magnets,
resulting in the concentration of ferromagnetic rods on a central
target.403 These concepts are still far away from clinics. Magnetic
drug targeting (MDT), based on intra-arterial administration of
drug-loaded SPIONs, is closer to application in patients. This
technology involves enriching SPIONS via a strong external
magnetic ﬁeld. A proof-of-principle preclinical study was
conducted to demonstrate successful application of SPIONs
for cancer treatment.404 Simultaneous injection of Mitoxan-
tone−SPIONs into the tumor-supplying vessel in rabbits and the
application of a strong external magnetic ﬁeld over a VX2
squamous cell led to complete tumor remissions without side
eﬀects. By applying only 5−10% of the conventional chemo-
therapeutic dose, complete tumor remissions were achieved.
The distribution proﬁle after MDT displayed 57.2% of the total
recovery of administered drug: with 66.3% of the particles
localized in the tumor region with magnetic targeting, compared
to less than 1% of drug and NPs reaching the tumor region
during conventional intravenous application. Magnetic drug
targeting enables better enrichment of drug formulations and,
consequently, enables more speciﬁc treatment. The majority of
magnetic material is based on magnetic NPs either encapsulated
or coated by diﬀerent inorganic core/shell coatings405 or by
various polymer-basedmatrices, which are from natural406−408 or
artiﬁcial origin.409,410 To translate these magnetic nanoparticles
for clinical applications, the development of methods for large-
scale synthesis is required. A promising approach to synthesizing
fatty acid-coated SPIONs, shielded with albumin and function-
alized with adsorptive mitoxantrone, was developed with easy
scale-up synthesis pathways in order to obtain antitumor-
eﬀective magnetic NPs.411 Nanoparticles derived from this
process have proven to be stable under appropriate storage
conditions.412
Delivery of Macromolecular Biopharmaceuticals
across Biological Barriers. Nanomedicines are also being
developed for diagnosing and treating infectious, neurodegener-
ative, or cardiovascular diseases.413 Anticancer drugs are typically
small organic molecules; however, the number and impact of
macromolecular biopharmaceuticals (i.e., polypeptides and
polynucleotides) are increasing enormously. Their size and
complexity impose signiﬁcant challenges to their use as safe and
eﬀective medicines, including fast elimination and poor metabolic
stability. Furthermore, this class of compounds notoriously
suﬀers from limited permeability across biological barriers, such
as cellular membranes or epithelial tissues (see Figure 23).414 On
the other hand, their medical use oﬀers not only the ability to
ameliorate symptoms, but also the opportunity to cure or to
prevent diseases, either by directly correcting hormonal disorders
(e.g., insulin in diabetes) or by correcting, inhibiting, or repro-
gramming genetically disordered cells. The delivery of macro-
molecular biopharmaceuticals, preferentially via noninvasive
(“needle free”) approaches, is therefore another important
future application of nanomedicines. This approach takes
advantage of the fact that NPs can both stabilize and protect
the therapeutic cargo, while translocating across epithelial tissue
barriers like those of the gastrointestinal (GI) tract, skin, or
lungs.415
Similar to the EPR eﬀect, which occurs at the endothelium of
tumor blood vessels, NPs can also accumulate in inﬂamed
mucosal areas. This phenomenon was demonstrated recently by
Figure 23. Cellular and noncellular barriers of the lung: after landing on lung lining ﬂuids, (1) the drug (or eventually entire NPs) must cross the
pulmonary epithelium (2) in order to reach the underlying tissue or the systemic circulation, respectively. Besides, inhalation,
nanopharmaceuticals must also overcome eﬀective clearance processes (3) provided by either mucus in the central lung (bronchi) or by
macrophages in the peripheral lung (alveoli). Reprinted with permission from ref 414. Copyright 2014 Elsevier.
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confocal laser endoscopy in colitis patients.416 In several colitis
mouse models, oral administration of enteric-coated NPs that
encapsulated an anti-inﬂammatory compound showed signiﬁ-
cant alleviation of symptoms and inﬂammatory markers
compared to the same dose of free drug and nanocarriers
without enteric coating. At the same time, adverse eﬀects elicited
by drugs can be reduced through targeted delivery, which reduces
the dosing frequency as well as adverse side eﬀects.417,418
Nanoparticles can also accumulate in hair follicles and skin
folds after transport through the stratum corneum (SC). This
phenomenon depends on the NP size and shape. As a medical
application, it oﬀers the potential to reach the perifollicular
antigen-presenting cells without impairing the SC barrier.
Transfollicular delivery of ovalbumin using polymeric NPs was
recently shown to induce a signiﬁcant cellular and humoral
immune response, without compromising the SC barrier by any
pretreatment, when combined with innovative adjuvants.419−421
Lastly, pulmonary delivery of inhalation nanopharmaceuticals
is an area of emerging interest for the treatment of both systemic
and pulmonary diseases. Market approval of several inhalative
formulations demonstrates the preference of the public for less
invasive means of drug delivery. However, the lung features
several biological barriers that normally protect our bodies
against potentially noxious substances, which need to be
overcome for eﬀective delivery.422
Transport of biomolecular pharmaceuticals across barriers
such as bioﬁlms has also been a topic of focus. For example,
patients suﬀering from cystic ﬁbrosis, a genetic disorder, typically
get infections by opportunistic bacteria, most notably
Pseudomonas aeruginosa. These Gram-negative bacteria protect
themselves from attacks from the immune system by forming
bioﬁlms. Interfering with their so-called quorum sensing
communication systems by novel types of anti-infectives may
prevent bioﬁlm formation, therefore combatting the bacteria
while minimizing the development of resistance. Using solid lipid
NPs (<100 nm), researchers observed about a 7-fold increase in
potency to reduce the virulence factor pyocyanin compared to
the free drug.423 Nanoparticles can also be used to address
respiratory problems with implications for bacterial or viral
infections. Aerosolized chitosan-coated PLGA nanoparticles
have been used for in vivo genome editing by nuclease-encoding
RNA of a lethally deﬁcient surface protein B. As opposed to viral
vectors, which caused lethal adverse eﬀects in clinical trials, the
nanotechnology-based nonviral carriers can be prepared by well-
controlled chemical processes and do not bear the typical risks of
viral vectors.424
Stimuli-Responsive Release. Controlled-release systems
can potentially reduce or alter toxicity by selectively controlling
the rate of drug release and directly killing diseased cells.
Researchers have thus far developed many diﬀerent controlled-
release methods.30 For instance, transporter polymers containing
pH-sensitive groups are protonated or deprotonated in the
local microenvironment. This responsiveness again leads to the
disruption of the hydrophilic−hydrophobic balance of the
nanocarriers, triggering drug release. Alternatively, cleavage of
chemical bonds in response to pH can degrade the nanocarrier
and release drug molecules. Acid-sensitive polypeptide nanogels
have been reported for eﬃcient DOX loading and release. Dual
pH-sensitive polymer−drug conjugates that reversed their
surface charges from negative to positive at tumor extracellular
pH (∼6.8) promoted cell internalization and DOX drug release
at pH 5.0 (endo/lysosomal pH) by cleaving acid-labile hydrazine
bonds.425
Besides pH, redox potential has recently emerged as a
ubiquitous natural stimulus for intracellular drug and gene
delivery because of the large concentration gradient of
glutathione (GSH) in healthy (∼2−10 mM) and tumor tissues
(∼10−25 mM). Glutathione-responsive nanocarriers have been
designed containing disulﬁde bonds,426,427 either in the hydro-
phobic block of amphiphilic copolymers,428 at the interconnec-
tion of two polymer blocks,429 or as cross-linkers.430 The redox
potential diﬀerences of disulﬁde and diselenide bonds431,432
could even facilitate a dual reduction-sensitive polyplex for
programmed gene transfection, by sequentially deshielding the
reductive conditions of tumor tissues and consequently
degrading in response. In addition, thioether bridges of higher
chemical stability have been introduced oﬀering better handling
and storage compared to disulﬁde bridges.433 Cleavage of the
thioethers is only triggered by high GSH concentrations above
10 mM, which maximizes the local speciﬁcity of redox triggered
drug release in tumor cells.
Another powerful stimulus to release NPs are enzymes, which
can be in overabundance under pathological conditions such as
cancer or inﬂammation. Elevated local concentrations of matrix
metalloproteinases (MMPs), phospholipases, or glycosidases
have been exploited to release drug molecules from drug
transporters containing the respective enzyme substrates. For
instance, MMP-sensitive nanocarriers have been designed by
conjugating DOX to silica NPs via a MMP-sensitive peptide.375
The delivery of the nanocarrier to the tumor exposed the carrier
to the presence of MMPs in the tumor, which degrades the
peptide linker and causes rapid release of the drug DOX from the
silica NP.
Tumor cells are characteristically heterogeneous in many
aspects.434 As a result, nanocarriers responding to a single type of
signal would release the drug only in the fraction of tumor cells
overexpressing that particular signal but not in other tumor cells,
thereby decreasing the overall therapeutic eﬃcacy of the drug
formulation.435 For instance, cancer cells may be under reducing
conditions as a result of their elevated intracellular GSH levels,
which may be several-fold higher than those of normal cells.436
Also, many tumor cells are reported to overproduce ROS, e.g.,
perhaps more than 1 order of magnitude higher than healthy
cells,437 and thus increase oxidative stress.438 These heteroge-
neous cells may exist in diﬀerent tumors, but may also coexist in
diﬀerent regions in one tumor. Tumor cells at diﬀerent stages
may also have diﬀerent GSH/ROS levels.435,436,438−440
To compensate for this observed tumor heterogeneity, Wang
et al. proposed an amphiphilic SN38-prodrug formed nano-
capsule that could respond to both intracellular GSH and ROS to
release the carried drug (see Figure 24).441 The thioether linker
of the prodrug was designed to undergo thiolysis in the presence
of GSH or fast hydrolysis due to ROS oxidation of the linker,
giving rise to high in vitro cytotoxicity and in vivo anticancer
therapeutic activity. The nanocapsules had a SN38 loading
content of 35 wt % and were able to target the tumor passively via
the EPR eﬀect, making them ideal for translational nano-
medicine.441
The development of intracellular stimuli-responsive drug-
loaded NPs has recently attracted substantial research eﬀorts.442
Speciﬁcally, the intracellular release of drugs by biomarker
triggers or intracellular environmental conditions holds great
promise as a means to localize the drug in disease-carrying cells.
Consequently, this decreases the dose of drugs required
for treatment and reduces harmful eﬀects on normal cells.
The recognition and catalytic properties encoded in nucleic acids
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have been implemented to developmesoporous SiO2NPs for the
intracellular controlled release of anticancer drugs. Figure 25A
exempliﬁes the controlled release of the anticancer drug
camptothecin (CPT) from mesoporous SiO2 NPs (100 nm
diameter) using intracellular triggers.443 The systemmakes use of
the fact that adenosine triphosphate (ATP) is overexpressed in
cancer cells due to their enhanced metabolism, and the fact that
speciﬁc enzymes, such as the exonuclease EndoGI, are produced
in certain cancer cells. Accordingly, the mesoporous SiO2 NPs
were loaded with the CPT anticancer drug, and the pores were
capped with bulky hairpin nucleic acid units. The hairpin
structures included programmed sequence-speciﬁc aptamer
domains, which recognize the ATP biomarker. The interaction
of intracellularly generated ATP with functionalized NPs
resulted in the reconﬁguration of the hairpin units into ATP−
aptamer complexes that were recognized by the secondary
intracellular cancer cell biomarker EndoGI. The biocatalytic
digestion of the duplex domains of the ATP−aptamer complexes
resulted in the regeneration of the ATP biomarker, and the
EndoGI-stimulated unlocking of the capped pores, leading to the
release of the CPT drug. Figure 25B shows the cytotoxic eﬀects
of the stimuli-responsive CPT-loaded mesoporous SiO2 NPs on
MDA-MB-231 breast cancer cells, panel I, and on normal
epithelial MCF-10a breast cells, panel II. After a time interval of
48 h, the cell viability of the MDA-MB-231 cells decreased by
65%, whereas the viability of normal cells only decreased by 20%.
The eﬀective cell-death of the cancer cells was attributed to the
ATP-EndoGI-driven release of CPT in cancer cells.
Mesoporous SiO2 NPs were also loaded with anticancer drugs,
such as DOX, and capped with various other stimuli-responsive
nucleic acids responding to substances or environmental
Figure 24. SN38 prodrug formed nanocapsule responsive to tumor GSH/ROS heterogeneity, releasing the parent drug SN38 via thiolysis in the
presence of GSH or via enhanced hydrolysis due to ROS oxidation of the linker. This process thereby gives rise to high in vitro cytotoxicity and
in vivo anticancer therapeutic activity. Reprinted with permission from ref 441. Copyright 2013 John Wiley & Sons, Inc.
Figure 25. ATP-EndoGI sense-and-treat system involving
CPT-loaded mesoporous SiO2 NPs: (A) Reconﬁguring the DNA
capping units via the formation of ATP−aptamer complexes,
followed by the Endo GI digestion of these complexes which leads
to the recycling of the ATP biomarker and the release of CPT.
(B) Cytotoxicity of the ATP/EndoGI-responsive CPT-loaded SiO2
NPs toward (I) MDA-MB 231 cells, (II) MCF-10a cells. Entries
(a) correspond to treatment of the cells with unloaded NPs and
(b) correspond to CPT-loaded SiO2 NPs. Gray bars correspond to
cell viability after 24 h, and black bars represent the cell viabilities
after 48 h. Adapted from ref 443. Copyright 2013 American
Chemical Society.
ACS Nano Nano Focus
DOI: 10.1021/acsnano.6b06040
ACS Nano 2017, 11, 2313−2381
2339
conditions existing in cancer cells. For example, the in vitro
release of DOX from mesoporous NPs was triggered by the
miR-21 biomarker present in cancer cells444 or by releasing the
i-motif locking units under the acidic conditions available in
cancer cells.445 Similarly, Zhang et al. reported the cleavage
of DNA-capped, DOX-loaded mesoporous SiO2 NPs by the
ATP-promoted activation of a catalyticMg2+-dependentDNAzyme
that was associated with the capping units.446 The intracellular
release of DOX from DNA-capped mesoporous nanoparticles
using photogenerated ROS species has also been demonstrated.447
In order to realize the potential of these stimuli-responsive NPs
fully, toxicity must be evaluated in cells and animals.
Although numerous internal stimuli have been investigated,
it remains a challenge to receive a sharp response to subtle changes
in environmental conditions. As a result, many exogenous stimuli-
responsive drug nanocarriers have been designed to respond to
external stimuli such as temperature changes, magnetic or electric
ﬁelds, and light (i.e., electromagnetic waves) to control the spatial
location of drug release.448,449 Particularly,magnetically responsive
transporters have been developed to target tumor tissue under
the inﬂuence of an external magnetic ﬁeld.450 This concept has
demonstrated great potential in cancer therapy and increased
therapeutic eﬃcacy at lower doses with fewer toxic eﬀects.
In addition, magnetic resonance imaging combines diagnostics
and therapy in the same system, as we will emphasize in the
theranostics section. Light is another attractive stimulus for the
construction of stimuli-responsive drug nanocarriers, since this
approach enables remote and spatiotemporal drug release by
tuning the wavelength, energy, and site of irradiation. The
advantages of phototriggered drug release are obvious; however,
accessibility of the body for light is limited.451 Skin treatment is
the most obvious application of this technology, but there are
numerous other methods used for drug release on or through the
skin by epitopical methods. Interestingly, Sykes and co-workers
showed that QDs and AuNPs can accumulate and transit through
the skin after tail vein injection. Their results suggest that skin
may be a depot for light-activated NP drug release.452
Photochemical drug release has also been studied in the lungs.
Practically all organs accessible by endoscopic tools may be
treated this way.453 For the combination of light and interven-
tional therapy, ﬁxed-point drug release can be realized by taking
advantage of optical ﬁbers. Near-infrared laser-triggered drug
nanocarriers are particularly promising due to deeper tissue
penetration, lower scattering properties, and minimal harm
imposed on tissues. Thus, NIR-responsive systems are promising
platforms for clinical applications.454−456 Several studies have
demonstrated that uponNIR irradiation,457 AuNPs incorporated
in the wall of the polymer-based delivery container can convert
light into heat through a series of photophysical processes.
The heat can directly destroy cancer cells or facilitate disruption
of thermoresponsive NPs, resulting in the release of encapsulated
drugs.458,459 Controlling this process by minimizing heat
accumulation can lead to nondestructive opening of capsules
and intracellular delivery of medicine.460−462 However, even
though these strategies have proven successful in several
examples, deep tissue penetration to reach less accessible targets
is still challenging and the accuracy is often low due to
complicated tissue and bone environments inside the body.
Thus, the future success of this strategy is not only dependent on
material design, but also on the development of advanced
instruments to position the therapeutic stimulus accurately.
In ophthalmology, there is a need to release drugs for the
treatment of secondary cataracts years after implantation of an
artiﬁcial intraocular lens. In this case, since the cornea is a good
ultraviolet light absorber, the use of ultraviolet light is not
appropriate for treatment. Photochemical drug release from
polymers by two-photon absorption can potentially overcome
these problems. In addition to low molecular weight drugs, NPs
can similarly be released by two-photon absorption.463 Examples
of such materials have been developed and successfully tested in
the lab and in animal models. Thermoresponsive drug nano-
carriers have been intensively investigated as drug delivery systems.
These transporters reveal high stability at body temperature
(∼37 °C) but rapidly release their drug cargos within locally
heated tissue (∼40−42 °C).464 This approach is particularly
attractive in combination with AuNP-assisted NIR plasmonic
photothermal therapy.
Alternative Delivery Strategies. An alternative delivery
strategy involves combining multiple antitumor drugs in
one carrier.465,466 The poor speciﬁcity of most drugs and the
complexity of tumors (e.g., multiple targets) contribute greatly to
the poor prognosis of chemotherapy. Passively or actively
targeted nanopreparations usually enhance the selectivity of
anticancer drugs while the combination of therapies against more
than one single tumor target improves the therapeutic out-
come.467 Co-delivery of chemotherapeutic drugs and nucleic
acids has shown promising results in overcoming multidrug
resistance. Simultaneous delivery of small-molecule drugs and
nucleic acids is challenging due to the pronounced diﬀerences in
their physicochemical properties, which may greatly aﬀect their
biodistribution and pharmacokinetics. The preparation of
delivery systems that enable the delivery of structurally diﬀering
drugs with comparable pharmacokinetics is attractive to inhibit
tumor growth eﬃciently. For example, Zhang et al. demonstrated
that the combined use of octreotide-modiﬁed paclitaxel micelles
and salinomycin micelles eradicated both breast cancer and
cancer stem cells.468 Zhou et al. have shown that treatment of
prostate cancer with a combination of two nanoconjugates, one
targeting the hedgehog-signaling pathway of stem cells (HPMA
copolymer-cyclopamine conjugate) and the other diﬀeren-
tiated cells (HPMA copolymer-docetaxel conjugate), improved
survival rates.469 Dai et al. reported a strategy combining the
mTOR inhibitor, rapamycin, and DOX-loaded octapeptide
liposomes to combat triple-negative breast cancer.470 Feng
et al. studied the synergistic inhibition of breast cancer by
codelivering VEGF siRNA and paclitaxel via vapreotide-modiﬁed
core/shell NPs.471 Fan et al. found that the reduction of tumor
interstitial ﬂuid pressure by liposomal imatinib improved the
antitumor eﬀect of liposomal DOX.472 Finally, Wang et al.
demonstrated the sequential killing of tumor vasculature and
tumor cells via integrin-targeted polymeric micelles loaded with
both combretastatin A4 and DOX.473
In addition to intravenous delivery, nanomedicines can be
delivered locally. Most chemotherapeutics are delivered systemi-
cally, where high doses result in severe side eﬀects and only a
limited amount of drug reaches the tumor site. Intratumor or
peritumor delivery is thought to improve these issues but the
challenge is in simultaneously achieving high drug loading,
sustained and stable drug release, and long-term local drug
retention. One platform achieved these requirements by
incorporating micelles or nanocrystals of a hydrophobic anti-
tumor drug, such as docetaxel and paclitaxel, into a thermo-
sensitive injectable hydrogel.474,475
Tumor metastasis accounts for 90% of cancer-associated
deaths and is almost inaccessible by chemotherapy, surgical
operation, or radiotherapy. A nanomedicine modiﬁed with a
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peptide-targeting metastasis can facilitate DOX in inhibiting
metastatic tumor growth and prevent the initiation and
progression of tumor metastasis.476 Its targeting to highly
metastatic tumors was demonstrated in a double tumor-bearing
model with both metastatic and nonmetastatic tumors in the
same mouse.477 Lymph-targeting peptides can enhance nano-
particle delivery to a highly metastatic tumor and its
lymphatics.478 Chlorotoxin, a venom peptide previously used
for brain targeting, was found to inhibit metastatic tumor growth
andmetastasis.479 After intravenous injection, CPTNPs accumu-
lated in the lungs, a major metastatic site for many types of
cancers, which led to greater antimetastatic eﬃcacy.480 Finally, a
macrophage-based biomimetic delivery system inhibited meta-
stasis due to its tumor-homing properties.481
Regulating Cells with RNA. Targeting protein-coding
messenger RNAs (mRNAs) and regulating noncoding RNAs
by delivering therapeutic RNA eﬀectors or modiﬁed derivatives
has become an important research topic in nanomedicine. In
principle, there are four diﬀerent strategies to deliver nucleic acid
eﬀector molecules: (i) through viral vectors that encode RNA
eﬀectors such as short hairpin (shRNAs), usually adeno-associated
viruses or lentiviruses;482−484 (ii) via NPs based on liposomes
(lipoplexes), polycations, or polyamines (polyplexes);485,486
(iii) as conjugates with hydrophobic molecules (e.g., cholesterol
or tocopherol),487,488 N-acetylgalactosamine,489 or aptamers;490
and (iv) by gymnotic (“naked”) delivery of chemically modiﬁed
RNA, which means functional delivery into cells without any
further formulation.491 There are various possibilities to form
nanoplexes with nucleic acid eﬀectors. For example, chitosans,
dendrimers, polyethylenimine, atelocollagen, or cyclodextrin can
be used to produce polymeric NPs for delivery. Cationic or
neutral liposomes, as well as zwitterionic polymer micelles are
available options among liposome-based NPs. Several of
these nanoplexes are now in clinical studies, illustrating that
RNA-based therapeutics are considered promising for future
healthcare. Functionalization of nanoplex delivery sytems opens
many perspectives for a more speciﬁc delivery of NPs to their
target cells.
We will focus our discussion on relatively small nucleic acid
eﬀectors, usually not exceeding 50 nucleotides (nt; U1 adaptors,
siRNA duplexes) and as short as 8 nt (tiny locked nucleic acids
[LNAs]). Such antisense oligonucleotide (ASO) eﬀectors are
routinely designed with strategic nucleotide modiﬁcations to
improve various features, such as stability in biological ﬂuids,
cellular uptake, target RNA aﬃnity, and speciﬁcity, or to
minimize toxicity, nonspeciﬁc immune stimulation, and oﬀ-
target eﬀects.492 At present, the most eﬀective and widely used
chemical modiﬁcations are phosphorothioates, ribose 2′-OH
modiﬁcations (e.g., 2′-O-methyl, 2′-ﬂuoro or 2′-O-methoxyethyl
modiﬁcations), and LNA residues with their ribose moiety
locked in the 3′-endo conformation by a methylene bridge con-
necting the 2′-oxygen and the 4′-carbon atom (see Figure 26A).
Locked nucleic acid modiﬁcations make ASOs nuclease-resistant
and increase duplex stability with target RNAs more than any
other known nucleotide modiﬁcation, without compromising
target speciﬁcity as long as immune stimulatory sequences are
avoided.493,494 Gapmers are ASOs carrying an internal stretch of
at least 6 DNA oligonucleotides for the recruitment of
endogenous RNase H activities that cleave the target RNA
in the RNA:DNA hybrid region. The 5′- and 3′-terminal
nucleotides of gapmers preferentially modiﬁed with LNA
residues (termed LNA gapmers)495 to optimize target aﬃnity
and to confer nuclease resistance (see Figure 26B). Such LNA
Figure 26. (A) Chemical nucleoside modiﬁcations frequently used for
nucleic acid eﬀectors. In many cases, phosphorothioate (PS)
modiﬁcations (one of the two nonbridging oxygens of the
phosphodiester replaced with sulfur) are incorporated, to improve the
pharmacokinetic properties and cellular uptake. (B) LNA gapmers
composed of terminal LNA residues and at least 6 central DNA
nucleotides enable cleavage of RNA target strands as part of RNA:DNA
hybrids by endogenous RNase H activities. (C) In the U1 adaptor
approach, a U1 small nuclear ribonucleoprotein (snRNP) (an abundant
spliceosomal RNP) is guided to the 3′-terminal exon of a target
pre-mRNA via a dual antisense oligonucleotide that simultaneously
anneals to the 5′-end of U1 RNA. This blocks polyadenylation via an
inhibitory interaction between poly(A) polymerase (PAP) and the
U1−70K protein. As a result, the pre-mRNA is still cleaved but not
polyadenylated, which induces its degradation. Eﬃcient down-
regulation by “U1 interference (U1i)”was observed with target domains
of 12−15 nt (with up to 15 LNA residues) and 10−13 nt in the U1 RNA
binding domain (good eﬃciency observed with eight 2′-O-methyl and
ﬁve LNA residues). A PS backbonewas also found to be compatible with
U1i.499,500 U1A, U1C, U1−70k and the Sm ring proteins are integral
components of the U1 snRNP. PAP: poly(A) polymerase; CPSF:
cleavage and polyadenylation speciﬁcity factor (including the
endonucleolytic subunit 73);CA: cleavage site. Adaptedwith permission
from ref 500. Copyright 2009 John Wiley & Sons, Inc.
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gapmers are applied to knocking down mRNAs and long
noncoding RNAs (lncRNAs) which have emerged, like miRNAs
(see below), as an abundant class of regulators of gene expres-
sion.496 Aberrant expression of lncRNAs is often causatively
linked to pathological processes.497,498
The classical RNAi eﬀectors are siRNAs, usually delivered in
the siRNA duplex format (19 bp plus 2 nt overhangs at the
3′-ends; see Figure 27), although other formats have been
reported, often combined with strategic chemical modiﬁca-
tions.492 siRNAs can be delivered indirectly by using viral vectors
(e.g., lentiviral vectors) that encode one or a few shRNAs (see
Figure 27). Such approaches have been explored for anti-HIV
therapy,484,501 as they permit controlled expression of shRNAs
and increase the duration of the RNAi eﬀect.
The miRNAs, representing the endogenous RNAi eﬀector
branch, are interesting targets because their aberrant expression
(down- or up-regulation) is also causatively linked to many
pathological processes such as tumorigenesis. Here, two diﬀerent
therapeutic strategies have emerged: (i) delivery of so-called
miRNA mimics (aiming at restoring the normal levels of a
miRNA), and (ii) ASOs that sequester overexpressed mature
single-stranded miRNAs, called anti-miRNAs as the overarching
term. Classical anti-miRs are complementary to 15 or more
nucleotides of the miRNA single strand and are modiﬁed with
2′-O-methyl groups and PS internucleotide bonds.502 Recently,
Miravirsen (Roche Innovation Center Copenhagen A/S), a
15-meric miR-122-speciﬁc anti-miR with a PS-modiﬁed back-
bone and a mixture of LNA and DNA residues,503−505 suc-
cessfully passed a phase 2 clinical trial after signiﬁcantly reducing
hepatitis C virus replication in liver cells.503−505 As a peculiarity
of miRNAs, the essential base-pairing interaction with target
mRNAs is conﬁned to the so-called seed region comprising the
5′-terminal 6−8 nt of the miRNA. In fact, there are families of
miRNAs whose members share the same seed sequence and are
likely to interact with the same target mRNAs. For the sake of a
strong therapeutic eﬀect, in many cases it appears reasonable
to inactivate all miRNA members of the same family. This inacti-
vation is achieved by a class of anti-miRs termed “tiny LNAs”
which are uniformly PS- and LNA-modiﬁed 8-mers directed
against the miRNA seed region. Tiny LNAs speciﬁc to miR-122
have been successfully delivered without any formulation to the
livers of primates and nonprimates, where they down-regulated
cholesterol levels.506 In addition, 14-meric fully LNA-modiﬁed
anti-miRs, termed antiseeds, carrying a natural PO backbone and
covering the seed region plus the central part of the target
miRNA, were shown to exert a remarkably persistent inhibition
Figure 27. Exogenous RNA eﬀectors utilizing the RNAi machinery of mammalian cells (siRNA duplexes, shRNAs, miRNAmimics) or interfering
with the function of endogenous miRNAs (antimiRs). siRNA duplexes, 19 bp long, mimicking the processing products of the RNase Dicer, are
incorporated into the RNA-induced silencing complex (RISC). One of the two siRNA strands (termed the guide strand) is selected by RISC to
guide the complex to complementary mRNAs sequences that are cleaved by the endonuclease Ago2 followed by mRNA decay. This catalytic
process is highly eﬃcient as one siRNA-programmed RISC can cleave many complementary mRNA molecules. In the case of small shRNA
expression vectors, a single ormultiple shRNAs are usually transcribed fromRNApolymerase III promoters after theDNA vector has reached the
nucleus; alternatively, miRNA polycistrons can be transcribed from RNA polymerase II (Pol II) promoters. The miRNA primary transcripts
(termed pri-miRNAs), vector-encoded shRNAs or polycistronic miRNA transcripts are processed by Drosha and DGCR8 and are exported as
precursor intermediates (pre-miRNAs or shRNAs) from the nucleus by the export factor exportin 5 (Exp. 5). The ﬁnal maturation to short
duplexes is catalyzed by the RNase Dicer in the cytoplasm. siRNA and miRNA pathways diﬀer after guide strand selection by RISC: whereas
siRNAs are fully complementary to the target mRNA and induce its cleavage, miRNA strands guide the RISC primarily to the 3′-UTR of their
target mRNAs where they form only partial base pairing interactions. The prevailing biological miRNA eﬀects are inhibition of the
5′-cap-dependent initiation of protein biosynthesis and/or induction of mRNA transfer into cytoplasmic “processing (P) bodies”, where the
mRNAs are stored or degraded; m7G: 7-methyl-guanosine-5′,5′-triphosphate cap at the 5′ end of mRNAs; An: poly(A) tail at the 3′-end of
mRNAs.
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eﬀect against miRNA families. Such antiseeds can also be
delivered as NPs with a branched low-molecular-weight poly-
ethylenimine (PEI LMW-25), whereas tiny LNAs can not.507
More eﬃcient formulation of longer antiseeds relative to tiny
LNAs may be of advantage for NP-based delivery into tissues not
accessible by gymnotic delivery. A PO instead of PS backbone
may reduce spurious interactions with extra- and intracellular
proteins.
Another promising ASO strategy is based on U1 adaptors,
which are dual antisense molecules that base-pair with the
3′-terminal region of U1 RNA as part of the highly abundant U1
snRNPs, and with an accessible sequence in the last exon of the
target mRNA.500 This recruitment of the U1 snRNP blocks
polyadenylation of the mRNA (but not its cleavage), which
consequently results in its degradation by exonucleases499
(see Figure 26C).508 It will be interesting to see if the U1
adaptor strategy is applicable to pathologically overexpressed
lncRNAs that also undergo polyadenylation.
Here, we have described short nucleic acid eﬀectors. Their
potential advantages are (i) cost-eﬀective synthesis, (ii) modu-
lation and control of their properties by introduction of chemical
modiﬁcations, and (iii) facile incorporation into many NP
platforms. Of course, more complex RNA-based therapeutics
have been conceived. As an example, Qiu et al. combined the
bacteriophage phi29 DNA packaging motor pRNA 3WJ with
folic acid targeting, a NIR marker for imaging and a BRCAA1
(breast cancer associated antigen 1, AF208045) siRNA for
RNAi43 (see Figure 20).
Inorganic NP-Mediated Cell Death. Most nanoparticle
formulations for cancer treatment act as delivery vehicles of
cytotoxic agents to induce a cytostatic eﬀect on tumors. Another
emerging application of nanomedicine is the direct use of NPs as
highly eﬃcient and low-toxic drugs without carrying drug
molecules: the inorganic NPs themselves are used as the
therapeutic agent. For example, Gd@C82(OH)22 with a dose
level as low as 10−7 mol/kg exhibits an antineoplastic eﬃciency in
tumor-bearing mice.509 The Gd@C82(OH)22 NPs directly
possess a strong capacity to improve immunity510,511 and
interfere with tumor metastases in vivo,512−515 with tolerable
toxicity in vivo and in vitro. The high antitumor eﬃciency of these
NPs is not due to direct toxic eﬀects induced on tumor cells,
indicating that the anticancer mechanisms are diﬀerent from
classical cancer therapeutics. Results from recent studies suggest
a new concept of “caging cancer”with Gd@C82(OH)22 NPs, versus
“killing cancer” by classical therapeutics. The “caging cancer”
concept515,516 refers to rendering the tumor microenvironment
inhospitable for tumor growth by forming an induced ﬁbrous
layer around the surface of a solid tumor, while using the
Gd@C82(OH)22 NPs to regulate the diverse components of
the tumor microenvironment. By employing this concept, the
Gd@C82(OH)22 NPs were able to prevent tumor resistance to
therapeutic drugs513 while reducing ROS production in tumor-
bearing mice. Furthermore, these NPs mitigated damage to the
main organs by decreasing all metalloprotease enzyme activities,
while restoring other parameters, such as oxidative stress, close to
normal levels.517,518 These NPs also induced dendritic cells to
become functionally mature and increased their capacity to
activate allogeneic T cells in tumor-bearing mice.510,511,519
Tumor angiogenesis can also be inhibited by simultaneously
down-regulating more than 20 angiogenic factors.513 More
interestingly, Gd@C82(OH)22 NPs were found to be capable of
inhibiting triple-negative breast cancer cells by blocking the
epithelial-to-mesenchymal transition, resulting in the eﬃcient
elimination of cancer stem cells (CSCs) in vitro and in vivo.520
In comparison, the use of classical anticancer drugs like paclitaxel
resulted in a relatively high enrichment of CSC and promoted
Figure 28. (A) Relative catalytic activity of galactosidase in the presence of three diﬀerent shapes of ZnO NPs. The relative catalytic activity of
galactosidase with each of the ZnONPs was normalized with respect to free enzyme activity. (B) Pictorial representation of pyramid-shaped NPs
interacting with the active site of galactosidase. (C−E) Lineweaver−Burk plots of galactosidase activity with various concentrations of ZnO
(C) nanopyramids, (D) nanoplates, and (E) nanospheres. Adapted from ref 524. Copyright 2015 American Chemical Society.
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tumor sphere formation and abrogation of tumor initiation and
metastasis, probably due to its selective toxicity to regular
tumor cells only but not to CSCs.520 However, the nontoxic
Gd@C82(OH)22 NPs selectively target CSCs but not regular
tumor cells under hypoxic conditions. Such eﬀects have not been
observed in normal stem cells. The direct use of nontoxic
nanomedicines with new acting mechanisms like “caging cancer”
instead of killing cancer can be considered a potentially
revolutionary shift in cancer therapeutics in clinical applica-
tions.521 In the future, such strategies based on shutting down the
tumor infrastructure will gain more importance due to their
reduced side eﬀects. Despite the broad medical utility of this NP
system, the use of Gd-based nanomedicine has recently faced
controversy related to potential toxicity issues.522,523
In another example, Cha et al. proposed ZnO NPs as a
therapeutic agent since these NPs can be engineered to speciﬁc
shapes that act like biomimetic enzyme inhibitors.524 The ZnO
NPs were able to inhibit the activity of beta-galactosidase
reversibly in a shape-dependent manner (see Figure 28A).
That inhibition was not the result of protein denaturation, but
rather a subtler conformational frustration of the enzyme that
more closely resembles the mechanism of naturally occurring
enzyme inhibitors. Furthermore, Cha et al. demonstrated that the
NP-based enzyme inhibition can be characterized using the
classical Michaelis−Menten and Eadie-Hofstee formalisms
(see Figure 28C−E). As many traditional pharmacological thera-
peutics are enzyme inhibitors, this work opens the door for
the design of a new class of degradation-resistant inorganic
NP enzyme inhibitors that can be particularly suitable for
antibiotic resistant bacteria exempliﬁed by methicillin-resistant
Staphylococcus aureus (MRSA, see below).
Another approach used to design NP-based drugs to induce
apoptosis in malignant cells is based on the cross-linking
induction of the surface noninternalizing receptors. Receptor
cross-linking involves the biorecognition of high-ﬁdelity natural
binding motifs with cell receptors or with side chains of water-
soluble polymers. The general design concept of drug-free macro-
molecular therapeutics is shown in Figure 29. An important feature
of these designs is the absence of low-molecular-weight cytotoxic
compounds. The concept was validated for the treatment of non-
Hodgkin lymphoma (NHL) using nanoconjugates that target
CD20 (noninternalizing) receptors on B cells. The system is
composed of two nanoconjugates: (a) an anti-CD20 Fab′ frag-
ment covalently linked to a biological moiety (oligopeptide or
oligonucleotide) and (b) a polyHPMA grafted with multiple
copies of the complementary oligopeptide/oligonucleotide.
Exposure of human NHL Raji B cells to anti-CD20 Fab′-Motif 1
decorates the cell surface with peptides/oligonucleotides.
Further exposure of the decorated cells to graft copolymer
P-(Motif 2)x results in heterodimerization or hybridization and
triggers the cross-link between CD20 receptors and initiating
apoptosis in vitro and in a NHL animal model in vivo.525−527
Magnetic resonance imaging and ﬂow cytometry analysis
indicated that no residual cancer cells were detectable in long-
term survivors (125 days).527 Multimodality imaging studies
investigating the interaction between cellular membranes and
nanoconstructs conﬁrmed that self-assembly plays a critical
role in this highly speciﬁc therapeutic system.528,529 This new
paradigm demonstrated activity in the treatment of cells isolated
from patients with chronic lymphocytic leukemia and mantle cell
lymphoma.530,531 This interdisciplinary strategy has potential
to overcome rituximab-related resistance and become a new
drug development pipeline for the treatment of NHL and other
B-cell-derived hematological neoplastic diseases and auto-
immune disorders.532
Killing Cells with Inorganic NPs upon External Stimuli.
Inorganic NPs can respond to external stimuli to elicit tumor cell
death. In the following section, we describe three common
examples of external stimuli-driven NP therapies, including
photodynamic therapy (PDT), photothermal therapy (PTT),
and magnetic hyperthermia.533−535
In its simplest form, PDT relies on the interaction between a
photosensitizer (PS), a light source, and oxygen. A PS is a
nontoxic compound capable of absorbing light and producing
ROS upon de-excitation, producing ROS. Photosensitizer
excitation is usually achieved via one-photon transition between
its ground state S0 and a singlet excited state, S1. At this point, the
molecule may return to its ground state via emission of a photon
(ﬂuorescence), but the excited PS may also generate a triplet
state T1 by intersystem crossing. The lifetime of T1 is longer
(microseconds) than S1 (nanoseconds), enabling the system to
react in one of two ways, called the Type I and Type II
mechanisms. The Type I mechanism involves electron transfer
between the PS and a substrate, yielding free radicals that can
then react with oxygen to form ROS, such as superoxide radical
anions. In the Type II mechanism, singlet oxygen is generated via
an energy transfer between the PS and triplet oxygen.536
Desirable characteristics of PSs are (i) high absorption
coeﬃcient in the spectral region of the excitation light, preferably
in the NIR emission range if PSs are to be used in PDT of cancer
states; (ii) a triplet state of appropriate energy (ET > 95 kJ mol−1)
to enable eﬃcient energy transfer to ground state oxygen;
(iii) high quantum yield (QY) for formation of the triplet state
and long triplet state lifetimes (τ > 1 μs); and (iv) high photo-
stability. Organic dyes and aromatic hydrocarbons are one
class of molecules that possess these properties. They include
dyes such as rose bengal, eosin, and methylene blue that are
eﬀective PSs because they possess triplet states of appropriate
energy. They have high singlet oxygen yields, with rose bengal
Figure 29. Schematic of overall design and possible mechanism of
drug-free macromolecular therapeutics for treatment of NHL.
Adapted from ref 527. Copyright 2014 American Chemical Society.
ACS Nano Nano Focus
DOI: 10.1021/acsnano.6b06040
ACS Nano 2017, 11, 2313−2381
2344
reaching a value of Φ = 0.71,537 and strong absorption bands in
the green region of the spectrum. Aromatic hydrocarbons such
as napthalenes, anthracenes, and biphenyls have also been
investigated as PSs. Studies found that the eﬃciency of energy
transfer to triplet oxygen is greatly aﬀected by the substituents on
the biphenyl ring and by the polarity of the solvent. Finally,
quinones are good PSs, with QYs in the range of 0.11−0.76,538
but sometimes they lack strong absorption bands at wavelengths
shorter than 600 nm. Porphyrins, phthalocyanines, and related
tetrapyrroles are another class of molecules that were identiﬁed
as excellent PSs. Porphyrins and their analogues are ideal PS
candidates because they occur naturally in biological systems and
therefore generally lack cytotoxicity in the absence of light.
These compounds have high QYs and properties that can be
easily tuned by changing the substituents on the macrocycle, but
they are susceptible to photobleaching. Also worth mentioning
are naphthalocyanines, which bear a second benzene ring on the
primary phthalocyanine ring. This addition is responsible for an
attractive red-shift in absorption from 680 to 770 nm. Chlorins,
derived from the porphyrin structure through saturation of one
or two double bonds, also have absorbance spectra red-shifted
into the therapeutic spectral window. The most studied member
of this class is hematoporphyrin, which has high singlet oxygen
production QY of 0.65 but unfortunately only a weak absorption
band at 630 nm (ε = 3500 M−1 cm−1). Some transition metal
complexes have been identiﬁed as eﬃcient photosensitizers,
having singlet oxygen QY comparable to the well-studied organic
compoundsmethylene blue and rose bengal. Ru(II) tris-bipyridine
and [Ru(bpy)3]
2+, in particular, are eﬀective singlet oxygen
producers with a QY of 0.73 in oxygen-saturated deuterated
methanol and 0.22 in water.539 Lastly, little attention has been paid
to semiconductorNPs as PSs.However, singlet oxygen production
and subsequent cytotoxicity from photoexcited semiconductors
such as TiO2 and ZnO have been reported.
540
In addition to the aforementioned requirements, the
application of PDT to the treatment of cancer or other patho-
logical conditions places other requirements on potential PSs.
First, the compound should have low dark toxicity (i.e., it should
not be toxic to the organism in the absence of light). Second, it
should selectively accumulate into the aﬀected tissue in order to
minimize side eﬀects and maximize cytotoxic eﬃciency. In fact,
the half-life of singlet oxygen in biological systems is <0.04 μs,
translating into a radius of action of <0.02 μm.541 Finally, strong
absorbance in the red-NIR portion of the spectrum would be
advantageous for the PS, as these wavelengths are able to
penetrate the deepest into biological tissue (see Figure 30).
The ability to excite a PS in this region would increase ROS
production eﬃciency, lowering the number of scattered photons,
and achieve maximum attainable treatment depth.
Keeping in mind these requirements, PSs for PDT of cancer
have been classiﬁed into three generations. (i) The ﬁrst
generation consists of hematoporphyrin derivative (HpD) and
its analogues. Beginning in the 1970s, this compound was
the ﬁrst tested and authorized for clinical use. HpD (stage 1)
is obtained from hematoporphyrin and is a mixture of ∼10 com-
ponents. Descending directly from HpD and now one of the
most widely used PSs, porﬁmer sodium (Photofrin, Sinclair) is
HpD stage 2, which is HpD puriﬁed from its monomeric fraction
via high performance liquid chromatography. Despite being the
most studied, this group of PSs suﬀers from major drawbacks;
their selectivity is poor and only 0.1−3.0% of injected PS is found
in tumor tissue.542 The cutaneous tissue can take up and retain
these compounds for up to 10 weeks after intake, thus causing
photosensitivity in the patient. Furthermore, their absorbance in
the NIR optical window is weak, limiting the eﬃciency of light
uptake. (ii) The second generation has been designed with the
aim of overcoming previous limitations and includes structurally
distinct compounds with long-wavelength absorption and high
singlet oxygen QYs. Part of this generation is hematoporphyrin
derivatives with enhanced solubility properties for faster
clearance from the organism and chlorins. Meso-tetrakis(m-
hydroxyphenyl)chlorin (m-THPC/Temoporﬁn, commercial-
ized as Foscan, Biolitech Pharma), for example, causes less
photosensitization than Photofrin but is 100 times more
photoactive. Other members of the group are purpurines,
which have the disadvantage of being highly hydrophobic, and
phthalocyanines. (iii) The third generation focuses on PSs with
additional properties through the use of composite structures.
Better selectivity toward the tumor tissue is often achieved by
conjugation of PSs to monoclonal antibodies or other ligands
that bind speciﬁcally to the surface of cancerous cells. Also, the
use of delivery vehicles like proteins or NPs leads to improved
overall hydrophilicity and higher PS loads. (iv) Emerging PDT
systems target the development of mesoscale carriers, which can
incorporate large numbers of sensitizer molecules. These
mesoscale particles are surface modiﬁed to minimize removal
by immunogenic response mechanisms and reduce nonspeciﬁc
binding. Speciﬁc antibodies attached to these larger functional
delivery particles oﬀer advantages over simpler PSs, which have
low absorption cross sections and which do not localize
speciﬁcally to tumors.
There are three main mechanisms by which PDT mediates
tumor destruction: direct killing, vascular damage, and activation
of an immune response against tumor cells. In the ﬁrst case, the
ROS generated by PDT can kill tumor cells directly. However,
complete eradication is not always realized because of the
nonhomogeneous distribution of the PS within the tumor, non-
homogeneous penetration of light, and the possibility of limited
oxygen availability within the tissue due to the photodynamic
process itself. Vascular damage, on the other hand, targets the
tumor vasculature system and, therefore, the concentration of
nutrients and oxygen that reach it. In this case, the precise action
Figure 30. Relative absorbance of body tissue components such as
water, hemoglobin (Hb), oxygenated hemoglobin (HbO2), and
melanin. The window that will allow the deepest penetration is the
600−1200 nm region, in the red-NIR. Adapted from ref 547.
Copyright 2001 Nature Publishing Group.
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mechanism is not yet fully understood, but a biphasic vascular
reaction following PDT has been suggested,543 namely, a ﬁrst
immediate response consisting of vasoconstriction and, after 3 h,
a second long-term response characterized by thrombus
formation. Both of these eﬀects were correlated with delay or
inhibition of tumor growth. Depending on the kind of pathology
to be treated, the interval between the sensitizer administration
and light exposure might be a deciding factor for one mechanism
over the other. When a short interval (minutes) is allowed
between drug and light administration, the sensitizer predom-
inantly accumulates in the vascular compartment, thus favoring
indirect tumor killing by vascular damage. Conversely, a longer
interval (hours) between intravenous drug injection and light
administration results in localization of the PS within the
extravascular compartment of the tumor and subsequent direct
tumor-killing action. Therefore, administration of PSs at multiple
time intervals before light activation (fractionated drug-dose
PDT) is found to be the most eﬀective way to target both tumor
blood vessels and tumor cells. More recent studies in the late
1980s and early 1990s reported inﬁltration of lymphocytes,
leukocytes, and macrophages into PDT-treated tissue, indicating
activation of the immune response. Diﬀerences in the nature
and intensity of the inﬂammatory reaction between normal and
cancerous tissues could contribute to the selectivity of PDT-induced
tissue damage.
Photodynamic therapy is a reliable tool for treatment of a
variety of diseases, whose clinical use is common and well
established. This process involves two major steps, the
administration of a PS and the delivery of light. The admini-
stration of a PS can be topical or intravenous, depending on the
pathology to be treated and the ease of access to the area: skin
diseases that allow for topical application will require drugs
with diﬀerent characteristics than will diseases for which an
intravenous approach is required. Alongwith vascular permeability
and interstitial diﬀusion, chemical properties like molecular size,
conﬁguration, charge, and the hydrophilic or lipophilic character of
the compound will all impact transport and retention of the PS.
Conventionally, PDT is administered as a single treatment
using the highest PS dose that avoids systemic toxicity and skin
photosensitivity, and the highest light ﬂuence rate that avoids
tissue heating and photochemical depletion of oxygen. However,
for reasons discussed above, there have been a few studies about
f ractionated PDT, in which the PS administration is spread over
time. Preliminary studies have shown improved responses to this
kind of metronomic PDT compared to single doses, most likely
due to the simultaneous action of direct tumor cell killing and
blood vessel damage. Light can be delivered by surface or
interstitial irradiation. Surface irradiation includes cases where
the light source is external to the body (e.g., treatment of skin
lesions), or is placed within and illuminates the inner surface of a
body cavity (e.g., a hollow organ or a surgical resection space).
Interstitial treatments are usually carried out by placing an optical
ﬁber that carries the light directly into the tissue. Typically,
1−5W of usable power are required in the 630−850 nm range at
irradiances of up to several hundred mW·cm−2 in order to deliver
treatments in tens of minutes. For this reason, there are three
main classes of clinical PDT light sources: lasers, light-emitting
diodes (LEDs), and ﬁltered lamps (see Figure 31). Lasers are
powerful and eﬃcient but they are expensive single-wavelength
devices where a separate unit is required for each photosensitizer.
In the past few years, LEDs have become a viable technology for
PDT, particularly for irradiation of easily accessible tissue
surfaces. The main advantages over (diode) laser sources are
the low cost and ease of conﬁguring arrays of LEDs into diﬀerent
irradiation geometries. On the other hand, the relatively poor
electrical-to-light conversion eﬃciency (less than 15%) remains
an obstacle, because the generated heat must be removed.
Finally, a number of lamp systems can be spectrally ﬁltered to
match any photosensitizer and they allow ﬂexible geometries.
Their drawback is that they are not suitable for endoscopic use
because they can be eﬃciently coupled only into optical ﬁber
bundles or liquid light guides (5−10 mm diameter).544
Photodynamic therapy design is still a relatively young
ﬁeld and substantial improvements could come from better
PSs: higher absorption in the optical window, larger extinction
coeﬃcients, more eﬃcient singlet oxygen production, and better
chemical and physical properties. Interesting new directions
that could overcome some of the intrinsic limitations of current
compounds are currently being explored. (i) In two-photon
PDT, the PS ground state is able to absorb two photons of NIR
light simultaneously, which can be administered in short pulses:
the total energy absorbed is the same as that from one-photon
absorption at λNIR/2 and the resulting photophysical and
photochemical processes are the same. This two-photon
absorption enables a much wider choice of PS absorbing at
high extinction coeﬃcients in the visible, while retaining the
possibility of using light in the biological optical window. Also,
the quadratic dependence of the two-photon absorption
probability can be exploited to give more precise spatial
conﬁnement of the PDT eﬀect by high-numerical-aperture
focusing of the activating laser beam. One of the drawbacks of
this technique is that, in order for the photons to be absorbed
simultaneously, the light pulse must typically be shorter than
ca. 100 fs, a factor that substantially increases the cost of light
sources. (ii) Another concept currently being investigated is the
use of molecular beacons to improve target selectivity. Molecular
beacons comprise a targeting moiety, a PS, and, optionally, a
quencher. In their simplest form, the targeting group is
responsible for accumulation of a higher number of PSs in the
cancer cells and therefore higher selectivity. Alternatively, a
target-labile linker keeps a PS and a quencher in close proximity,
so that FRET prevents activation of the PS. Upon interacting
with the target, the linker is either broken or opened so that the
PS and quencher are separated, enabling FRET-driven PDT
action to occur. (iii) Finally, NP technology provides several
Figure 31. Surgeons delivering laser light through an optical ﬁber for
the treatment of an internal tumor.
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diﬀerent novel approaches to PDT. A ﬁrst approach is the use
of NPs as PS carriers, a method already applied to many other
imaging contrast agents and therapeutic compounds. The advan-
tages are that the loading of PSmolecules per NP can be high and
that theNPs can impart new desirable qualities to the compound,
such as greater hydrophilicity or targeting ability. Examples
include the incorporation of PS into modiﬁed silica NPs or into
lipoprotein NPs with antibody targeting capabilities, the
decoration of AuNPs with PS, or the use of NPs that are
themselves photoactive. Another approach is the use of NP−PS
conjugates, where the NP serves as the primary light absorber
that, through FRET, activates the PS. An issue with all these NP
strategies, besides potential toxicity, is the delivery of the NPs or
NP−PS conjugates to the target tissues, because the pharma-
cokinetics are strongly dependent on the NP properties.
In contrast to PDT, which kills cells by the generation of ROS,
hyperthermia kills cells by heat. Tumor treatment by heat is one
of the oldest ways to cure cancer. The application of pyrogens
induces endogenous hyperthermia, where heat is generated by a
substance or agent that reacts with the human immune system.
This was the standard treatment for inoperable tumors until the
middle of the 20th century. After administration of various
bacterial toxins (or later on, vaccines) and the subsequent
feverish reaction, a signiﬁcantly higher survival rate was observed.
Because of the inability to control the induced fever and the
insuﬃcient outcome, it is now applied only rarely.545 Modern
hyperthermia can be performed using plasmonic NPs and light,
as well as magnetic NPs and alternating magnetic ﬁelds. Inorganic
NPs act as local heat sources, triggered by light or alternating
magnetic ﬁelds. Hyperthermia can be used as a stand-alone
approach, or in combination with certain chemotherapeutics.
One of the most promising therapeutic strategies in
nanomedicine is that of photothermal cancer therapy.546
In this drug-free therapy, these NPs absorb energy at a
wavelength of 700−1000 nm547 and generate heat. They can
burn oﬀ the tumor when the irradiation occurs after the particles
have accumulated in the tumor. Intensity of the incident laser
irradiation, the nature of the NPs (i.e., the localization of the
surface plasmon resonance), and the size of NPs are the factors
that will determine the eﬃciency of the localized heating. It was
shown at an in vitro level that such localized heating can be
applied to kill cancer cells.459,548−552 In vivo, the highly localized
hyperthermic response induced by resonant laser irradiation
results in tumor remission for subcutaneous tumors with high
eﬃcacy (see Figure 32).553 Researchers have demonstrated both
passive and active uptake of nanoshells, a type of heat-generating
NPs, into tumors.554,555 In addition to nanoshells, other plas-
monic NPs such as gold nanorods and gold nanocages have been
shown to be useful for hyperthermia applications.549,556
In preparation for transition to clinical trials, the toxicity of
nanoshells was investigated extensively. No toxic eﬀects were
found in this study.557 Recent improvements in nanoshell design
can enhance their clinical utility. The addition and integration of
imaging functionalities with the therapeutic function of these
NPs resulted in NIR-enhanced ﬂuorescence and NIR-enhanced
imaging of tumors.558−560 Smaller diameter, multilayer NPs
known as “nanomatryoshkas”, which also have NIR-absorptive
responses, can enhance NIR ﬂuorescence for emitters encased
between their inner and outer gold layers.561 These NPs have
shown increased uptake in tumors relative to nanoshells and
outstanding remission rates with active targeting of aggressive
triple negative breast cancer tumors.562
Local heat can also be produced by magnetic NPs upon
exposure to alternating magnetic ﬁelds.564−567 The basic
precondition for eﬀective magnetic heating is that the NPs
have adequate magnetization values. Iron oxides (magnetite/
maghemite) are particularly preferred since they have been used
as contrast agents in radiology for many years, e.g., in the
detection of cancers in the liver and spleen. The generation of
heat is based on NP morphology as well as on the energy
dissipation during the NPs magnetization process.568−570
This means that the magnetization reversal of NPs with core
diameters larger than 100 nm is governed by the motion of
magnetic domain walls. In contrast, cores that are smaller than
100 nm behave like single-domain NPs where no domain walls
exist. Even smaller NPs behave as if they are superparamagnetic
and the magnetization reversal proceeds either by rotation of the
magnetic moment inside the core (Neél relaxation) or by
mechanical rotation of the whole NP (Brown relaxation) during
exposure to an alternating magnetic ﬁeld. It has been demon-
strated that suﬃcient thermal energies can be obtained with NPs
with core sizes between 10 to 50 nm.571−573 Concerning NP
synthesis, the current challenge is the stabilization of NPs with a
One of the most promising therapeutic
strategies in nanomedicine is that of
photothermal cancer therapy.
Figure 32. Evaluation of tumor response to PTT by bioluminescence
imaging. The bioluminescence signal is generated only in living
cancer cells, as a result of luciferase activity. (A) Representative mice
of each experimental group showing the luciferase activity in the
tumor. The mice injected with nanomatryoshkas or nanoshells and
treated with laser experienced loss of bioluminescence in the area
illuminated by the laser, as seen after therapy. Mice were euthanized
when tumor volume reached 1500 mm3 or if the tumor persisted at
60 days after treatment. (B) Luciferase activity in the tumor. The
luciferase signal was normalized to the signal before treatment.
Adapted from ref 563. Copyright 2014 American Chemical Society.
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relatively larger core size distribution.574 Promising materials in
this context are magnetosomes derived from magnetotactic
bacteria, which were successfully deployed in a mouse breast
cancer model.575 To enhance treatment eﬃcacy, coapplied
chemotherapeutics or drug-carrying magnetic NPs are included.
Cisplatin, in combination with magnetic heating, exhibits
additive cytotoxic eﬀects, particularly when it reaches its target
site of action where it forms DNA adducts after its chloride ions
have been displaced by hydroxyl groups.576 A promising
NP formulation with cisplatin payloads was developed
by Unterweger et al.406 Most magnetic hyperthermia develop-
ments for treating diseases are in the preclinical stage with a few
used in the clinic.
Biodegradation. There is increasing awareness of the
potential threats of using exogenous nanomaterials in vivo.
In particular, the development of increasingly sophisticated
nanocarriers further increases the risk of undesired side eﬀects,
discussed below. Therefore, it is highly desirable that drug
delivery vehicles exert only minimal eﬀects on the biological
system after their cargo has been delivered, where the vehicles
should ideally be eliminated after delivery to target tissues.
Consequently, in vivo degradation with well-deﬁned rates and
with the formation of nontoxic and degradable byproducts
that can be excreted becomes increasingly important.577,578
Currently, there are a number of organic NPs that can be
degraded, which will be discussed below.
Water-soluble polymeric drug carriers are one such class of
compounds that can be designed to be biodegradable. For these
carriers, molecular weight and molecular weight distribution are
important factors in their design, impacting both their
therapeutic eﬃcacy and their biocompatibility. The higher the
molecular weight of the polymer carrier, the higher the
accumulation of polymer−drug conjugate in the tumor tissue
with concomitant increase in therapeutic eﬃcacy.331,579 How-
ever, the renal clearance threshold limits the molecular weight of
nondegradable polymeric carriers (such as HPMA-based) to
below 50 kDa.580 This issue lowers the retention time of the
conjugate in circulation with simultaneous decrease in
pharmaceutical eﬃciency. Consequently, higher molecular
weight drug carriers with nondegradable backbones deposit
and accumulate in various organs, impairing biocompatibility.
These concerns can be addressed by the incorporation of
degradable polymer backbones, such as those seen in backbone
degradable (second generation) HPMA copolymer carriers.
These carriers have long circulation times while preserving
biocompatibility and are based on the combination of
controlled/living radical polymerization and click chemis-
try.355,581,582 The backbone degradable HPMA copolymer−
drug conjugates provide long-circulating water-soluble ther-
apeutics that eﬀectively accumulate in tumor tissue. They are
eliminated from the body after enzymatic cleavage of the
oligopeptide segments in the backbone (producing polymer
fragments below the renal threshold) and in side chains
(releasing the drug). The synthesis procedures proposed are
versatile; they provide a platform for the preparation of a large
variety of polymer−drug conjugates with tailor-made properties,
such as predetermined circulation time and composition.
Controlled degradationnonspeciﬁc cargo release from slow
hydrolysis in physiological ﬂuids like the bloodstreamremains
a challenge. Therefore, design of biodegradable polymers
requires incorporation of fast and eﬃcient polymer degradation
at the target site while retaining high stability in circulation and at
oﬀ-target sites. Polypeptides oﬀer great potential in this aspect,
since their stability can be adjusted based on their monomer
sequence, their molecular weight, or by attaching stabilizing or
degradable side chains along the backbone. The most commonly
used hydrophilic polypeptides have protonated amino side
chains, e.g., poly(lysine), poly(arginine), poly(glutamate), and
poly(aspartate), which ensure excellent water solubility and
increase the interaction with the negatively charged cell
membrane to facilitate cellular uptake. Amphiphilic block
copolymers of two or three homopolypeptides have been
prepared with hydrophobic segments such as poly(leucine)
and hydrophilic segments such as poly(lysine) that form
polymersomes and encapsulate hydrophobic drugs. However,
highly positively charged polypeptides often reveal uncontrolled
protein absorption, immediate immune responses, opsonization
by macrophages, or rapid clearance from the bloodstream by
renal or hepatobiliary excretion. To overcome these limitations
while taking advantage of the aforementioned properties,
innovative materials in biological systems that have a degradable
but peptidic nature are highly desirable.
Polymers based on the body’s own amino acid sarcosine
(N-methylated glycine) have been obtained and are one of the
ﬁrst polymers synthesized by living ring-opening polymer-
ization.583 The polypeptoid polysarcosine oﬀers high water
solubility, nonimmunogenicity,584−586 and protein resistance587
due to its special characteristics, e.g., weak hydrogen bond
acceptor with the lack of hydrogen donor capabilities.588
Polysarcosine is a nonionic and highly water-soluble polymer
that is similar to PEG but potentially oﬀers in vivo degradability as
suggested from in vitro studies under physiologically relevant
conditions.589 The synthesis of block copolymers based on
polysarcosine and polylysine, polycysteine, polyglutamic acid, or
derivatives thereof, by ring-opening polymerization of the
corresponding α-N-amino acid carboxyanhydrides in a con-
trolled fashion, oﬀers high end-group integrity, precise control
over molecular weight, and low dispersities of around 1.1. The
amphiphilic block copolypeptides are nontoxic up to concen-
trations of 3 mg/mL and stabilize hydrophilic/hydrophobic
interfaces in drug formulations and mini emulsion techniques.589
The deprotected polymers polysarcosine-block-polylysine
enabled the formation of core/shell polyplexes for eﬃcient
in vitro transfections.590 Degradable polypeptide copolymers
have been achieved from natural protein precursors. Unlike
synthetic polypeptides, which consist of repeating amino acid
sequences, the polypeptide backbone of proteins provides a
higher diversity of reactive functional groups, which enables
further chemical modiﬁcations. Moreover, depending on the
precursor protein chosen, these polypeptides oﬀer distinctive
and adjustable molecular weights, precisely deﬁned sequences,
low cytotoxicity, and full degradability. They have been applied
for coating ﬂuorescent NPs as well as for the delivery of cytotoxic
drug molecules.
A challenge when using inorganic NPs is the ability of the
animal to degrade and to eliminate them. Sub-5 nm NPs such as
NDs can be eliminated from the body renally without
biodegradation and without leaving toxic residues.591 However,
larger inorganic NPs are more diﬃcult to clear from the body.
Studies have shown that AuNPs reside in macrophages after
uptake and do not appear to be degraded;592 ZnS-CdSe QDs
have also been shown to remain stable in mice and rats after
several months.593,594 There is evidence to suggest that some
inorganic NPs (e.g., CdSe QDs and hollow AuNPs) can break
down by oxidation or other chemical processes. This process is
slow but there is evidence to show they are excreted through the
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kidneys.35,595,596 The chemistry and design of the inorganic NPs
can inﬂuence the degradation pattern. Although the core
composition is diﬃcult to degrade for most inorganic NPs, the
organic surface coating has been shown to degrade in vivo.
This eﬀect was demonstrated by using multiplexed radiolabels
that tag the inorganic core and surface coating with an organic
molecule. This labeling strategy enabled the measurements of
diﬀerential temporal biodistribution of all diﬀerent parts of a NP
after in vivo administration. It was discovered that inorganic NPs
stabilized by an amphiphilic polymer shell via amide bonds lose
parts of the organic shell upon enzymatic cleavage in vivo.37
Taking the concept further, a number of researchers have started
to use organic molecules to assemble inorganic NPs into complex
systems for in vivo medical applications. For example, DNA can
assemble inorganic NPs into a complex core−satellite system
that can target tumors, but these NPs can subsequently enter
liver macrophages.36 The enzymes in these cells degrade the
DNA linker and release the inorganic NPs back into the
bloodstream to be eliminated through the kidneys. Linker
molecules to build nanosystems are not limited to DNA but can
also be polymers that can potentially be responsive to enzymatic
degradation.597,598 The clinical translation of inorganic NPs may
depend on whether they are cleared from the body, as the long-
term toxicity of metal-containing NPs remains unclear. This
research area will continue to be active from the fundamental
(i.e., understanding the clearance mechanism of inorganic NPs)
to the design (i.e., using assembly techniques to build degradable
nanosystems containing inorganic NP components) perspec-
tives.
LABORATORY-BASED MATERIAL PRODUCTION FOR
TREATMENT (“IMPLANTS MADE WITH
NANOTECHNOLOGY”)
While some nanomaterials are designed to deliver a drug or an
action to diseased tissue and programmed to degrade afterwards,
researchers are also synthesizing nanomaterials that can be
introduced into the body with the intention “to stay”. Surface
modeling on the nanoscale can provide new functions and
properties to implants, etc.599 Incorporation of nanomaterials
with key features for driving tissue engineering is a useful
means to achieve unprecedented performance.600,601 In par-
ticular, carbon nanostructures (e.g., single- or multiwall CNTs
(SWCNT/MWCNT), graphene, carbon nanohorns, NDs,
fullerenes, etc.) can provide mechanical strength and useful
electronic properties, thanks to their chemical structures.602
They have been shown to be biocompatible with and to support
the growth and proliferation of many classes of cells. Despite the
issues associated with CNT use in medicine,603 there is a growing
body of work showcasing their utility in nanomedicine after
appropriate chemical functionalization.604 For example, CNT
addition to hydrogels are biomaterials that can be designed to
respond to diverse stimuli, e.g., for drug release applications.605
Some selected examples and applications are detailed below.
Nano- and Microengineered Implants. Nanodiamond−
polymer composites can be used in tissue engineering and
regenerative medicine, particularly showing potential for
restoring damaged tissue. Excellent mechanical properties of
NDs in combination with ﬂuorescence, delivery of drugs and
biologically active molecules, and biocompatibility are used
for reinforcement of implantable polymers to create multifunc-
tional tissue engineering scaﬀolds. Octadecylamine-modiﬁed
NDs incorporated into poly L-lactic acid (PLLA) provided
ﬂuorescence for monitoring the implant biodegradation (see
Figure 33). While biodegradable polymers such as PLLA are not
mechanically robust, the incorporation of NDs brings the
composite properties close to those of human cortical bone. It
increased the composite’s mechanical strength and strain to
failure, and enabled the use of the composite as a bioresorbable
bone-growth scaﬀold for manufacturing bone ﬁxation devices.31
In terms of toxicity, murine 7F2 osteoblast morphology and
proliferation were unaﬀected when cultured with the ND-PLLA.
These composites possess clinically relevant properties while
being nontoxic and highly scalable to produce.606
Naturally, for such implants the interface between the
implanted devices and surrounding cells and tissues is important.
Selection of the geometry oﬀers a useful handle in this direction.
Elongated objects, such as nanoneedles, for example, have
suitable properties for the delivery of bioactive agents to cells and
tissues. This ﬁeld of nanoneedles for cell-interfacing, which is still
emerging, is now growing rapidly and shows great promise.
A number of interesting nanoneedles have been developed
recently with a multitude of capabilities. Some of these capabilities
include transferring biological information to many cells in
parallel,607 sensing intracellular biological signaling such as the
presence of enzymes,608 and measuring intracellular pH at many
points across individual cells.609 The nanoneedles can deliver to
the cell cytosol and yet, due to their nanoscale dimensions, are
not destructive to the cells. These nanoneedles represent a highly
promising technology for intracellular delivery, probing, and
interfacing. Porous silicon-based nanoneedles were developed
and utilized to deliver DNA and siRNA to cells in vitro eﬃciently
and showed transfection eﬃciencies greater than 90% while
silencing (of GAPDH expression) was quantiﬁed as 80%
eﬀective,610 encouraging for in vivo applications. The authors
showed that they could achieve neo-vascularization in the
muscles on the backs of mice by using porous silicon nano-
needles to deliver human VEGF165 plasmid DNA.610 This
ﬁnding is of interest when considering the potential to
prevascularize sites at which tissue engineered implants might
be transplanted in vivo. It also has the added advantage that
nucleic acids can simply be loaded into the nanoneedles and no
covalent modiﬁcations are required. The nanoneedles are a
platform technology that could potentially be used to deliver a
wide range of nucleic acids and other bioactive agents for all types
of tissues.
Toward Interfacing Electrically Active Tissues. Electrical
signals can be used to control the interactions of nanomaterials
with tissues. This strategy to control tissue function may be
important for many applications such as in the design of neuro-
prostheses. Below, we describe a number of these applications.
Figure 33. Bone ﬁxation screw made of a biodegradable polymer
(PLLA) reinforced with octadecylamine (ODA)-funtionalized
ﬂuorescent nanodiamond NPs (ND-ODA) that provide reinforce-
ment, monitoring of biodegradation, and, eventually, drug delivery.
Adapted with permission from ref 606. Copyright 2011 Elsevier.
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First attempts for electrically interfacing cells were based on
microstructured devices,611−613 but more recently, nanostruc-
tured devices such as nanowires have been used.614 Two criteria
for building successful devices are “wiring” and size, where
“wiring” involves the connection of the recording sites to the
outside,615 and size is essential for brain implants to avoid local
inﬂammation.616 Neuroprosthetic implants made from LbL
biomimetic nanocomposites investigated by Kotov and coworkers
provide a unique combination of properties that enable manu-
facturing of smallest possible brain implants that can be safely
integrated within brain tissues.617 Some of these properties
include high strength, conductivity, toughness, and biocompat-
ibility.618,619 Additionally,615−617 brain implants have been made
with gold nanowires.620
A major step forward in this ﬁeld has emerged by exploring the
interactions of CNTs with neuronal systems. Indeed, the
presence of CNTs inﬂuences the electrical activity of neurons,
especially in terms of synaptic events. In the past decade, it has
been established that CNT-based substrates are able to impact
neuronal physiology profoundly from the functional (electrical)
point of view. With their exceptional properties of small size,
ﬂexibility, strength, inertness, electrical conductivity, and ease of
combination with various biological compounds, CNTs are the
excellent candidates for interfacing with damaged neuronal
tissues. In 2000, it was found that neurons deposited on func-
tionalized CNTs were not only surviving, but also elongating
their neurites in all directions.621 Since then, the study of these
materials as functional components of composites for the
support of the regeneration of neural tissue has been set up by
many research groups.
Carbon nanotubes have high electronmobility, have an aﬃnity
for neurons, and can integrate with cell membranes at both
dendrites and somas. As a result of these tight interactions, not
only neurons, but also entire 3D slices of spinal cord (SC) tissue
exhibit desirable behavior.622−625 The most important results
obtained can be summarized in three points: (i) neuronal
signaling is enhanced when brain circuits are cultured inter-
faced to CNT ﬁlms, (ii) CNT networks are able to induce the
formation of a higher number of new synaptic contacts with
respect to reference substrates, and (iii) CNT interfaces promote
nerve ﬁbers regrowth, potentiating growth cone activity and
synaptic responses in entire SC slices: this is an eﬃcient translation
from single cell to complex tissues such as SC explants.
It has been found that neonatal hippocampal neurons, laid
over a ﬁlm of CNTs, increase their spontaneous electrical
activity. Thereafter high-resolution electron microscopy eluci-
dated the intimate contacts between regrown neuronal processes
and CNTs where the boundary line between organic and
inorganic matter is ambiguous.623,625 The most outstanding
results concerning the interface between CNTs and neurons are
related to the eﬀects on the electrical activity of neuronal
networks. Lovat et al. compared the electrical activity of
hippocampal neuronal networks directly grown on a MWCNT
mat with that of networks grown on control substrate by means
of the patch-clamp technique.622 The frequency of spontaneous
events (postsynaptic currents) in networks cultured on CNTs
was strongly increased (approximately 6-fold) compared with
controls. The balance between inhibitory and excitatory
components in the neuronal network was not aﬀected.622
By means of single-cell electrophysiology techniques, electron
microscopy analysis and theoretical modeling, it was hypothe-
sized that CNTs can provide a kind of shortcut between the
proximal and distal compartments of the neuron.624 This
hypothesis, supported by the observation that neuronal
membranes establish tight contacts with the CNT substrate,
was further corroborated by other experiments. When cells were
forced to ﬁre trains of action potentials, reverberations were
detected following depolarization potentials and this reverber-
ation occurred more frequently on CNT-deposited cells than on
those grown on inert glassy supports. This type of back-propagating
action potential represents a regenerative ability that neurons
exhibit in cellular processes, such as the tuning of synaptic
activity, the expression of spike-timing-dependent plasticity, the
release of modulatory messengers and the modulation of
synaptic plasticity.
Another interesting observation concerns the impact of CNTs
on the synaptic activity of neuronal networks. The probability of
ﬁnding synaptically connected pairs of neurons is almost doubled
in the presence of the CNT substrate. The synaptic plasticity
was also aﬀected because cells grown on CNTs demonstrate
potentiated short-term synaptic conditions instead of normal
depression in response to aﬀerent presynaptic spike trains.
This activity mimicked the high frequency ﬂow of information.
All this gain of function is entirely attributable to the peculiar
features of conductivity and physiochemical properties of CNTs
that aﬀect the network activity and spike propagation.624
The ability of CNT substrates to have an eﬀect on central
nervous system tissue has been tested by coculturing embryonic
spinal cord and dorsal root ganglia multilayered explants chronically
interfaced to a ﬁlm of puriﬁed MWCNTs.625 With respect to the
controls, spinal explants cultured on CNTs displayed higher
numbers of longer neuronal processes growing in tight contact
with substrates bearing higher numbers of growth cones at their
tips. These neuronal processes seemed to be slack on the CNT
carpet that increased their contact surface but were less stiﬀ than
in the control, apparently integrating CNTs as their own
supports or exoskeletons. The overall interactions of the spinal
tissue with the substrate appear to be intimate and similar to the
results reported for isolated cell cultures. When sensory aﬀerent
pathways, preserved in spinal explants diﬀerentiated in vitro were
exogenously activated, the resulting synaptic responses recorded
from single neurons not in direct contact with the CNT layer
were strongly increased. This result indicates that the boosting
eﬀects of CNTs at the interface were transferred from the layers
of neurons directly exposed to the CNTs to those functionally
connected yet physically far from the interface.
In order to improve the biocompatibility of unconstrained
CNTs, groups have tried to incorporate CNTs into polymeric
scaﬀolds. In addition to improved biocompatibility, they aim to
produce 3D structures that are able to be colonized by neuronal
cells and to foster the communication among them, where the
CNTs play strengthening and electrically functional roles. To
this end, CNTs have been integrated into various biopolymer-
based hydrogels as collagen, chitosan,626 and agarose.627 In
general, all these substrates are good supports for neuronal cells,
able to sustain their growth and their ability to extend neurites
and growth cones without a remarkable toxicity. None of these
scaﬀolds have yet been tested in vivo, however. Similar results
have been achieved by CNT composites based on synthetic
polymers, mostly polyester polymers such as electrospun
ﬁbers of PLGA628 and of poly(L-lactic acid-co-caprolactone).629
Bosi et al. have recently produced a nanocomposite systemwhere
CNTs are integrated into a polymeric matrix that can bemodeled
into diﬀerent porosities, stiﬀnesses, and shapes. This nano-
composite consists of a microporous, self−standing, elastomeric
scaﬀold whose skeleton material is made of PDMS, while the
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micrometric cavities are generated by dissolving a sugar template
embedded in PDMS.630 This 3D structure showed viability as a
supporting scaﬀold allowing neuronal colonization and 3D
synaptic network reconstruction, but was soft enough to match
the viscoelastic nature of native hippocampal neural tissue.631
The PDMS porous scaﬀold surfaces was then enriched of
MWCNTs, endowing the structure with nanofeatures and imple-
menting its electrical conductivity.
Because of their peculiar electrical features, CNTs are useful as
interfaces with other electrically active tissues such as cardiac
tissue. Martinelli et al.632 discovered outstanding eﬀects on
cardiac cells cultured on CNT substrates. Neonatal rat
ventricular myocytes (NRVM) were able to interact with
nonfunctionalized MWNTs deposited on glass coverslips by
forming tight contacts with the material (see Figure 34). Cardiac
myocytes modify their viability, proliferation, growth, matura-
tion, and electrophysiological properties when interacting with
CNT scaﬀolds. Two opposing eﬀects on the development appear
to take place. Cells prolong the proliferative state, which
maintains some cells in an undiﬀerentiated state. They accelerate
the maturation of the diﬀerentiated cardiac myocytes in terms of
a more negative NRVM resting potential compared to the
control so that the cells become more “adult-like”. By trans-
mission electron microscopy it has been observed that CNTs
establish irregular tight contacts with the membranes, in a
way that is morphologically similar to neurons cultured on
MWNTs.622 It is not excluded that other modiﬁcations indirectly
brought about by MWNTs, such as the deposition of the
extracellular matrix (ECM) or the cell contact driven cytoskeletal
dynamics, are ultimately responsible for the positive eﬀect.
Such an eﬀect holds promise to solve the issue of arrhythmias
arising from nonconductive scaﬀolds, as exempliﬁed also by a
chitosan-based hydrogel, where the inserted CNTs act as
nanobridges that electrically connect cardiomyocytes.633 Anoth-
er interesting cardiac construct has been produced by Shin and
colleagues:634 CNTs were embedded into photo-cross-linkable
gelatin methacrylate (Gel-MA) hydrogels, resulting in ultrathin
2D patches where neonatal rat cardiomyocytes were seeded.
These cells showed strong spontaneous and stimulated
synchronous beating. In addition, a protective eﬀect against
DOX (cardiotoxic) and heptanol (cardio-inhibitor) was
observed. When released from glass substrates, the 2D cardiac
patches (centimeter size) formed 3D soft actuators with
controllable linear contractile, pumping, and swimming
actuation behaviors. For heart tissue engineering, CNTs can
also constitute a templating guide for the electrospinning of
hybrid hydrogel nanoﬁbers that form a superb biomimicking
scaﬀold that is capable of matching the orientation index of the
left ventricular tissue, thus promoting cardiomyocyte alignment
and synchronous beating.635,636
The high potential of CNTs in the ﬁeld of excitable tissue
engineering stems from their exceptional nature and the desire to
develop synthetic materials with appropriate nanostructure and
cell-recognition properties that are able to regulate cell adhesion,
survival, and growth. The in vivo application of nanotechnology
tools and of CNT-based platforms, in particular, is largely
directed to basic research applications. However, the extra-
ordinary eﬀects of these materials hint at developing safer devices
to promote tissue reconstruction. A major challenge for
biomedical applications of CNTs is to overcome the current
limitations of CNT degradation time, elimination, and/or safety
of use.
Biological Cell-Based Implants. Implants used for
regenerative medicine can also be of biological origin. Cell-
based therapies oﬀer great potential. For example, stem cells
delivered to injured tissue have the potential to regenerate
defective tissue.637,638 One general problem with cell-based
therapies, however, is that individually delivered cells have
limited retention times in the target tissue. In order to improve
retention times, cells can, for example, be delivered in already
connected form (so-called cell patches), or they can be seeded
into matrices to which they have high binding aﬃnity. Treatment
based on connected cell patches instead of isolated cells thus may
oﬀer decisive advantages. However, it is not trivial to cultivate cell
patches, as at one point connected cells need to be isolated from
the culture substrate. Cell adhesion typically can be suspended
by enzymatic treatment (e.g., with trypsin) or by depletion in
calcium. However, while this enables the collection of cells from
culture substrates it also interferes with intracellular contacts.
Nanotechnology has helped create culture substrates that enable
switching on and oﬀ adhesive properties to cells. For example,
smart surfaces enable switching from hydrophobic to hydrophilic
properties upon changes in temperature. In this way, whole cell
patches can be detached from the culture substrate and can be
used for transplants.639 Also, plasmonic heating may be a useful
technique in this direction.640 Such advanced culture methods
pave the way for future cell and tissue-engineering therapies.
Cell sheet patch therapies were clinically applied to human
patients suﬀering from diseases such as cornea epithelium
deﬁcient disease, recovery from endoscopic submucosal
dissension surgery for esophageal epithelial cancer, cardiomy-
opathy,641,642 periodontal regeneration,643 and osteoarthritis.644
While the number of cell layers grown on top of each other
within one cell patch is limited as transport of nutrients and
oxygen to the cells needs to be warranted,645 subsequent
transplantation of several cell patches of up to ∼100 μm
thickness is possible and vascularization of the transplants has
been demonstrated.646,647 Cells can also be seeded into matrices
resembling replicas of cell surfaces,648 into decellularized
matrices,649 or even into completely synthetic scaﬀolds to
improve their biocompatibility and engraftment.650,651 There
have been some attempts for translation to the clinic,652,653 but
results have been and are still heavily scrutinized.654−656 The
basic requirements such transplants need to fullﬁll involve
vascularization, in order to warrant continuous blood supply,657
and, in case of exposure to the environment (e.g., air, food),
antimicrobial coatings. Severe skepticism toward the use of these
technologies in general is reported.658
Figure 34. Left: Scanning electron microscopy (SEM) image of a
spinal explant peripheral neuronal ﬁber on a MWCNT substrate.
Note the tight and intimate contacts (red arrows) between the
neurite membrane and the MWCNTs. Scale bar: 500 nm. Reprinted
from ref 625. Copyright 2012 American Chemical Society. Right:
SEM image of cardiac myocyte deposited on a layer of MWNT.
Adapted from ref 636. Copyright 2013 American Chemical Society.
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Toward Artiﬁcial Organs. A current need in medicine is
with the construction of whole organs in vitro to address the issue
of shortages in organ donation.659 Nanotechnology is emerging
as a powerful tool that can help to fulﬁll this need by assisting in
the engineering of artiﬁcial organs for regenerative medicine
as well as organs-on-a-chip applications.660,661 The need for
nanoscale architecture is derived from the ability of cells to
sense the nanoscale structures in their microenvironment.662
In particular, many ECM molecules that surround cells form
nanoﬁbrous structures that help to organize cellular architecture
and to induce directional migration and alignment.663 As
outlined in the case of implants, one approach to engineer
such nanoscale structures is through the generation of 3D-ﬁbrous
scaﬀolds.663−665 Techniques like electrospinning and micro-
ﬂuidic-based ﬁber fabrication have emerged as methods to
engineer 3D scaﬀolds for inducing cellular organization and
alignment.666−669 Furthermore, self-assembling peptides have
been used to form nanoﬁbrous structures, which mimic the
complex nanoscale architecture of native ECM molecules.
Utilization of biomimetic composite coatings made using LbL
assembly on inverted colloidal crystal scaﬀolds on ceramics,670
gels,671,672 PLGA polymer673 enabled, for instance, the creation
of ex vivo models of bone marrow,674 thymus,675 and liver.676
One of the advantages of the ex vivo organs is that they enable
multifaceted evaluation of the toxicity of NPs in human tissues in
the cellular constructs replicating real organs.677
In addition, nanomaterials can be integrated into hydrogels to
direct cellular behavior. For example, the integration of nano-
scale silicate materials can induce the directed diﬀerentiation of
mesenchymal stem cells (MSCs) into osteogenic fates.678
Polymeric nano- and microparticles that release growth factors
and cytokines in a controlled manner can be integrated into
scaﬀolds to regulate the surrounding biology. For example,
controlled release of angiogenic factors, such as VEGF and
PDGF, through polymeric NPs can induce the formation of
blood vessels. Other types of nanomaterials such as CNTs and
grapheneNPs can be incorporated into hydrogels to change their
mechanical and electrical properties, as described above.
The resulting gels have been shown to enhance the formation
of cardiac and skeletal muscle tissues.634,679,680
Nanoscale tools also provide means to form tissues with
controlled microarchitectures. For example, cell-laden hydrogels
can be induced to assemble into particular structures that better
mimic the microarchitecture of tissues in the body through the
use of nanoscale “programmable glues”.681 In this approach, the
various sides of microgels of controlled shapes were coated with
adhesive, long, single-stranded DNA where the function of the
strands is to induce programmed assembly. It was demonstrated
that the resulting DNA strands form nanoscale objects on the
surface of gels that uniquely recognized their complementary
base-paired strands on other gels to induce assembly. Such
structures could 1 day provide scalable ways of engineering tissue
structures with predeﬁned architectures.
These and many other examples have shown the power of
nanotechnology to direct cellular behavior for inducing tissue
formation. It is anticipated that with our increased knowledge of
how nanoscale objects interact with cells along with our ability to
engineer more controllable nanomaterials will lead to a new era
of nanomedicine for regenerative medicine applications.
Antibacterial Coatings. Bioﬁlm formation and dissem-
ination of antibiotic-resistant bacteria by indirect transmission
through contaminated surfaces is becoming a major global public
health threat. Steel and aluminum surfaces, commonly present
in hospital settings as knobs, buttons, frames, taps, etc. possess
limited or very low antimicrobial activity. A promising approach
for limiting indirect transmission is the realization of stable and
eﬀective antimicrobial surfaces obtained by nanostructured
coatings. Similarly, infections associated with medical devices
(catheters, implants, etc.) have become a major concern.
The adhesion of bacteria to the devices’ surfaces during the
initial 24 h is believed to be a decisive period for implant-
associated infections and the design of optimal antiadhesion of
microbes in this period is key. Multilayer coating by LbL self-
assembly provides a robust method to design multifunc-
tional dynamic antibacterial surfaces. For example, a multilayer
of (heparin/chitosan)10−(polyvinylpyrrolidone/poly(acrylic
acid))10 [(HEP/CHI)10−(PVP/PAA)10] provides the properties
of contact killing of bacteria due to the underlying (HEP/CHI)10
while the top (PVP/PAA)10 multilayer ﬁlm shows a top-down
degradable capability in the determined period. This activity
leads to almost no adhesion of bacteria within 24 h. The com-
bination of the adhesion resistance and the contact-killing prop-
erties shows enhanced antibacterial capability through targeting
the “decisive period” of implantation and may have potential for
applications in medical implants, tissue engineering, etc.682
Surfaces with immobilized antimicrobial peptides present high
and broad antimicrobial activity.683 Similarly, a topic worth
exploring involves immobilizing antimicrobial ligands onto NPs
to enhance their antimicrobial activity. A quaternary ammonium
cationic surfactant, didodecyldimethylammonium bromide
(DDAB), was immobilized onto silica NPs to develop anti-
microbial NPs. These NPs revealed much lower minimal
inhibitory concentrations against bacteria and fungi than the
soluble surfactant. The electrostatic interaction of the DDAB
with the NP is strong since no measurable loss of antimicrobial
activity was observed after suspension in aqueous solution for
60 days. This result means that the antimicrobial activity of the
NP does not require the leaching of the surfactant from the
surface of the NPs. More interestingly, the NP properties
expanded to virucidal activity. The versatility, relative facility in
preparation, low cost, and large antimicrobial activity of those
NPs makes them attractive as coatings for biomedical devices.684
Suspensions of ZnO NPs are eﬀective against a broad
spectrum of microbial organisms685−687 but there are many
misconceptions about their mechanism(s) of killing bacteria.524
Generation of ROS was often considered to be the source of
antibacterial activity.688 However, according to analysis of the
mechanism of bacterial inhibition by ZnO NPs of diﬀerent
shapes,524 at least part of the antibacterial activity originates from
enzyme inhibition. Anisotropic ZnO and potentially other NPs
can mimic biological inhibitors by partially matching their
geometries with those of the protein inhibitors. Such activity
originates from the similarity of the surface chemistry and size of
water-soluble NPs and those of many globular proteins.6
Applerot et al. used ultrasound irradiation to generate ZnO
NP-coated surfaces that resist bacterial bioﬁlm formation.689
Layer-by-layer coatings of ZnO NPs reduce bioﬁlm growth of
MRSA by 95%. Silver in bulk and nanomaterial forms has been
A current need in medicine is the
construction of whole organs in vitro to
address the issue of shortages in organ
donation.
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used extensively as medical device coatings but these devices
have not lived up to the promise of their in vitro data.690 Silver’s
antimicrobial function is based on the concentration of silver ions
and their associated toxicity.691,692 Unfortunately, the therapeu-
tic window between eﬃcacy and toxicity for silver is quite narrow,
which has led to disappointing clinical eﬀectiveness of silver-
coated medical devices.690 ZnO is signiﬁcantly less expensive
than silver and has selective toxicity for bacteria over mammalian
cells.693,694 ZnO is generally recognized as safe by the FDA.
Nanoparticles can be designed with antibacterial coatings to
circulate in the blood to target bacterial infections post-tumor
surgery. During chemotherapy, some patients may be more
susceptible to bacterial infections.695,696 This susceptibility
cannot be addressed using antibiotics alone, however, as some
antibiotics may lead to serious side eﬀects for some patients
postsurgery. Abuse of antibiotics has caused the emergence of
more resistant and virulent strains of pathogens. As a result, in
some cases, clinicians need to prescribe multiple antibiotics in
addition to anticancer drugs before and after the surgery.
Particles can be engineered with antibacterial properties to target
bacteria in vivo speciﬁcally, which can potentially minimize
resistance. For example, a polymer vesicle antibacterial drug
carrier has been developed recently. The chitosan-based carrier
is grafted with an antibacterial polypeptide and demon-
strated to kill both Gram-positive and Gram-negative bacteria
(see Figure 35). This polymer vesicle has excellent blood
compatibility and low cytotoxicity, which may beneﬁt patients
after tumor surgery.697,698 The enhanced antibacterial eﬃcacy
of polymer vesicles compared with an individual antibacterial
polymer chain results from the high concentrations of local
positive charges in the polymer vesicles.
IN VIVO COMBINATION OF DIAGNOSIS AND
TREATMENT (“THERANOSTICS”)
Theranostics involves the combination of both diagnosis and
treatment. Image-guided tumor resection is one such application
that uses theranostics. The diagnostic use of NPs to label cancer
cells, in particular tumor borders and small metastatic regions,
can be used to guide the surgeon for subsequent therapeutic
surgical removal of the tumors.699 These diagnostic NPs could
also be loaded with therapeutic agents for treating postsurgery.
Another interesting application of theranostic agents is NPs that
can deliver therapeutic agents into tumors while tracking NP
drug delivery.700 These agents enable noninvasive imaging
to provide information on the fate of the drug once they are
administered in vivo. Theranostics research is an exciting area of
research as many diﬀerent combinations of diagnostic and
therapeutic strategies can be built into NP systems.
Image-Guided Surgery. Recently, ﬁrst-in-human pilot
studies have successfully used both passive and active targeting
agents for image-guided surgery of human tumors.701
The speciﬁc tumor types studied include breast, lung, ovarian,
and pancreatic cancers. Although still preliminary, the results
have helped clarify two important issues: (i) most human tumors
(but not all) have moderately leaky vasculatures, so the EPR
eﬀect provides a general means for passive delivery of imaging
agents (5−6 nm albumin-bound indocyanine green) to a broad
range of human tumors; (ii) ﬂuorescent dyes such as ﬂuorescein
can be conjugated to targeting ligands such as folic acid for
speciﬁc targeting and high-contrast imaging of human tumors.
In the ﬁrst approach, passive ﬂuorescent agents do not involve
targeting ligands, but rely simply on the biodistribution of the
free ﬂuorophore. Singhal and co-workers conducted a small trial
on nontargeted NIR dyes, enrolling 5 patients undergoing
surgery for removal of their cancers (3 lung nodules, 1 chest wall
mass, and 1 anterior mediastinal mass).701,702 Two surgeons
reached a consensus about the clinical stage and operative
approach prior to surgery. All enrolled patients were thought to
have limited disease, be amenable to surgery, and have no
metastases (i.e., potentially curable). Patients were injected with
indocyanine green (ICG) prior to surgery.703 At the time of
surgery, the body cavity was opened and inspected. The results
demonstrated that NIR imaging can identify tumors from normal
tissues, provides excellent tissue contrast, and facilitates the
resection of tumors.701 In situations where there is signiﬁcant
peritumoral inﬂammation, NIR imaging with ICG is not helpful.
This suggests that nontargeted NIR dyes that accumulate in
hyperpermeable tissues will have signiﬁcant limitations in the
future, and receptor-speciﬁc NIR dyes may be necessary to over-
come this problem.
In contrast to passive agents, active ﬂuorescent agents are
linked to targeting ligands that are designed to recognize speciﬁc
receptors at the target tissue. Near-infrared-dye-labeled antibod-
ies (MW ∼ 150 kDa) that are currently used in the clinic for
targeted cancer therapy, such as VEGF antibody (bevacizumab),
EGFR antibody (cetuximab), and HER2 antibody (trastuzu-
mab), have been evaluated as targeted optical imaging probes in
preclinical animal tumor models.704−706 Several antibody-based
imaging probes are approved for clinical trials for image-guided
surgery.707 Potential limitations for antibody-based optical
imaging probes include increased background ﬂuorescence
resulting from relatively long blood circulation times, as well
as low eﬃciency in penetrating through tumor tissues.704
To address these issues, smaller antibody fragments, such as
aﬃbodies (MW ∼ 7−8 kDa) against HER2 or EGFR, were
labeled with NIR dyes for targeted optical imaging. Speciﬁcity
and sensitivity of those aﬃbody optical imaging probes have been
demonstrated in various animal tumor models,704,708−710 with
several groups in the process of conducting clinical trials. For
intraoperative imaging of tumor margins, a class of protease
activatable optical imaging probes can detect tumor edges since
many proteases are highly expressed in the invasive tumor areas
that are close to the tumor edge.711 The ﬁrst-in-human results
have been reported from intraoperative tumor-speciﬁc ﬂuo-
rescence imaging by using ﬂuorescein-conjugated agents to
target the folate receptors in both ovarian cancer and lung
Figure 35. Antibacterial polypeptide-grafted chitosan-based vesicles
capable of delivering anticancer and antiepileptic drugs simulta-
neously. Reprinted from ref 697. Copyright 2013 American
Chemical Society.
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cancer.712,713 In patients with lung cancer, the results show that
targeted molecular imaging could identify 46 (92%) of the
50 lung adenocarcinomas, and had no false positive uptake in the
chest. In vivo, prior to exposing the tumor, molecular imaging
could only locate 7 of the lesions. After dissecting the lung
parenchyma, 39 more nodules could be detected. Four nodules
were not ﬂuorescent, and immunohistochemistry showed
these nodules did not express FRα (folate receptor alpha).
In 46 positive nodules, tumor ﬂuorescence was independent of
size, metabolic activity, histology, and tumor diﬀerentiation.
Tumors closer to the pleural surface were more ﬂuorescent than
tumors deep in the parenchyma. In two cases, this strategy was
able to discover tumor nodules that were not located preop-
eratively or intraoperatively by standard techniques. These pilot
clinical trials have demonstrated that targeted intraoperative
imaging may lead to more complete surgical resections and
potentially better staging.
Fluorescent NPs can be used for similar image-guided
applications as organic ﬂuorophores. Targeted NP-based optical
imaging probes have been developed by conjugating peptides,
natural ligands, antibodies, antibody fragments, and small
molecules, to NPs that have optical imaging properties or are
labeled with ﬂuorescence dyes. Results of preclinical studies were
promising, showing increased speciﬁcity and sensitivity in tumor
imaging by systemic delivery of targeted NP optical imaging
probes as opposed to nontargeted probes.714,715 It has been
shown that optical imaging probes can be targeted to highly
expressed tumor cell receptors and active tumor stromal ﬁbro-
blasts and macrophages, such as urokinase plasminogen activator
receptor (uPAR). They are good imaging probes for sensitive
detection of tumor margins.716 In many solid tumors, active
tumor stromal cells with a high level of uPAR expression are
found in the peripheral tumor areas. Even at the early stage of
tumor development, for example in ductal carcinoma in situ of
the breast, small tumor lesions were surrounded by uPAR
expressing macrophages and ﬁbroblasts. Therefore, optical
imaging probes targeting active tumor stromal cells oﬀer the
opportunity of intraoperative detection of small tumor lesions
(<1 mm) that lack tumor vessels that may enable EPR eﬀect to
occur or that cannot be delivered to tumor cells.717 However,
clinical translation of targeted NP imaging probes has been a
challenging task. The preclinical studies required for ﬁling an
Investigational New Drug Application to the FDA for a clinical
trial are much more extensive compared to those required
for developing small-molecule, peptide, or antibody-based
imaging probes. Additionally, the cost of production of targeting
ligand-conjugated imaging NPs in good manufacturing practice
(GMP)-grade for human use is higher than those of peptide and
antibody-based imaging probes.
Tracing of Drug Delivery.Nanoparticles can be engineered
to observe the delivery process directly. Theranostic nanocarriers
oﬀer high capacity drug loading as well as the ability to track and
image the in vivo pathway of both the transporter and the drug in
the body. Human tumors are highly heterogeneous in their
tumor vascular structures, microenvironment, and tumor cells.
Eﬃciency of intratumoral drug delivery and distribution varies
among diﬀerent tumors. Drug delivery using theranostic NPs
enables noninvasive in vivo imaging of the NP delivery process
and may enable assessment of treatment responses at an early
stage. As a tool to visualize cellular uptake and cargo release,
ﬂuorescent NPs/polymers have been widely used. Quantum
dots, AuNPs, iron oxide NPs, and NDs have emerged as valuable
tools for combined therapy and diagnostic imaging due to their
high stability in vivo. DNA, as well as drug transport and release of
polycationic QDs and NDs into cells has been visualized by
confocal imaging, which, in principle, oﬀers monitoring of the
entire gene delivery pathway inside cells.363,718
Polymer NPs with intrinsic imaging properties that do not
require conjugation of imaging groups have recently been
developed. For instance, the weakly ﬂuorescent polyethyleni-
mine (PEI) polymer was conjugated to hydrophobic polylactide
(PLA), yielding amphiphilic PEI with a high payload capacity for
the antitumor drug paclitaxel. After conjugation with PLA, the
formed NPs exhibited bright and multicolor ﬂuorescence, which
could be tuned to the NIR region. Although ﬂuorescence enables
spatially resolved imaging at the cellular and tissue levels, it is not
applicable for in vivo imaging deep inside the body. The high
background autoﬂuorescence from the organism, the poor
penetration of the ﬂuorescent signal in and out of the animal, and
the risk of tissue damage by high intensity excitation light limit
the application of ﬂuorescence-based imaging in vivo. Magnetic
resonance imaging, PET, and CT imaging are considered more
attractive and promising for clinical applications. Nanoparticles
can be designed to containMRI contrast agents (e.g., Gd-DOTA)
or magnetic iron oxide NPs and to carry drugs using polymers to
construct a theranostic agent.
Vasiljeva and co-workers developed an eﬀective delivery
system for targeting both tumors and their stromal components
based on ferrimagnetic nanoclusters.719 This multiplexed
targeting strategy is important for imaging and treating tumors
as the tumor microenvironment has many diverse components
including extracellular matrix components and stroma cells.
The universal lipidated magnetic NPs (called ferri-liposomes by
the authors) enhance the MRI contrast properties and are
eﬀectively taken up by tumors and their stromal components.
Chemical compounds within the ferri-liposomes are successfully
released when administered in vivo and can be visualized at both
the cellular and tissue levels. Furthermore, this theranostic agent
oﬀers an exciting possibility to deliver and to detect therapeutic
agents simultaneously in vivo. As such, the cathepsin inhibitor
JPM-565 was targeted by ferri-liposomes to the peri-tumoral
region of mouse breast cancer, which resulted in a signiﬁcant
reduction in tumor size.
Another class of theranostic NPs uses light for activation. One
example incorporates a second-generation PDT drug, Pc 4, with
a cancer-targeting ligand and iron oxide NPs as a MRI-guided
PDT platform (see Figure 36).720 The delivery of Pc 4 by NPs
enhanced the treatment eﬃcacy and reduced the required PDT
drug dose. The targeted IO-Pc 4 NPs have potential to serve as
both an MRI agent and PDT drug.
Other NPmaterials may also be used for simultaneous imaging
and therapy. One example involves chlorin e6-conjugated C-dots
as the light-triggered theranostics NP platform. This platform
uses simultaneous enhanced photosensitizer ﬂuorescence detec-
tion (PFD) and PDT by FRET.721 Huang et al. reported folic
acid-conjugated silica-modiﬁed gold nanorods, showing highly
selective targeting, enhanced radiation therapy, and PTT eﬀects
on MGC803 gastric cancer cells, and also strong X-ray
Drug delivery using theranostic NPs
enables noninvasive in vivo imaging of
the NP delivery process and may
enable assessment of treatment
responses at an early stage.
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attenuation for in vivo X-ray and CT imaging.722 In a similar
strategy, multifunctional PEGylated gold nanostar NPs were
prepared with CD44v6 monoclonal antibodies conjugated as the
targeting ligands.723 The prepared NPs had high aﬃnity toward
gastric cancer stem cell spheroid colonies. Upon NIR laser
treatment with a low power density (790 nm, 1.5W/cm2, 5 min),
those spheroid colonies could be completely destroyed in vitro,
while being simultaneously observed with X-ray/CT imaging
and photoacoustic imaging. Orthotopic and subcutaneous
xenografted nude mice models of human gastric cancer were
established. Computed tomography imaging observed in situ
gastric cancer clearly at 4 h postinjection, and photoacoustic
imaging revealed that CD44v6-modiﬁed NPs could actively
target the gastric cancer vascular system at 4 h postinjection,
while the NPs inhibited tumor growth upon NIR laser irradiation,
and even extended survivability of the gastric cancer-bearing mice.
These NPs exhibited good potential for applications of gastric
cancer targeted imaging and PTT treatment.
Hybrid materials are increasingly attracting attention since
they enable the combination of diﬀerent properties and functions
in one multipurpose material with high adaptability. Phosphate-
based inorganic−organic hybrid NPs (IOH-NPs) are attractive
tools as imaging and therapeutic drugs.724 The NPs are generally
composed of [ZrO]2+[Rfunction(O)PO3]
2− (Rfunction = functional
organic group such as drug and/or ﬂuorescent dye) and enable
multipurpose and multifunctional combination of a wide range
of properties such as drug delivery (e.g., chemotherapeutic agents
or anti-inﬂammatory drugs) as well as optical and CT-based
detection or MRI. For example, the anti-inﬂammatory poten-
tial of [ZrO]2+[BMP]2−0.996[DUT]
2−
0.004 was tested in vitro
on an alveolar macrophage cell line, where MHS cells were
treated with the endotoxin lipopolysaccharide (LPS, 200 ng/mL)
to provoke an inﬂammatory response. Cells were simultaneously
incubated either with IOH-NPs (10−10 to 10−5 M) or the
control drug dexamethasone (DM, 10−7 M). Incubation of
LPS-stimulated macrophages with increasing amounts of
[ZrO]2+[BMP]2−0.996[DUT]
2−
0.004 resulted in a dose-dependent
reduction in TNFα, IL-6, and NO secretion, with an eﬃcacy of
10−5 M IOH-NPs comparable to 10−7 M of dissolved molecular
DM. Fluorescence microscopy conﬁrmed these results.
Another eﬃcient way to implement theranostic delivery
carriers is to design multicompartment nanomedicine
vehicles.725 This approach is based onmulticompartment capsules,
which can be designed in the form of concentric, pericentric,
innercentric, and anisotropic or acentric structures.726 Themulti-
compartments are composed of smaller nanocapsules or NPs,
which are often assembled around a bigger nano- or micro-
capsule or particle. In such an arrangement, some multicompart-
ments are responsible for diagnostics by, for example,
incorporating sensing molecules,727 while other subcompart-
ments are constructed for therapy and treatment, i.e., for
on-demand delivery of biomedicine. Among other alternative
structures are capsosomes and polymersomes. Capsosomes
represent delivery carriers formed by adsorbing liposomes and
polymers on a particle template, followed by removal of template
cores. A number of interesting applications have been demon-
strated for capsosomes, including controlling the rates of
enzyme-catalyzed reactions, and pH- and temperature triggered
release.728 Polymersomes, on the other hand, are delivery carriers
based on block copolymers.729 The versatility of controlling their
properties makes them, together with polymeric vesicles,730 an
indispensable class of drug delivery vehicles.
Theranostic NPs not only provide signals for imaging the
locations of drug delivery vehicles, they also may respond to the
local environment and thus report delivery by a change in
the read-out signal. A ﬁrst look at delivery in vitro helps to
demonstrate this concept. When NPs are incorporated into cells
via endocytotic pathways, the NPs experience radical changes in
their ambient environments. This involves a change in pH from
neutral/slightly alkaline extracellular medium, to highly acidic
endosomes/lysosomes, which, for example, enables reporting
cellular internalization by observing pH changes by pH-sensitive
ﬂuorophores integrated into the NPs.128,171 Endosomes and
lysosomes are also rich in proteolytic enzymes, which act on
internalized NPs. Fluorescence markers that change signal upon
proteolytic activity enable the detection of intracellular internal-
ization.731,732 These principles have been applied for online
observation of the delivery of micelles. Here, a color change
reports successful delivery upon degradation of the micelles.
The delivery of embedded drugs can be imaged directly.9,733,734
Murakami and co-workers demonstrated this approach using
micelles of BODIPY FL-PEG-b-poly(glutamic acid)-BODIPY
TR loaded with 1,2-(diaminocyclohexane)platinum(II). The
micelles were built to emit due to the shell-conjugated dye, while
the core-conjugated dye was quenched. The micelle degradation
is triggered by changes in pH and concentration of chloride ions,
i.e., changes that occur in late endosomes. The last approach was
tested in vivo using confocal laser scanning microscopy. Despite
rapid progress in this ﬁeld, theranostic NPs are still at an early
stage of development.
Nanoparticle-Labeled StemCells for Targeted Imaging
and Therapy. Stem cell nanotechnology, as a newly emerging
interdisciplinary ﬁeld, refers to the application of nano-
technology in stem-cell research and development. Hundreds
of clinical trials with autologous or allogeneic MSCs are currently
ongoing, with eﬀorts being made to ensure the safety and eﬃcacy
of these advanced therapy medicinal products. Although
Figure 36. Construction of targeted NPs carrying the PDT drug Pc 4.
Quantitative measures of T2 values show that the cells with Fmp-iron
oxide (IO) NPs had lower T2 values as compared to those with only
SPIONs. Reprinted from ref 720. Copyright 2014 American
Chemical Society.
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signiﬁcant advances in the ﬁeld of stem cells have been, and are
continuously being made, several obstacles must be over-
come before their therapeutic application can be realized.
These steps include the development of advanced techniques to
understand and to control functions of microenvironment
signals as well as novel methods to track and to guide trans-
planted stem cells. The application of nanomaterials and
nanotechnology in stem-cell research and development exhibits
attractive technological prospects to solve current problems of
stem-cell research and development.735 Mesenchymal stem cells
are multipotent stem cells that can diﬀerentiate into a variety of
cell types, including osteoblasts (bone cells), chondrocytes
(cartilage cells), and adipocytes (fat cells). In addition, MSCs
possess immunosuppressive or immunomodulatory properties
and have the tendency to home to the sites of active tumo-
rigenesis. Thus, MSCs can be considered as a candidate cell type
for cell-based tissue engineering, cancer therapeutics, and
regenerative medicine applications.
One fascinating and upcoming application is the generation of
induced pluripotent stem cells (iPSC) fromMSCs with potential
in regenerative medicine. Combining negatively charged nucleic
acids such as transcription factors and siRNA with cationized
NP formulations provided superior reprogramming eﬃciency
compared to conventional “Yamanaka factors” (see Figure 37).736
The highly tumorigenic c-MYC and KLF4 oncogenes were
dispensable in this approach, which employed polysaccharides to
form self-assembling NPs instead of lentiviral transduction for
iPSC generation from MSCs.
However, the distribution and ﬁnal fate of MSCs inside the
human body have still not been clariﬁed, for which novel labeling
and in vivo tracking technologies are urgently needed. Nano-
particles are potentially suitable labels. However, little is known
about alteration of MSC biology after exposure or uptake of NPs.
As an example, silica-coated ﬂuorescent supermagnetic NPs
were evaluated for their eﬀects on MSCs, and then used to label
MSCs. The distribution and ﬁnal sites of the labeled MSCs were
observed in vivo in nude mice models with gastric cancer.
Mesenchymal stem cells were eﬃciently labeled with NPs,
yielding stable ﬂuorescent signals and magnetic properties within
14 days. The NP-labeled MSCs targeted and could be used to
image in vivo gastric cancer cells after being intravenously
injected for 14 days (see Figure 38).737 Nanoparticle-labeled
MSCs could signiﬁcantly inhibit the growth of gastric cancer
in vivo based on hyperthermia eﬀects of the NPs, and the
CCL19/CCR7 and CXCL12/CXCR4 axis loops may play key
roles in targeting MSCs to gastric cancer in vivo. This NP-based
labeling and tracking technology has potential in applications
such as labeling and tracking in implanted cells, evaluating
cell therapeutic eﬀects, and recognizing andmapping early gastric
cancer cells.
Dendritic cells (DCs) also display promising potential in
cancer immunity. However, enhancing DCs’ immunotherapeutic
eﬀect in cancer-targeted immunotherapy and prevention remains
a challenge. Li et al. reported an allogenic DC and tumor cell
fused vaccine combined with cytokine-induced killing cells
(CIKs) for targeted imaging and enhanced immunotherapeutic
eﬃcacy of gastric cancer (GC).738 The fused vaccine was
prepared by PEG-mediated fusion between mature DCs and
inactive GC MGC803 cells. The immunotherapeutic and
prophylactic potentials of the fused cells (FCs) were evaluated
in tumor-bearing, postsurgery, and tumor-free mice models.
Themigration and homing process of NIR-QD-labeled FCs were
investigated with a real-time animal-imaging system. Results
showed that the FCs and FC + CIKs could trigger the tumor-
speciﬁc cytotoxic T lymphocytes against GC cells. They target
the tumor tissue, enhance the prophylactic eﬀects, and suppress
Figure 37. Negatively charged plasmid mixture (encoding Oct4,
Sox2, miR302-367) and the positively charged cationized Pleurotus
eryngii polysaccharide (CPEPS) self-assembled into NPs, named as
CPEPS- OS-miR NPs, which were applied to human umbilical cord
mesenchymal stem cells for iPSCs generation. Adapted from ref 736.
Copyright 2015 American Chemical Society.
Figure 38. Fluorescence and MR imaging of NP-labeled MSCs targeting gastric cancer cells in vivo. (A) In vivo ﬂuorescence images show that
(right) tumor sites of the mice in the test group had ﬂuorescence signals of NP-labeled MSCs postinjection after 7 and 14 days, and (left) tumor
sites of the mice in the control group had no ﬂuorescence signal of NPs postinjection after 7 and 14 days. (B) Fluorescence images of major
organs show that (left) no signal was detected in the tumor and organs of the control group, and (right) obvious ﬂuorescence signals were
detected in the tumor tissues of the test group. (C) MR imaging of NP-labeled MSCs targeting gastric cancer cells after 7 and 14 days
postinjection. Adapted with permission from ref 737. Copyright 2012 Ruan et al.
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the tumor growth in vivo. These allogenic DC and tumor cell
fused vaccine can be used for targeted imaging and enhanced
immunotherapeutic eﬃcacy of GC. Similarly, the FC + CIK
strategy shows potential in clinical applications, such as early
therapy and prevention of tumor metastasis and relapse in near
future.
REDUCING SIDE EFFECTS WITH SAFE-BY-DESIGN
APPROACHES
Potential Risks of Nanomedicines. While there are many
applications of nanomedicines, there are concerns over their
potential side eﬀects when they are used in patients. These
concerns may limit their translation to patients. Thus, the ques-
tions of how to reduce risks and to increase beneﬁts are vital for
the development of safe and eﬀective nanomedicines. First, we
need to understand how physicochemical properties of nano-
carriers and nanomedicine relate to their biological behavior and
fate in vivo.577,739 These physicochemical properties include size,
shape, surface chemistry, hydrophobicity and hydrophilicity,
chirality, aggregation, degradability, and catalytic ability. All of
these properties may inﬂuence their fate and subsequent bio-
logical responses. The other issue to take into consideration is
the protein corona. When nanocarriers and nanomedicine
are injected in the blood, they can quickly adsorb blood proteins,
such as albumin, ﬁbrinogen, transferrin, immunoglobulin,
lipoproteins, and so on.740−743 This corona determines the
distribution and transport behavior of such NBCDs.744 Altered
biokinetics, which are dependent on the types of polymer used
and on surface chemistry, may enhance the transport velocity
but, at the same time, they may cause the NPs to enrich
undesirably in some speciﬁc tissues, thereby leading to high local
concentrations at these parts of the body.745,746 These distri-
bution and metabolism changes may induce new and
unpredictable eﬀects that must be taken into consideration.
Second, we need to design and to utilize those properties
rationally to optimize their application for therapeutic eﬃcacy
and safety. As an example, if the NPs are coated with “stealth”
components to keep them in the bloodstream longer, the release
of the drug molecules should be low at this stage in order not to
treat the blood cells and endothelium with the drug.
The much more complex structure of nanomedicines
compared to simple drug molecules makes it important to
characterize them carefully. This is relevant not only for the
understanding of their activity and eﬀects but also for the
responsible production of such structures. For this purpose,
in Europe, the “Nanomedicine Characterization Laboratory”
(http://www.euncl.eu) was founded and is funded by the European
Council.
A further critical issue and major problem for nanomedicine is
the quick uptake by cells typically in the reticuloendothelial
system (RES), which results in their high accumulation in the
liver and spleen.747−749 Toxicity against these cells and tissues
should be carefully tested. Besides these “normal” distribution
kinetics, NPs may have novel metabolic and excretion proﬁles
which arise due to the interactions of NPs with tissue micro-
structure and speciﬁc biomicroenvironments.750−752 Small NPs
might be removed from the blood by renal clearance (<5 nm) or
rapid liver uptake (10−200 nm),753 whereas large NPs are
ﬁltered in the sinusoidal spleen (>200 nm)754 or are recognized
and cleared by the RES.755 Renal clearance studies in mice using
QDs with zwitterionic cysteine demonstrated that the size
threshold for glomerular ﬁltration of QDs was about 5.5 nm,
while renal excretion was prevented when the diameter was
above this value.123 Therefore, NPs between 20 and 200 nm can
remain in the circulation for extended periods of time,754 though
there is still debate in the literature on this front.756
Usually, the increased drug uptake by cells and favorable drug
release proﬁles can be easily achieved using nanodelivery
systems. However, toxicity, stability, and degradation properties
of such NPs are yet to be well evaluated. Moreover, toxicity
testing with NPs is not easy, as good models for testing are not
available and most simple in vitro systems have not been suitable
so far.757 There are signiﬁcant variabilities in how diﬀerent organs
interact with NPs and this variability is diﬃcult to capture in vitro.
It is well accepted that the transport of NPs across tissue barriers
is clearly size-dependent. This has been demonstrated for various
uptake pathways and diﬀerent tissues such as the gastrointestinal
tract,758 the lung,759 the blood−brain barrier,760,761 or the human
placenta.762,763 Logically, these tissues have to be tested intensely
in toxicity assays.747,758−764
For assessment of the safety and therapeutic eﬃcacy, proper
methodology and state-of-art techniques are necessary to study
biological behaviors and transformation of nanomaterials and
nanomedicine in vivo and in vitro. Systemic and quantitative
information from proteomics, genomics, transcriptomics, and
metabolomics can capture the changes on metabolism, signaling
pathways, and biological functions as well.765,766
Safe-by-Design Approaches. An important consideration
in the development of new nanotherapeutics is the intrinsic
safety of the design platform, from conception to implementa-
tion. Appropriate consideration should be given to material
compositions that are already considered safe by the FDA and
contain degradable ingredients that do not lead to biopersistance
or bioaccumulation. It is also important to consider intrinsic
nanomaterial properties that are generally known to be more
hazardous for nanomaterial proﬁling studies, including high
cationic density, high surface reactivity, dissolution and shedding
of potentially toxic metal ions (e.g., gadolinium522,523), high
aspect ratio, etc. One approach involves the selection of the initial
NP composition and subjecting its components to multi-
parametric high-throughput screening. This screening would
enable one to discern possible eﬀects on cells of potential target
tissues and could be used to eliminate hazardous in vitro eﬀects
such as cytotoxicity, membrane disruption, organellar damage
(e.g., mitochondria and lysosomes), unwanted redox activity
leading to oxidative stress, biopersistance, oﬀ target genotoxicity,
etc. Attempts are made to relate any adverse in vitro eﬀects to
speciﬁc physicochemical properties, which could then be
adapted, eliminated, or redesigned to render a safer in vitro
proﬁle. This approach reduces the number of subsequent animal
studies to be performed, if the intrinsic material design is
intended to be safe. However, ultimately, the design’s eﬃcacy
and safety need to be demonstrated through the performance of
in vivo studies, including making use of well-established safety
screening procedures as well as screening for speciﬁc material
properties that cannot be assessed in vitro, e.g., immunogenicity
of PEG-coated particles.
The questions of how to reduce risks
and to increase beneﬁts are vital for the
development of safe and eﬀective
nanomedicines.
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Carbon nanomaterials, including one-dimensional CNTs and
2D graphene, exhibit unique physical, chemical, and electrical
properties, that make them attractive candidates for electronics,
energy technologies, medical diagnostics, and drug delivery.767
Due to this signiﬁcant potential for industrial applications,
methods for safe handling and use of these nanomaterials are of
critical importance. Furthermore, emerging biomedical uses of
these nanomaterials768,769 necessitate the development of
strategies to minimize toxicity. For example, in a series of studies
involving SWCNTs,770 MWCNTs,771 and graphene,772 it was
shown that stable aqueous dispersions of carbon nanomaterials
can be achieved with the amphiphilic block copolymer surfactant
Pluronic F108.773 In contrast to aggregated samples, carbon
nanomaterials that are eﬀectively dispersed with Pluronic
F108 further minimize toxicity in vivo.770−774 This same
dispersion strategy also minimizes negative environmental
outcomes of these nanomaterials in aquatic environ-
ments.775−778 The positive beneﬁts of Pluronic block copolymer
surfactants have also recently been realized for related 2D
nanomaterials,779 such as transition metal dichalcogenides
(e.g., MoS2), both in vivo
780 and in aquatic environments.781
Challenges to Clinical Translation. To reach the patient
and to contribute to the beneﬁt of society, medical nanomaterials
need to succeed in an industrial technology transfer phase and in
clinical translation. This translation is a lengthy, costly, and
complex process that should be considered early on in the
development process of novel nanotechnology-based thera-
pies.308 For nanomedicine to be considered for “from the
benchtop to the bedside”, clinical translation, high therapeutic
eﬃcacy alone is not suﬃcient.782−785 The nanomedicine must
simultaneously meet the basic requirement triangleshigh
therapeutic eﬃcacy, material excipientability, and scale-up
ability313to meet the safety, eﬀectiveness, and producibility
requirements for a drug (see Figure 39). Typical roadblocks for
clinical translation of academic research projects into nano-
medicine include: (i) the failure either to target an unmet clinical
need, or to do so beyond what can be expected with simpler
products in the near future; (ii) reproducibility and character-
ization problems of the nanomaterials involved; (iii) design
complexity forbidding economic production; (iv) scale-up
challenges; (v) lack of eﬃcacy in humans; (vi) unexpected
clinical toxicity; (vii) lack of a convincing business case; (viii) a
fragile patent situation; (ix) a delay in the registration process of
nanomaterials and nanodevices; and (x) crowding of research
project topics toward speciﬁc disease groups (cancer) while
other important disease classes (e.g., poverty diseases, metabolic
disease, vascular diseases) are neglected.
Lack of eﬃcacy is frequently seen in humans, despite success in
animal models of disease, because the physiology of humans
diﬀers from that of small animals in many aspects. This is parti-
cularly important in cancer, where the usual xenograft models of
human cancer in mice are often curable by nanotechnologies,
while current clinical success in cancer therapy remains limited
with diﬀerences in tumor vascularization playing a key role.786
To achieve rational, prospective design criteria for the develop-
ment of future nanomaterials for particular tasks, a strong
scientiﬁc understanding of nano−bio interactions will be
required. Predictive models of such interactions can be used to
design novel materials in silico,where their interaction with blood
components, biological barriers, cell membranes, and intra-
cellular structures can be predicted using the model. This goal
can be achieved in part by utilizing the combined power of
macromolecule modeling, supramolecular modeling, cell model-
ing, pharmacokinetic modeling, and computational toxicology.
Toxicity, as discussed in the prior section, is a second key
reason for the pharmaceutical industry to abandon a therapy after
it has reached ﬁrst-in-human and phase 1 or phase 2 clinical trials.
Excipientability, i.e., the feasibility of the carrier material(s) to
be ﬁnally proven as an excipient used in humans, is directly
related to the safety of the nanomedicine.313 To have good
excipientability, the carrier material itself should be nontoxic and
easy to excrete completely from the body via the liver (into bile)
or the kidneys (into urine) or both. According to Choi and
Frangioni,782 safety and clearance (renal or hepatic) should be
included among the basic criteria for clinical translation of
formulation/materials administered to humans. Accumulation of
any foreign material in the body, even inert polymers like PVP,
can cause health problems.787−789 Additionally, in order to
expedite and to increase the probability of successful translation,
the carrier materials should have a clear and simple structure with
known degradation products. An even better case, as mentioned
earlier, would be for the carrier material to be made of FDA-
approved building blocks. In addition to concerns surrounding
accumulation, complement activation upon intravenous injec-
tion by nanomaterials is a frequent and potentially dangerous
event.790 The potential for complement activation of novel
nanomaterials can be assessed by combining in vitro tests and
in vivo models,791 but a full mechanistic understanding of
complement activation on nanosurfaces is still missing. Rational
design of nanomaterials that will not react with complement by
design is highly desirable but not yet reality.
For the pharmaceutical industry, the lack of clear and
standardized pathways to regulatory approval for nanosystems
renders development riskier and therefore less attractive, unless
highly convincing ﬁrst-in-human studies can be demonstrated by
academia. Patent protection is also of key importance for
industry, but the ﬂooding of the patent ﬁeld by a myriad of
nanoscience patents in the past decade, with content that is often
overlapping and insuﬃciently examined, has rendered the
business case for nanomaterials more diﬃcult. Too many
open-ended promises of new technologies may paradoxically
reduce the propensity of managers and regulators to act.792 Joint
eﬀorts by the scientiﬁc community, industry, and international
regulatory bodies to ﬁnd a common ground through annual,
interdisciplinary discussion of the challenges of nanomedicine
design and toxicity, and regulation in the CLINAM conferences
Figure 39. Essential requirements for a nanomedicine to be
translational. Adapted with permission from ref 313. Copyright
2012 Elsevier.
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(http:/www.clinam.org) have contributed to streamlining the
regulatory aspects of nanomedicine in recent years.
Process scale-up ability is the feasibility of making large
volumes of NPs with consistent and reproducible quality to
establish GMP.313 For instance, a nanomedicine of drug-loaded
micelles made of block copolymers must be produced with
reproducible NP size, NP size distribution, and drug-loading
eﬃciency and content. As the nanomedicine structures become
more complex, the number of quality-control parameters
dramatically increases,793,794 which makes it increasingly diﬃcult
to produce acceptably consistent formulations. A nanomedicine
requiring only simple production processes is more favorable
for the establishment of a GMP process. For instance, self-
assembling prodrugs can spontaneously form nanomedicines
with advantages that include clear and well-characterized molecular
structures, ﬁxed drug loading contents, 100% loading eﬃciency, no
burst-release problems, and easy fabrication, all of which are
favorable for clinical translation.441,795,796 For nanomedicine aimed
at clinical translation, it is advisable to look into excipientability and
scale-up ability issues early at the bench to expedite the process.
CONCLUSIONS AND PROSPECTS
New NPs tuned for nanomedicine applications are emerging,
especially in the ﬁelds of drug delivery, antibiotic resistance,
imaging, diagnostics, and cancer therapies. Recent studies have
shown that the use of multiple nanomaterials (i.e., NDs and
proteins) or a single nanoplatform functionalized with several
therapeutic agents can successfully image and treat tumors with
improved eﬃcacy. NPs-based drug delivery has been included
in the rational, biomimetic, and systematic design of optimal
therapeutic combinations.
Nanomedicine in cellular, preclinical, and clinical studies has
led to many important advances, both fundamental and
translational. Many of these advances, however, have been in
the ﬁeld of cancer diagnosis and treatment. This dispropor-
tionate focus is expected to be addressed in upcoming years with
research focuses expanding to other medical challenges such as
antibiotic resistance and artiﬁcial organs. Nanomedicine is poised
to be of beneﬁt in these areas by virtue of the versatility of the
nanomaterial platform design, be it through multimodal
therapeutic approaches or through highly specialized multi-
faceted design for relevant biological applications.
Although nanomedicine has raised exciting expectations for
many medical problems, scientiﬁc challenges have arisen as well,
mainly due to the lack of knowledge about the behavior of
nanomaterials inside living organisms. However, due to the basic
research focused on these issues, we are now closer to solving
them and to reaching “real” medical solutions based on
nanomedicine.
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